
<html lang="en"     class="pb-page"  data-request-id="5c36e23e-884e-4845-a7d0-973fc3cd34a3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b01947;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-5;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity" /></meta><meta name="dc.Creator" content="Ellen  Watts" /></meta><meta name="dc.Creator" content="David  Heidenreich" /></meta><meta name="dc.Creator" content="Elizabeth  Tucker" /></meta><meta name="dc.Creator" content="Monika  Raab" /></meta><meta name="dc.Creator" content="Klaus  Strebhardt" /></meta><meta name="dc.Creator" content="Louis  Chesler" /></meta><meta name="dc.Creator" content="Stefan  Knapp" /></meta><meta name="dc.Creator" content="Benjamin  Bellenie" /></meta><meta name="dc.Creator" content="Swen  Hoelder" /></meta><meta name="dc.Description" content="Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fr..." /></meta><meta name="Description" content="Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 21, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01947" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01947" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01947" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01947" /></link>
        
    
    

<title>Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01947" /></meta><meta property="og:title" content="Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0015.jpeg" /></meta><meta property="og:description" content="Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN. Starting from known dual polo-like kinase (PLK)-1–BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK–BRD4 profile. These efforts led to compound (R)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5H)-one (16k) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds’ on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01947"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01947">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01947&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01947&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01947&amp;href=/doi/10.1021/acs.jmedchem.8b01947" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2618-2637</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01927" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01949" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ellen Watts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ellen Watts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ellen++Watts">Ellen Watts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Heidenreich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Heidenreich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, D-60438 Frankfurt am Main, Germany</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, BMLS, Goethe-University Frankfurt, 60438 Frankfurt, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Heidenreich">David Heidenreich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth Tucker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth Tucker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Paediatric and Solid Tumour Biology and Therapeutics Group, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Tucker">Elizabeth Tucker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monika Raab</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monika Raab</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Gynecology and Obstetrics, Johann Wolfgang Goethe-University, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monika++Raab">Monika Raab</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Klaus Strebhardt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Klaus Strebhardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Gynecology and Obstetrics, Johann Wolfgang Goethe-University, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Klaus++Strebhardt">Klaus Strebhardt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Chesler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Chesler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Paediatric and Solid Tumour Biology and Therapeutics Group, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Chesler">Louis Chesler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Knapp</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Knapp</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, D-60438 Frankfurt am Main, Germany</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, BMLS, Goethe-University Frankfurt, 60438 Frankfurt, Germany</div><div class="loa-info-affiliations-info">German Cancer Network (DKTK), Site Frankfurt/Mainz, D-60438 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Knapp">Stefan Knapp</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5995-6494" title="Orcid link">http://orcid.org/0000-0001-5995-6494</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin Bellenie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin Bellenie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d99bbcb7b3b8b4b0b7f79bbcb5b5bcb7b0bc99b0baabf7b8baf7acb2"><span class="__cf_email__" data-cfemail="7537101b1f14181c1b5b37101919101b1c10351c16075b14165b001e">[email protected]</span></a>. Phone: +44 (0) 2087224602 (B.B.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin++Bellenie">Benjamin Bellenie</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Swen Hoelder</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Swen Hoelder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7d2e0a1813533512181119180f3d141e0f531c1e530816"><span class="__cf_email__" data-cfemail="613216040f4f290e040d050413210802134f00024f140a">[email protected]</span></a>. Phone: +44 (0) 2087224353 (S.H.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Swen++Hoelder">Swen Hoelder</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8636-1488" title="Orcid link">http://orcid.org/0000-0001-8636-1488</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01947&amp;href=/doi/10.1021%2Facs.jmedchem.8b01947" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2618–2637</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 21, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 December 2018</li><li><span class="item_label"><b>Published</b> online</span>21 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01947" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01947</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01947"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4795</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01947" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ellen&quot;,&quot;last_name&quot;:&quot;Watts&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Heidenreich&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Tucker&quot;},{&quot;first_name&quot;:&quot;Monika&quot;,&quot;last_name&quot;:&quot;Raab&quot;},{&quot;first_name&quot;:&quot;Klaus&quot;,&quot;last_name&quot;:&quot;Strebhardt&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Chesler&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Knapp&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;Bellenie&quot;},{&quot;first_name&quot;:&quot;Swen&quot;,&quot;last_name&quot;:&quot;Hoelder&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2618-2637&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01947&quot;},&quot;abstract&quot;:&quot;Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN. Starting from known dual polo-like kinase (PLK)-1–BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK–BRD4 profile. These efforts led to compound (R)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5H)-one (16k) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds’ on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01947&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01947" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01947&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01947" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01947&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01947" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01947&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01947&amp;href=/doi/10.1021/acs.jmedchem.8b01947" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01947" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01947" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01947%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DWatts%26date%3D2019%26atitle%3DDesigning%2BDual%2BInhibitors%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%2Band%2BBromodomain-4%2B%2528BRD4%2529%2Bby%2BTuning%2BKinase%2BSelectivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D5%26spage%3D2618%26epage%3D2637%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/jmcmar.2019.62.issue-5/20190314/jmcmar.2019.62.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of <i>MYCN</i>. Starting from known dual polo-like kinase (PLK)-1–BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK–BRD4 profile. These efforts led to compound (<i>R</i>)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16k</b>) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds’ on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Neuroblastoma is a pediatric cancer of neural crest origin and is the most common extracranial solid tumor in childhood.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In high-risk patients, mutations within the kinase domain of the anaplastic lymphoma kinase (ALK), such as ALK<sup>F1174L</sup>, co-segregate with amplification of the <i>MYCN</i> gene. Since the ALK mutation increases transcription and expression of MYCN, both oncogenic gene changes cooperate to upregulate this well-established driver of neuroblastoma proliferation, resulting in poor prognosis and clinical outcome.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Several selective inhibitors of the ALK kinase have been disclosed and entered clinical trials for different indications. However, crizotinib is clinically ineffective in neuroblastoma and many second-generation ALK inhibitors are predicted to be ineffective for neuroblastoma patients harboring the F1174L mutation due to insufficient inhibition of the mutant kinase.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Recently, the third-generation ALK inhibitor lorlatinib was shown to potently inhibit ALK<sup>F1174L</sup> and has now entered phase I clinical trials in relapsed or refractory neuroblastoma patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Inhibition of bromodomain-4 (BRD4) has recently emerged as an essential transcriptional co-regulator of MYCN, and inhibition of the bromodomain has been shown to be an effective therapeutic approach to target dysregulated <i>MYCN</i> in neuroblastoma.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Several compounds have progressed to clinical trials for adult malignancies but have yet to reach pediatric trials.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a></div><div class="NLM_p">It is increasingly recognized that targeting multiple pathways that support cancer growth and survival is necessary to treat aggressive cancers, provide a more durable response, and overcome resistance.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Given the clinical challenge that high-risk neuroblastoma cases pose, combining ALK and BRD4 inhibition may represent an effective therapeutic approach for this high medical need. Combining both ALK and BRD4 inhibition would serve two purposes. First, it would target the two most common and co-segregating events that drive high-risk neuroblastoma and curb <i>MYCN</i> expression, potentially resulting in strong antiproliferative or proapoptopic effects. Moreover, blocking two targets at once reduces the risk of resistance to the therapy since the probability of clonal adaptation to targeted therapy is lower for combination therapies.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">A key barrier in clinical implementation of new agents or treatment strategies in children is that combination trials of multiple drugs are challenging in pediatric patients. This is in part due to the increased chance of off-target toxicity when two agents are tested and length of trials because tolerable dose must be established for each new agent separately in very small patient populations.</div><div class="NLM_p">An alternative approach to using two drugs in combination is to explore dual inhibitors that block both targets of a therapeutic combination, in the case of high-risk neuroblastoma, BRD4 and ALK<sup>F1174L</sup>. A dual inhibitor is likely to reduce the liabilities associated with combination treatments, particularly, off-target toxicities, drug–drug interactions, and additive effects. Furthermore, combinatorial treatment in the form of a dual inhibitor reduces the length and complexity of trials as well as costs.<a onclick="showRef(event, 'ref10 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref12 ref13">(10,12,13)</a></div><div class="NLM_p">Dual inhibitors are thus an attractive therapeutic approach, but the design and development of drugs that specifically inhibit two targets, particularly, where these are structurally distinct and not members of the same protein family, are challenging. In particular, combining two pharmacophores into a single druglike compound while also achieving selectivity and physicochemical and pharmacokinetics properties consistent with clinical development is regarded as very difficult.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">However, precedent for dual kinase–bromodomain inhibitors has recently emerged. Through systematic screening efforts, Ember et al. and Ciceri et al. identified a total of 24 kinase inhibitors that interact with BRD4.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Cocrystal structures of these dual inhibitors revealed insights into how the BRD4 and kinase pharmacophores can be combined into a single druglike molecule. Although these reports provide important precedence for dual kinase–bromodomain inhibition and structural insights, the combination of bromodomain and kinase inhibited by these dual inhibitors was discovered serendipitously by screening selective kinase inhibitors against the bromo- and extra-terminal domain (BET) bromodomains. To date, there are a few published reports of discovery efforts that aim to combine inhibition of a particular kinase with bromodomain inhibition into a single dual inhibitor to explore a specific disease hypothesis.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a></div><div class="NLM_p last">Herein, we describe our efforts to discover dual ALK–BRD4 inhibitors to target both oncogenic drivers of high-risk neuroblastoma. We chose the dual polo-like kinase (PLK)-1–BRD4 inhibitor BI-2536 as our starting point and investigated if this inhibitor series can be reoptimized to show potent inhibition of mutant (F1174L) ALK kinase, reduced PLK-1 activity while maintaining BRD4 activity, and acceptable kinome selectivity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our goal at the start of the project was to discover starting points that showed significant activity against BRD4 and the ALK kinase. We were particularly intrigued by the dual kinase–bromodomain inhibitor BI-2536 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The compound was discovered and developed as a PLK-1 kinase inhibitor but was found to potently inhibit BRD4 by Knapp and Schönbrunn’s labs.<a onclick="showRef(event, 'ref14 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref19 ref20">(14,19,20)</a> BI-2536 has been reported to show high specificity within the kinase family, partially due to the methoxy substituent. Some kinases are not able to accommodate this substituent due to a steric clash with a larger tyrosine or tryptophan residue in the hinge region. Among the exceptions are PLK-1 and importantly ALK due to the presence of a smaller leucine at this position.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> We thus hypothesized that although BI-2536 showed excellent overall kinase selectivity it may show sufficient activity against ALK and ALK<sup>F1174L</sup> to serve as a starting point. We analyzed the publicly available data, and indeed a <i>K</i><sub>d</sub> of 160 nM had been disclosed for ALK.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In our assays, BI-2536 showed comparable, albeit modest, activity (IC<sub>50</sub>s of 390 and 190 nM against ALK and ALK<sup>F1174L</sup>, respectively).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biochemical potencies of the dual PLK-1–BRD4 inhibitor BI-2536 and moieties of the molecule that form key interactions with BRD4 (orange) and the PLK-1 hinge region (violet).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, we confirmed inhibition of BRD4 and PLK-1. In fact, the potency of BI-2536 against PLK-1 was beyond the dynamic range of the assay (IC<sub>50</sub> < 2.6 nM) consistent with a published <i>K</i><sub>d</sub> of 0.19 nM.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">BI-2536 thus was a suitable starting point for the discovery of a dual ALK–BRD4 inhibitor, not least because it inhibited a few other kinases apart from PLK-1 and ALK.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We thus decided to investigate if BI-2536 can be optimized toward a dual ALK–BRD inhibitor. In particular, we sought to reduce activity against PLK-1, improve ALK activity, and maintain BRD4 activity. To analyze the scope for modifications as well as derive design hypotheses, we first analyzed the published structures of BI-2536 bound to BRD4 and PLK-1.<a onclick="showRef(event, 'ref14 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref21">(14,21)</a> In addition, we docked BI-2536 into ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>) using Glide. We chose this structure for our docking experiment due to structural similarity between the ALK inhibitor NVP-TAE684<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and BI-2536, in particular, the aminopyrimidine hinge binding motif and the <i>ortho</i>-methoxy phenyl group.</div><div class="NLM_p">In BRD4, the methyl amide moiety acts as the acetylated lysine (KAc) mimetic, interacting with Asn140 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a). As described in more detail previously,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> additional interactions arise between the aminopyrimidine group and conserved waters in the ZA channel. The PLK-1-bound structure showed that the aminopyrimidine forms the key interactions with the hinge region of the kinase including Cys133 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). Docking into ALK not surprisingly predicted that aminopyrimidine of BI-2536 interacted with the ALK hinge region including residue Met1199 in a manner similar to that for PLK-1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c). The amide carbonyl was also predicted to interact with conserved water in the back of the ALK pocket.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structures of BI-2536 in complex with (a) BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OGI">4OGI</a>) and (b) PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>) highlighting key interactions. (c) Docking pose generated using Glide showing BI-2536 in complex with ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>), highlighting key interactions. (d) Four chosen areas for modification on BI-2536.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the ALK docking and BRD4 X-ray structure, we wanted to maintain the key kinase and bromodomain binding motifs on the dihydropteridinone core and thus decided to leave these regions of the compound untouched.</div><div class="NLM_p">Our analysis also suggested that several positions around the core structure offered significant scope for modification (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d). The first area chosen for modification was the (<i>R</i>)-ethyl group (R<sup>1</sup>), which fits into a hydrophobic pocket in both PLK-1 and BRD4. The docking of BI-2536 in ALK also suggests that the (<i>R</i>)-ethyl is pointing toward a pocket formed by residues Val1130, Ala1148, Lys1150, and Leu1196. It has been reported that changing the chirality of the ethyl group has little effect on the potency at PLK-1 and BRD4, whereas removing the group afforded a 26-fold reduction in potency at BRD4.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a></div><div class="NLM_p">We were also interested in the cyclopentyl substitution off the dihydropteridinone core (R<sup>2</sup>), which has been shown to be a region where BRD4 and PLK-1 selectivity can be tuned.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For example, changing the cyclopentyl to a 3-bromobenzyl group increases BRD4 affinity due to improved hydrophobic interactions with the WPF shelf but decreases PLK-1 activity, suggesting that modifications in this region could be used to improve selectivity against PLK-1.</div><div class="NLM_p">Next, we considered the methoxy group at the R<sup>3</sup> position. Docking of BI-2536 suggests that the alkoxy group is pointing toward a known region for achieving ALK selectivity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The majority of kinases have a bulkier residue at this region, allowing ALK selectivity to be achieved as seen with ceritinib and alectinib.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> In addition, larger alkoxy groups were known to improve interactions at BRD4.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We thus hypothesized that larger alkoxy groups will lead to increased selectivity against PLK-1 while maintaining BRD4 activity.</div><div class="NLM_p">The final area chosen for modification is the solvent channel methylpiperidine group (R<sup>4</sup>). Published structure–activity relationship (SAR) data for ALK inhibitors suggested that a wide variety of groups are tolerated in this region.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> We particularly decided to prepare analogues without the amide group to reduce PLK-1 activity by removing a hydrogen-bonding interaction with Leu59 and a water molecule in the PLK-1 pocket.</div><div class="NLM_p">Following this structure-based analysis and docking, we decided to focus modifications on four areas (R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup>) and to keep the dihydropteridinone core unchanged to maintain the key kinase and bromodomain binding interactions (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">We prepared a series of analogues of BI-2536 by adapting and optimizing previously described syntheses.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For aniline intermediates containing the R<sup>3</sup> and R<sup>4</sup> modifications, two routes were used as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. For the amide-containing intermediates, the isobutyl group was first introduced by alkylation to 3-hydroxy-4-nitrobenzoic acid <b>1</b> via protection and subsequent deprotection of the benzoic acid. The 4-nitrobenzoic acid <b>3a</b> was coupled to 4-amino-1-methylpiperidine using <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HBTU) to give amide <b>4a</b>, followed by reduction using SnCl<sub>2</sub> to give aniline <b>5a</b>. The ethoxy analogue <b>5b</b> was made via the same route from commercial compound <b>3b</b>. The synthesis of anilines <b>10a</b> and <b>10b</b> began with a Suzuki coupling between an alkoxy-nitrobenzene (<b>6a</b> and <b>6b</b>) and 4-pyridineboronic acid. Pyridines <b>7a</b> and <b>7b</b> were methylated to give <b>8a</b> and <b>8b</b> as the iodonium salts and then partially reduced using sodium borohydride (<b>9a</b> and <b>9b</b>). Hydrogenation of the dihydropyridine and nitro group gave aniline intermediates <b>10a</b> and <b>10b</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, 70 °C, 90%; (b) 1-iodo-2-methylpropane, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 50 °C, 88%; (c) LiOH, H<sub>2</sub>O, room temperature (rt), 71%; (d) 4-amino-1-methylpiperidine, HBTU, Et<sub>3</sub>N, DMF, rt, 77–86%; (e) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOAc/EtOH, 10:3, 50 °C, 53–55%; (f) 4-pyridylboronic acid, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/water 6:1, 110 °C, 54–65%; (g) MeI, MeCN, 50 °C, 91–99%; (h) NaBH<sub>4</sub>, MeOH, rt, 56–95%; (i) H<sub>2</sub>, PtO<sub>2</sub>, AcOH, 50 psi, 75–85%.</p></p></figure><div class="NLM_p">Meanwhile, intermediates <b>15a</b>–<b>g</b> were prepared according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The appropriate amino acids <b>11a</b>–<b>c</b> underwent reductive amination with various aldehydes to give intermediates <b>12a</b>–<b>g</b> followed by regioselective S<sub>N</sub>Ar with 2,5-dichloro-4-nitropyrimidine to give <b>13a</b>–<b>g</b>. Reductive heterocyclization using iron and acetic acid formed the dihydropteridinone scaffold (<b>14a</b>–<b>g</b>), which was methylated to give intermediates <b>15a</b>–<b>g</b>. The final step was acid-promoted S<sub>N</sub>Ar between intermediates <b>15a</b>–<b>g</b> and anilines <b>5a</b>, <b>5b</b>, <b>10a</b>, and <b>10b</b> to yield final compounds <b>16a</b>–<b>l</b>. Hydrogenation of compounds <b>16f</b> and <b>16h</b> to remove the bromine yielded compounds <b>16g</b> and <b>16i</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, NaOAc, 1,2-dichloroethane (DCE), rt, 16 h, 39–94%; (b) 2,4-dichloronitropyrimidine, NaHCO<sub>3</sub>, cHex, 16 h, 50 °C, 34–90%; (c) Fe, AcOH, 3–4 h, 70 °C, 25–42%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 59–75%; (e) conc. HCl, EtOH/dioxane/H<sub>2</sub>O, 1:1:1, 120 °C, 24–48 h, 7–53%; (f) H<sub>2</sub>, 10% Pd·C, MeOH, rt, 1 h, 41–46%.</p></p></figure><div class="NLM_p">A key obstacle to preparing a significant number of analogues at the R<sup>2</sup> position was that this substituent was introduced early and preparation of each example required five steps (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). To our surprise, there was no precedent for synthetic routes for late stage variation at this position. To facilitate preparation of these derivatives, we developed an alternative approach. This approach maintained many elements of the initial route (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) but started with a dimethoxybenzyl (DMB) protecting group at the R<sup>2</sup> position. This strategy allowed us to remove the DMB group by refluxing the advanced intermediate (<b>20</b>) in trifluoroacetyl (TFA) and to subsequently introduce a wide range of R<sup>2</sup> groups. A key challenge was that the reductive cyclization step on intermediate <b>18</b> employing iron and acetic acid partially removed the DMB group. We tested a range of hydrogenation conditions and, gratifyingly, PtO<sub>2</sub> and VO(acac)<sub>2</sub> gave an excellent yield of 98%.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This route enabled us to prepare the key intermediate <b>21</b> on a multigram scale and convert it into a range of final products (<b>23a</b>–<b>f</b>) in only two steps. Chiral shift NMR and chiral high-performance liquid chromatography (HPLC) confirmed that no racemization took place under either the strongly basic or strongly acidic conditions. However, on a later repeat of this synthesis, we observed that epimerization could occur during the alkylation of <b>19</b> to yield <b>20</b>. Reanalysis of previous batches confirmed that no epimerization was observed in the synthesis of the batch used to prepare the compounds described in this article (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Figure 1</a>). Furthermore, we reanalyzed products of reactions obtained under similar alkylating conditions (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), confirming that racemization had not occurred here either. All final products described here were thus unaffected by the epimerization. However, due to the potential for racemization, we sought to reoptimize this step. By reducing the number of equivalents of sodium hydride or replacing this with a weaker base such as sodium hydroxide, enantiomeric ratios of 9:1 or greater could be obtained.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, NaOAc, DCE, rt, 16 h, 97%; (b) 2,4-dichloronitropyrimidine, NaHCO<sub>3</sub>, cHex, 16 h, 50 °C, 78%; (c) H<sub>2</sub>, PtO<sub>2</sub>, VO(acac)<sub>2</sub>, tetrahydrofuran (THF), 98%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 86%; (e) TFA, 80 °C, 4 h, 66%; (f) R<sup>2</sup>–X, NaH, DMF, rt, 16 h, 37–68%; (g) conc. HCl, EtOH/dioxane/H<sub>2</sub>O, 1:1:1, 120 °C, 24–48 h, 9–32%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Biological Testing</h3><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows the derivatives of BI-2536, modifying the R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> positions, and their activities at ALK<sup>F1174L</sup>, BRD4, and PLK-1. The primary assays for biochemical testing were LanthaScreen for ALK<sup>F1174L</sup> and thermal shift against BRD4 (10 μM compound concentration). For selected compounds, this was followed by isothermal calorimetry against BRD4 and/or a PLK-1 Z-Lyte assay.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationships of the R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> Groups</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data represents the geometric mean; see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 1</a> for full statistics. n.d. = not determined.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last"><i>T</i><sub>m</sub> shift determined at compound concentration of 10 μM, <i>n</i> = 2.</p></div></div><div></div></div><div class="NLM_p">We started by analyzing the effect of the amide functionality in the solvent channel group (R<sup>4</sup>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d). Removal of the amide group (compound <b>16a</b>) had little effect against ALK<sup>F1174L</sup> and BRD4 potency. However, consistent with our hypothesis, it significantly decreased PLK-1-1 activity. Based on the measured IC<sub>50</sub> value of 2.6 nM, <b>16a</b> showed a four-fold reduction in potency against PLK-1. The real effect on PLK-1 potency of this structural change may be significantly greater, however, as the potency of BI-2536 is below the dynamic range of our assay. Next, we analyzed the effect of the R<sup>3</sup> substituent (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d) and prepared analogues with an ethoxy and an isobutoxy group at this position. The ethoxy group on compound <b>16c</b> gave a small reduction in potency against ALK<sup>F1174L</sup> but a greater decrease in PLK-1 potency. An increase in the size of the group further to a butoxy group (compound <b>16b</b>) resulted in a much larger drop in potency against ALK<sup>F1174L</sup>. For BRD4, increasing the group to ethoxy and isobutoxy gave only a small decrease in activity, confirming the tolerance of larger groups at this position. Compound <b>16c</b> provided the best balance of potency and selectivity thus far, so the ethoxy group was maintained.</div><div class="NLM_p">We started testing the effect of the R<sup>1</sup> group by removing the (<i>R</i>)-ethyl group (<b>16e</b>). This removal reduced potency at BRD4 and PLK-1 very likely due to the loss of favorable interactions with the aforementioned pockets in BRD4 and PLK-1. Similarly, removal of the (<i>R</i>)-Et group also reduced ALK<sup>F1174L</sup> potency 3-fold. We also synthesized the opposite enantiomer <b>16d</b>, which also significantly reduced potency at all three targets. The reduction in PLK-1 and BRD4 activity was not in agreement with a published study but consistent with loss of productive interactions of the (<i>R</i>)-Et group with both PLK-1 and BRD4 and supported by modeling, which suggests that the ethyl group is too big to be accommodated on the lower face of the PLK-1 pocket. Finally, we analyzed substitution at the R<sup>2</sup> position. Compounds <b>16f</b> and <b>16g</b> with a 3-bromobenzyl and benzyl group, respectively, maintained BRD4 activity and led to a 30–40-fold decrease of the PLK-1 activity, as expected from previous reports.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compounds <b>16f</b> and <b>16g</b> were equipotent in ALK<sup>F1174L</sup> activity, compared with <b>16c</b>. Importantly, the divergent SAR between ALK and PLK-1 with <b>16f</b> and <b>16g</b> supported our hypothesis that it is possible to optimize the ALK/PLK-1 selectivity window at the R<sup>2</sup> position.</div><div class="NLM_p last">To conclude this initial SAR investigation, we combined modifications that showed a decrease in PLK-1 potency. Compounds <b>16h</b> and <b>16i</b> with the combined modifications of the benzyl or 3-bromobenzyl group at R<sup>2</sup>, ethoxy group at R<sup>3</sup>, and removal of the amide at R<sup>4</sup> gave a greater decrease in PLK-1 activity (>100–200-fold). With benzyl compound <b>16i</b>, we also saw a 2-fold increase in ALK<sup>F1174L</sup> potency and maintained potent BRD4 activity. This was the first analogue demonstrating greater potency at ALK<sup>F1174L</sup> than at PLK-1.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> R<sup>2</sup> SAR</h3><div class="NLM_p">So far, the greatest change in PLK-1 activity resulted from modifying the cyclopentyl to a benzyl or 3-bromobenzyl group (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further inspection of this region in ALK and PLK-1 structures shows that PLK-1 has a larger phenylalanine residue (Phe183) at the bottom of this pocket compared with a smaller leucine residue (Leu1286) in ALK (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,b). We hypothesized that PLK-1 inhibition would be less tolerant to substitution at the R<sup>2</sup> position due to this geometric constraint compared to that in the more open ALK structure. To investigate this hypothesis further, we performed docking studies of 3-bromobenzyl analogue <b>16h</b> in PLK-1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). The aminopyrimidine moiety was still predicted to bind to the hinge region including Cys133, but a shift in the core was observed. Additionally, the core of the molecule adopts a more strained, puckered conformation. Both differences from the observed binding mode were likely caused by clashes of the bromobenzyl group with the side chain of Phe183 and were consistent with the decrease in activity observed with benzyl analogues <b>16f</b>–<b>i</b>. We thus decided to explore if this key amino acid difference can be exploited to discover compounds with improved ALK potency and PLK-1 selectivity.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Surfaces of (a) ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>) and (b) PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>) highlighting residues Leu1256 and Phe183. (c) Docking pose generated using Glide showing <b>16h</b> (orange) in complex with PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>), overlaid with X-ray structure of BI-2536 (yellow) in PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To enable structure-based design, we attempted to solve cocrystal structures of our compounds bound to ALK. However, these attempts failed, likely due to the still modest activity. Due to the lack of structural information, we decided to probe the ALK pocket through systematic synthesis and testing.</div><div class="NLM_p">Using the modified route in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> to facilitate preparation of analogues at the R<sup>2</sup> position, we prepared compounds <b>23a</b>–<b>c</b> to analyze the effect of different substitutions at the 3-benzyl position. While these compounds maintained the BRD4 activity, we did not observe improvements in ALK<sup>F1174L</sup> potency or PLK-1 selectivity, aside from compound <b>23b</b> that contains a 3-cyanobenzyl group. The PLK-1 IC<sub>50</sub> was 1.8 μM, a >700-fold decrease from starting compound BI-2536, leading to an improved (5-fold) ALK selectivity over PLK-1. Compound <b>23b</b> demonstrated that PLK-1 activity can be substantially reduced by varying this position, but we were still yet to find a group that achieved this while maintaining or improving ALK<sup>F1174L</sup> potency. Next, we considered changing the substitution position on the benzyl ring. However, the <i>ortho-</i> and <i>para-</i>bromobenzyls <b>23d</b> and <b>23e</b> showed no improvement in ALK<sup>F1174L</sup> potency compared with meta-analogue <b>16h</b> and were still not as potent as unsubstituted benzyl analogue <b>16i</b>.</div><div class="NLM_p">We then considered heterocycle substituents. Thiazole <b>23f</b> showed a decrease in ALK<sup>F1174L</sup> activity, but exploring thiophenes proved to be more productive. Compound <b>16j</b> gave encouraging IC<sub>50</sub>s against ALK<sup>F1174L</sup> and BRD4, yet the ALK/PLK ratio dropped to 1:1. Following from this result, we moved the methyl group around the thiophene ring. Derivative <b>16k</b> with the methyl group at the 4-position showed potent inhibition of ALK<sup>F1174L</sup> (IC<sub>50</sub> = 17 nM) and through this gain in potency also a 7-fold selectivity window over PLK-1. Gratifyingly, the compound retained BRD4 activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationships of the R<sup>2</sup> Group<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data represents the geometric mean; see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 2</a> for full statistics. n.d. = not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Final compounds synthesized using <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>T</i><sub>m</sub> shift determined at compound concentration of 10 μM, <i>n</i> = 2.</p></div></div><div></div></div><div class="NLM_p">We next determined the cocrystal structures of <b>16i</b> and <b>16k</b> with BRD4 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 3</a>). The compounds bound into the acetyllysine-binding site with the methyl amide moiety retaining the key hydrogen bond interaction with asparagine N140. The methyl amide and pyrimidine moieties in both compounds retain interactions with conserved waters in the BRD4 pocket, whereas the thiophene and benzyl R<sup>2</sup> substituents are situated in the hydrophobic WPF shelf region.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Cocrystal structure of <b>16i</b> with BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y">6Q3Y</a>) and associated |2<i>F</i><sub>O</sub>| – |<i>F</i><sub>C</sub>| refined electron density map contoured at 1σ. (b) Cocrystal structure of <b>16k</b> with BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z">6Q3Z</a>) and associated |2<i>F</i><sub>O</sub>| – |<i>F</i><sub>C</sub>| refined electron density map contoured at 1σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With compound <b>16k</b>, we had a compound in hand that showed satisfactory IC<sub>50</sub>s against ALK<sup>F1174L</sup> and BRD4 and a selectivity window over PLK-1. We decided to profile <b>16k</b> further by examining the physicochemical properties and broader kinase and bromodomain selectivity. Lipophilicity was measured using the SiriusT3 potentiometric method, giving a high log <i>P</i> of 6.1 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It is notable that the measured log <i>D</i><sub>7.4</sub> of 4.2 is significantly lower due to protonation of the piperidine basic center, which can also account for the good solubility. In addition, the compound shows good permeability as measured in a PAMPA permeability assay.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Physicochemical Properties of <b>16k</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (HPLC)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">90 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA pH<sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">49 × 10<sup>–6</sup> cm/s</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>P</i></td><td class="colsep0 rowsep0" align="left">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">4.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Solubility measured via an in-house HPLC method from phosphate buffer at pH 7.4.</p></div></div></div><div class="NLM_p">Next, we considered the broader kinase and bromodomain selectivity of <b>16k</b> to assess if the compound maintained the selectivity across both protein families. Compound <b>16k</b> was first tested against a panel of BET and non-BET bromodomains. In this panel, <b>16k</b> exhibited excellent BET family selectivity, in common with BI-2536 and other BET inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 4</a>).<a onclick="showRef(event, 'ref14 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref14 ref33 ref34">(14,33,34)</a> We then tested <b>16k</b> against the DiscoverX <i>scan</i>EDGE panel of 97 kinases at a single point concentration of 1 μM.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Gratifyingly, only four kinases were identified as hits, confirming that we had maintained broad kinome selectivity; the greatest inhibition was observed for ALK wild type (WT) and PLK-1 followed by insulin receptor (INSR) and PLK-3 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). We attributed the observed broad kinase selectivity of <b>16k</b> at least partially to be due to the ethoxy group.<a onclick="showRef(event, 'ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref27">(21,27)</a> This was based on the observation that the kinases that showed significant inhibition (ALK, PLK-1, PLK-3, and INSR) indeed feature a smaller leucine residue in the hinge region that can accommodate the ethoxy group (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 5</a>).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Screening of <b>16k</b> against a panel of 25 bromodomains, showing Δ<i>T</i><sub>m</sub> as circles. Larger circles indicate greater Δ<i>T</i><sub>m</sub>. (b) Screening of <b>16k</b> against the DiscoverX <i>scan</i>EDGE panel of 97 kinases at a single point concentration of 1 μM. Larger circles indicate a stronger hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>K</i><sub>d</sub>s of <b>16k</b> against the Kinase Screening Hits</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">hits at 1 μM (% control)</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK WT</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="char" char=".">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INSR</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLK-1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLK-3</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK<sup>F1174L</sup></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Demonstrating Target Engagement in Cells</h3><div class="NLM_p">We next tested our lead compounds in the cellular context to confirm that we had on-target engagement of ALK and BRD4 in cells. We first tested the effect of compound <b>16k</b> on autophosphorylation of the ALK<sup>F1174L</sup> mutant in Kelly neuroblastoma cells using an meso-scale discovery (MSD) assay (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). For comparison, we also tested our starting point BI-2536 and the Food and Drug Administration-approved ALK inhibitor ceritinib<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> as a positive control. Compound <b>16k</b> showed inhibition of ALK<sup>F1174L</sup> phosphorylation levels, in line with what was expected from the biochemical IC<sub>50</sub> and representing a significant improvement from starting compound BI-2536.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ALK MSD immunoassay measuring ALK phosphorylation in the Kelly cell line. The plot shows the ratio of phosphorylated ALK to total ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also measured the cellular potency of our lead compounds against BRD4 and ALK WT using NanoBRET assays (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 6</a>). Compound <b>16k</b> showed a cellular potency of 470 nM against ALK WT and 260 nM against BRD4. The BRD4 cellular potency was comparable to that of starting compound BI-2536, consistent with the compound’s minimal disruption to the key interactions with the BRD4 pocket. The results of the ALK autophosphorylation assay and NanoBRET experiments demonstrated that <b>16k</b> inhibited both ALK<sup>F1174L</sup> and BRD4 in cells.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. NanoBRET data for lead compounds <b>16i</b>–<b>k</b> against ALK and BRD4 in HEK293T cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cellular Kinase Selectivity</h3><div class="NLM_p">The observation that the biochemical potency of <b>16k</b> translated efficiently into cellular assays with a relatively minor drop-off consistent with other ALK inhibitors prompted us to investigate the selectivity against PLK-1 in cells. Despite very good overall selectivity in the DiscoverX scan, <b>16k</b> showed similar <i>K</i><sub>d</sub>s for the ALK<sup>F1174L</sup> mutant and PLK-1 (23 vs 11 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). However, given the small cellular drop-off for ALK mentioned above, we speculated that a larger drop-off for PLK-1 may lead to a better selectivity window. To investigate this hypothesis, we investigated markers of PLK-1 inhibition in cells, namely, mitotic arrest in the G2/M phase and increased concentrations of PLK-1, cyclin B1, and phosphohistone H3. Indeed, BI-2536 has been published to show effects on these markers at concentration around 50 nM, which is a 250-fold drop-off from its <i>K</i><sub>d</sub> of 0.19 nM.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> As compound <b>16k</b> is structurally similar to BI-2536, we would expect to see a similar potency drop-off in cells, in this case to >2.5 μM. To assess the cellular selectivity, we assessed the effect of compounds <b>16k</b> and BI-2536 on HeLa cells. Consistent with data mentioned above, BI-2536 induced mitotic arrest and increased concentrations of PLK-1, cyclin B1, and phosphohistone H3 at a concentration as low as 50 nM (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In addition, we observed an increase in PLK-1 phosphorylation at sites T210 and S137. In strong contrast, compound <b>16k</b> did not cause an increase in levels of these mitotic markers and phosphorylation sites up to concentrations of 10 μM and thus well beyond the concentration where ALK<sup>F1174L</sup> and BRD4 are inhibited in the cellular context. Quantitative analysis of the cell cycle distribution by flow cytometry supported the data obtained by Western blot analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Figure 2</a>).</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Induction of mitotic arrest by BI-2536 and <b>16k</b> in HeLa cells. Changes in the fraction of cells arrested in mitosis were analyzed by Western blots against phosphorylation sites pT210 and pS137 and mitotic markers PLK-1, cyclin B1, and phosphohistone H3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Based on the cellular data, the combination of the reduction in PLK-1 activity and the improvement in ALK<sup>F1174L</sup> activity thus resulted in a >10–20-fold selectivity window for ALK<sup>F1174L</sup> over PLK-1 in cells. Compound <b>16k</b> thus represented a significant step toward discovering drugs that concomitantly target mutant ALK and BRD4.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To our knowledge, we report the first combined ALK–BRD4 inhibitor (<b>16k</b>). Moreover, our work is one of the few examples where medicinal chemistry design was applied to combine inhibition of a specific kinase (in this case ALK) with BRD4 inhibition to discover a dual inhibitor for a clearly defined therapeutic hypothesis.</div><div class="NLM_p">We started from the known dual inhibitor BI-2536 that inhibits PLK-1 and BRD4. Interestingly, although tuning the PLK-1 and BRD4 activity of BI-2536 has been disclosed, changing the kinase activity to another target and hence to a new dual kinase–bromodomain combination has not been reported.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Exploring a structure-based design, we discovered compounds with significantly improved ALK activity and greatly reduced PLK-1 activity while maintaining BRD4 potency and overall kinome selectivity. Our lead compound demonstrates on-target engagement of ALK and BRD4 in cellular assays and favorable broad kinase and bromodomain selectivity. In particular, the compound showed selectivity over PLK-1 in cells underlining the design effort to change the kinase selectivity from PLK-1 to ALK.</div><div class="NLM_p">Our work also highlighted the well-known challenges of designing and discovering dual inhibitors that inhibit two, structurally distinct proteins. A particular challenge is to incorporate two distinct pharmacophores that ensure not only potent inhibition of both targets but also selectivity within these protein families (in our case, kinases and bromodomains) into one druglike compound.</div><div class="NLM_p">Despite these challenges, we achieved significant steps toward a dual ALK and BRD4 inhibitor. Key to this progress was choosing a starting point that contained an alkoxy group that is tolerated only by a few kinases including ALK and PLK-1. By maintaining this throughout, we achieved a compound with satisfactory overall kinome selectivity.</div><div class="NLM_p">Our main optimization goal starting from BI-2536 was to significantly improve ALK activity and PLK-1 selectivity. The challenge here was that key regions of BI-2536 had to remain untouched to maintain the BRD4 activity. In particular, the methyl substituent that points toward the gatekeeper and the ethyl group would have been promising places to improve activity for ALK and selectivity over PLK-1. However, both moieties are essential for potent binding to BRD4 and could hence not be changed. Crucially, our structure-based analysis also suggested that the R<sup>2</sup> substituent can be modified without losing BRD4 activity and that optimizing this part of the molecule was a promising approach to achieve our goal of shifting kinase selectivity, as exemplified by <b>16k</b>.</div><div class="NLM_p last">We thus conclude that, not surprisingly, the quality and properties of the selected starting point matter even more for programs aiming at dual inhibitors since the options for chemical optimization will be significantly more limited. Directly related to that, the challenge of discovering dual inhibitors is somewhat less daunting when both targets tolerated a range of different chemotypes and inhibitors, thus increasing the chance that a starting point with already favorable properties can be explored.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Synthetic Information</h3><div class="NLM_p">All anhydrous solvents and reagents were obtained from commercial suppliers and used without further purification. All reactions were carried out under a positive pressure of N<sub>2</sub>, and moisture-sensitive reagents were transferred via a syringe. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure at a bath temperature of up to 60 °C. Column chromatography was carried out using a Biotage SP4 purification system using Biotage SNAP Kp-Si cartridges. Semipreparative separations were carried out using a 1200 series preparative HPLC over a 15 min gradient elution (Grad15min20mls.m) from 90:10 to 0:100 water/methanol (both modified with 0.1% formic acid) at a flow rate of 20 mL/min. Microwave-assisted reactions were carried out using a Biotage Initiator microwave system. In general, the course of reactions was followed by thin layer chromatography or mass spectroscopy. All final compounds were purified to ≥95% purity.</div><div class="NLM_p">NMR spectra were recorded on a Bruker AMX 500 (500 MHz) spectrometer using a deutrated solvent. NMR data is presented in the form of chemical shift δ (multiplicity, coupling constants, and integration) for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane as an internal standard. High-resolution mass spectrometry (HRMS) was assessed using an Agilent 1200 series HPL and diode array detector coupled to a 6120 time-of-flight mass spectrometer with a dual multimode atmospheric-pressure chemical ionization/electrospray ionization (ESI) source. Analytical separation was carried out at 30 °C on a Merck Purospher STAR column (RP-18e, 30 × 4 mm<sup>2</sup>) using a flow rate of 1.5 mL/min in a 4 min gradient elution; solvents: aqueous (0.1% formic aid) and methanol, monitored at a wavelength of 254 nm. Optical rotation was determined by an ADP 440 polarimeter. Specific rotations [α]<sub>D</sub> are given in deg cm<sup>3</sup>/(g dm).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Methyl 3-Isobutoxy-4-nitrobenzoate (2)</h4><div class="NLM_p last">Step 1: 3-Hydroxy-4-nitrobenzoic acid <b>1</b> (500 mg, 2.73 mmol) was suspended in MeOH (0.1 M), and SOCl<sub>2</sub> (0.40 mL, 5.46 mmol) was added slowly at 0 °C. The reaction was heated at reflux for 4 h. Upon completion, the volatiles were removed in vacuo and the residue was triturated with diethyl ether. The resulting solid was filtered and dried under vacuum to afford methyl 3-hydroxy-4-nitrobenzoate (HCl salt) as a yellow solid (576 mg, 90%). δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 10.51 (s, 1H), 8.18 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (d, <i>J</i> = 1.6 Hz, 1H), 7.62 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 3.97 (s, 3H). Step 2: To the crude product in DMF (0.1 M) was added K<sub>2</sub>CO<sub>3</sub> (592 mg, 4.28 mmol) and 1-iodo-2-methylpropane (142 μL, 1.20 mmol), and the reaction was stirred at 50 °C for 16 h. Upon completion, EtOAc was added and the mixture was washed with water (×2) and brine (×1), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (cHex/EtOAc, 0–20%) to afford <b>2</b> as a colorless oil (158 mg, 0.62 mmol 73%). δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.81 (d, <i>J</i> = 8.2 Hz, 1H), 7.71 (d, <i>J</i> = 1.6 Hz, 1H), 7.67–7.64 (m, 1H), 3.96 (s, 3H), 3.92 (d, <i>J</i> = 6.3 Hz, 1H), 2.20–2.11 (m, 1H), 1.05 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 3-Isobutoxy-4-nitrobenzoic Acid (3a)</h4><div class="NLM_p last">To <b>2</b> (150 mg, 0.59 mmol) in a solvent mixture of THF/H<sub>2</sub>O (1:1, 0.1 M) was added LiOH (142 mg, 5.92 mmol), and the reaction was stirred for 18 h. Upon completion, the aqueous layer was acidified with 1 M HCl until pH 1 was reached and extracted with EtOAc (×3). The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford <b>3a</b> as a yellow solid (100 mg, 0.42 mmol, 71%). δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.85 (d, <i>J</i> = 8.2 Hz, 1H), 7.79 (d, <i>J</i> = 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 3.95 (d, <i>J</i> = 6.3 Hz, 1H), 2.23–2.14 (m, 1H), 1.08 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 3-Isobutoxy-<i>N</i>-(1-methylpiperidin-4-yl)-4-nitrobenzamide (<b>4a</b>)</h4><div class="NLM_p last">To a solution of <b>3a</b> (50 mg, 0.21 mmol) in DMF (0.1 M) was added HBTU (127 mg, 0.33 mmol), Et<sub>3</sub>N (58 μL, 0.41 mmol), and 1-methylpiperidin-4-amine (23.9 mg, 0.21 mmol), and the reaction was stirred for 18 h. Upon completion, the reaction mixture was partitioned between EtOAc and water and the aqueous layer was extracted with EtOAc (×2). The organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (dichloromethane (DCM)/MeOH, 0–10%) to afford <b>4a</b> as a yellow solid (60 mg, 0.18 mmol, 86%). HRMS (ESI +ve): found [M]<sup>+</sup> 336.1927, [C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub>]<sup>+</sup> requires 336.1923; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>) 7.81 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 1.6 Hz, 1H), 7.28 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 6.44 (d, <i>J</i> = 7.6 Hz, 1H), 4.06–3.97 (m, 1H), 3.92 (d, <i>J</i> = 6.3 Hz, 2H), 2.94 (d, <i>J</i> = 11.7 Hz, 2H), 2.37 (s, 3H), 2.30–2.25 (m, 2H), 2.18–2.10 (m, 1H), 2.09–2.03 (m, 2H), 1.78–1.69 (m, 2H), 1.04 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 3-Ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)-4-nitrobenzamide (<b>4b</b>)</h4><div class="NLM_p last"><b>4b</b> was synthesized in 77% yield (orange solid, 111 mg, 0.36 mmol) according to the same procedure as <b>4a</b>, from <b>3b</b> (100 mg, 0.47 mmol) and 1-methylpiperidin-4-amine (54.1 mg, 0.47 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 308.1624 [C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>]<sup>+</sup> requires 308.1610; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.82 (d, <i>J</i> = 8.2 Hz, 1H), 7.58 (d, <i>J</i> = 1.9 Hz, 1H), 7.23 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 5.99 (d, <i>J</i> = 7.3 Hz, 1H), 4.26 (q, <i>J</i> = 7.2 Hz, 2H), 4.05–3.94 (m, 1H), 2.87 (d, <i>J</i> = 11.2 Hz, 2H), 2.33 (s, 3H), 2.19 (t, <i>J</i> = 11.2 Hz, 2H), 2.10–2.03 (m, 2H), 1.65–1.56 (m, 2H), 1.49 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-Amino-3-isobutoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>5a</b>)</h4><div class="NLM_p last"><b>4a</b> (60 mg, 0.18 mmol) was dissolved in a solvent mixture of EtOAc/EtOH (10:3, 0.1 M) to which tin(II) chloride dihydrate (202 mg, 0.89 mmol) was added. The reaction was stirred for 16 h at 50 °C. Upon completion, NaHCO<sub>3</sub> was added and the aqueous layer was extracted with EtOAc (×3). The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford <b>5a</b> as a yellow solid (30 mg, 99 μmol, 55%). HRMS (ESI +ve): found [M]<sup>+</sup> 306.22161, [C<sub>17</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup> requires 306.2176; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>) 7.32 (d, <i>J</i> = 1.9 Hz, 1H), 7.10 (d, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.66 (d, <i>J</i> = 8.2 Hz, 1H), 5.86 (d, <i>J</i> = 6.3 Hz, 1H), 4.12 (s, 2H), 4.02–3.92 (m, 1H), 3.83 (d, <i>J</i> = 6.3 Hz, 2H), 2.83 (d, <i>J</i> = 11.0 Hz, 2H), 2.31 (s, 3H), 2.22–2.09 (m, 3H), 2.07–2.00 (m, 2H), 1.57 (qd, <i>J</i> = 11.7, 3.6 Hz, 2H), 1.04 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-Amino-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>5b</b>)</h4><div class="NLM_p last"><b>5b</b> was synthesized in 53% yield (yellow solid, 46 mg, 0.16 mmol) according to the same procedure as <b>5a</b>, from <b>4b</b> (95 mg, 0.31 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 278.1874 [C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup> requires 278.1863; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>) 7.33 (d, <i>J</i> = 1.9 Hz, 1H), 7.11 (dd, <i>J</i> = 8.1, 1.9 Hz, 1H), 6.66 (d, <i>J</i> = 8.1 Hz, 1H), 5.86 (d, <i>J</i> = 7.3 Hz, 1H), 4.18–4.09 (m, 4H), 4.05–3.94 (m, 1H), 2.86 (d, <i>J</i> = 11.0 Hz, 2H), 2.33 (s, 3H), 2.23–2.18 (m, 2H), 2.04 (d, <i>J</i> = 10.4 Hz, 2H), 1.61–1.57 (m, 2H), 1.45 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-(3-Ethoxy-4-nitrophenyl)pyridine (7a)</h4><div class="NLM_p last">4-Bromo-2-ethoxy-1-nitrobenzene <b>6a</b> (1.5 g, 6.10 mmol), pyridine-4-ylboronic acid (749 mg, 6.10 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.1 g, 10.0 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (160 mg, 0.23 mmol) were dissolved in a solvent mixture of dioxane/water (6:1, 0.38 M) and heated at 110 °C for 45 min under microwave irradiation. Upon completion, the mixture was partitioned between EtOAc and water and the aqueous phase was extracted with EtOAc (×2) and DCM (×1). The organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (DCM/MeOH, 9:1) to afford <b>7a</b> as a yellow solid (81 mg, 3.32 mmol, 54%). HRMS (ESI +ve): found [M]<sup>+</sup> 245.0917 [C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 245.0921; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.74 (dd, <i>J</i> = 4.4, 1.19 Hz, 2H), 7.96 (d, <i>J</i> = 8.5 Hz, 1H), 7.49 (d, <i>J</i> = 4.4, 1.6 Hz, 2H), 7.27–7.24 (m, 2H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 1.53 (dt, <i>J</i> = 7.0 Hz, 3H)</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-(3-Methoxy-4-nitrophenyl)pyridine (7b)</h4><div class="NLM_p last"><b>7b</b> was synthesized in 65% yield (yellow solid, 200 mg, 0.87 mmol) according to the same procedure as <b>7a</b>, from 4-chloro-2-methoxy-1-nitrobenzene <b>6b</b> (250 g, 1.33 mmol) and pyridine-4-ylboronic acid (164 mg, 1.33 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 231.0803 [C<sub>12</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 231.0770; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.74–8.72 (dd, <i>J =</i> 4.4, 1.6 Hz, 2H), 7.99 (dd, <i>J</i> = 8.8 Hz, 1H), 7.51 (dd, <i>J</i> = 4.4, 1.6 Hz, 2H), 7.28–7.25 (m, 2H), 4.05 (s, 3H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(3-Ethoxy-4-nitrophenyl)-1-methylpyridin1-ium Iodide (8a)</h4><div class="NLM_p last"><b>7a</b> (600 mg, 2.47 mmol) and methyl iodide (0.54 mL, 8.65 mmol) were dissolved in acetonitrile (0.1 M), and the reaction was heated for 4 h at 50 °C. Upon completion, the mixture was concentrated in vacuo to afford <b>8a</b> as a yellow solid (945 mg, 2.45 mmol, 99%). HRMS (ESI +ve): found [M]<sup>+</sup> 259.1076 [C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 259.1082; δ<sub>H</sub> (500 MHz, MeOD<sub>4</sub>) 8.99 (d, <i>J</i> = 6.7 Hz, 2H), 8.48 (d, <i>J</i> = 6.7 Hz, 2H), 7.99 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (d, <i>J</i> = 1.8 Hz, 1H), 7.65 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 4.46 (s, 3H), 4.38 (q, <i>J</i> = 6.9 Hz, 2H), 1.49 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(3-Methoxy-4-nitrophenyl)-1-methylpyridin1-ium Iodide (8b)</h4><div class="NLM_p last"><b>8b</b> was synthesized in 91% yield (yellow solid, 295 mg, 0.79 mmol) according to the same procedure as <b>8a</b>, from <b>7b</b> (200 mg, 0.87 mmol) and methyl iodide (0.19 mL, 3.04 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 245.0920 [C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 245.0926; δ<sub>H</sub> (500 MHz, MeOD<sub>4</sub>) 8.99 (d, <i>J</i> = 6.7 Hz, 2H), 8.49 (d, <i>J</i> = 6.7 Hz, 2H), 8.01 (d, <i>J</i> = 8.2 Hz, 1H), 7.81 (d, <i>J</i> = 1.9 Hz, 1H), 7.66 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 4.45 (s, 3H), 4.10 (s, 3H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(3-Ethoxy-4-nitrophenyl)-1-methyl-1,2,3,6-tetrahydropyridine (9a)</h4><div class="NLM_p last"><b>8a</b> (945 mg, 2.45 mmol) was dissolved in MeOH (0.05 M) and cooled to 0 °C. NaBH<sub>4</sub> (943 mg, 24.5 mmol) was slowly added in batches, and the reaction was stirred at rt for 2 h. The reaction was quenched with 1 M HCl, and MeOH was partially removed in vacuo. The residue was partitioned between EtOAc and 1 M NaOH until pH 12 was reached. The EtOAc layer was washed with 1 M NaOH, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give <b>9a</b> as a yellow oil (609 mg, 2.32 mmol, 95%). HRMS (ESI +ve): found [M]<sup>+</sup> 263.1387 [C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 263.1390; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.85 (d, <i>J</i> = 8.5 Hz, 1H), 7.04–7.00 (m, 2H), 6.21–6.18 (m, 1H), 4.20 (q, <i>J</i> = 6.9 Hz, 2H), 3.17–3.14 (m, 2H), 2.69 (t, <i>J</i> = 5.7 Hz, 2H), 2.60–2.56 (m, 2H), 2.43 (s, 3H), 1.49 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-(3-Methoxy-4-nitrophenyl)-1-methyl-1,2,3,6-tetrahydropyridine (9b)</h4><div class="NLM_p last"><b>9b</b> was synthesized in 56% yield (yellow oil, 80 mg, 0.32 mmol) according to the same procedure as <b>9a</b>, from <b>8b</b> (212 mg, 0.57 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 245.1239 [C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> requires 249.1243; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.85 (d, <i>J</i> = 8.5 Hz, 1H), 7.04 (d, <i>J</i> = 1.9 Hz, 1H), 7.02 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 6.20 (tt, <i>J</i> = 3.5, 1.6 Hz, 1H), 3.96 (s, 3H), 3.16 (d, <i>J</i> = 2.85 Hz, 2H), 2.71–2.67 (m, 2H), 2.60–2.56 (m, 2H), 2.42 (s, 3H).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Ethoxy-4-(1-methylpiperidin-4-yl)aniline (10a)</h4><div class="NLM_p last"><b>9a</b> (600 mg, 2.32 mmol) and PtO<sub>2</sub> (158 mg, 0.70 mmol) were dissolved in acetic acid (0.03 M), and the mixture was purged with N<sub>2</sub>. The mixture was placed under 50 psi of H<sub>2</sub> gas at rt for 16 h. The mixture was filtered through celite, washed with MeOH, and concentrated in vacuo. The residue was purified by Biotage column chromatography (DCM/MeOH, 9:1) to afford <b>10a</b> as an orange oil (410 mg, 1.75 mmol, 75%). HRMS (ESI +ve): found [M]<sup>+</sup> 235.1819 [C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O]<sup>+</sup> requires 235.1809; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>) 6.68–6.60 (m, 3H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.20 (d, <i>J</i> = 11.7 Hz, 2H), 2.46–2.38 (4H, m) 2.29 (td, <i>J</i> = 11.7, 2.5 Hz, 2H), 1.99–1.89 (m, 2H), 1.88–1.82 (m, 2H), 1.42 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Methoxy-4-(1-methylpiperidin-4-yl)aniline (10b)</h4><div class="NLM_p last"><b>10b</b> was synthesized in 85% yield (yellow oil, 30 mg, 0.14 mmol) according to the same procedure as <b>10a</b>, from <b>9b</b> (600 mg, 2.32 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 221.1649 [C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O]<sup>+</sup> requires 221.1648; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>) 6.65–6.61 (m, 3H), 3.83 (s, 3H), 3.08 (dt, <i>J</i> = 12.1, 2.5 Hz, 2H), 2.46–2.37 (m, 1H), 2.38 (s, 3H), 2.16 (td, <i>J</i> = 12.1, 4.1 Hz, 2H), 1.91–1.81 (m, 4H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-Methyl 2-(Cyclopentylamino)butanoate (<b>12a</b>)</h4><div class="NLM_p last">(<i>R</i>)-Methyl 2-aminobutanoate <b>11a</b> (HCl salt, 1.50 g, 9.77 mmol) and cyclopentanone (0.87 mL, 9.77 mmol) were dissolved in DCE (0.1 M). The reaction was cooled to 0 °C, and NaOAc (801 mg, 9.77 mmol) and NaBH(OAc)<sub>3</sub> (4.14 g, 19.5 mmol) were added. The reaction was stirred at rt for 16 h. Upon completion, sat. NaHCO<sub>3</sub> was added and the aqueous phase was extracted with DCM (×3). The combined organic phases were washed with water, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford compound <b>12a</b> as a yellow oil (1.45 g, 7.83 mmol, 80%). HRMS (ESI +ve): found [M]<sup>+</sup> 186.1498, [C<sub>10</sub>H<sub>20</sub>NO<sub>2</sub>]<sup>+</sup> requires 186.1494; [α]<sub class="stack">D</sub><sup class="stack">21.8</sup>: −12.0 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 3.73 (s, 3H), 3.22 (t, <i>J</i> = 6.6 Hz, 1H), 2.97 (quin, <i>J</i> = 6.7 Hz, 1H), 1.83–1.60 (m, 6H), 1.55–1.47 (m, 2H), 1.35–1.27 (m, 2H), 0.92 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-Methyl 2-(Cyclopentylamino)butanoate (<b>12b</b>)</h4><div class="NLM_p last"><b>12b</b> was synthesized in 88% yield (brown oil, 1.42 g, 7.68 mmol) according to the same procedure as <b>12d</b>, from (<i>S</i>)-methyl 2-aminobutanoate <b>11b</b> (HCl salt, 1.34 g, 8.72 mmol) and cyclopentanone (0.78 mL, 8.72 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 186.1498, [C<sub>10</sub>H<sub>20</sub>NO<sub>2</sub>]<sup>+</sup> requires 186.1494; [α]<sub class="stack">D</sub><sup class="stack">21.9</sup>: +11.8 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 3.71 (s, 3H), 3.20 (t, <i>J</i> = 6.6 Hz, 1H), 2.96 (quin, <i>J</i> = 6.7 Hz, 1H), 1.83–1.58 (m, 6H), 1.55–1.47 (m, 2H), 1.35–1.27 (m, 2H), 0.91 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Methyl Cyclopentylglycinate (12c)</h4><div class="NLM_p last"><b>12c</b> was synthesized in 39% yield (yellow oil, 535 mg, 3.40 mmol) according to the same procedure as <b>12d</b>, from glycine methyl ester <b>11c</b> (HCl salt, 1.10 g, 8.77 mmol) and cyclopentanone (0.62 mL, 7.01 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 158.1176, [C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub>]<sup>+</sup> requires 158.1176; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 3.73 (s, 3H), 3.42 (s, 2H), 3.07 (quin, <i>J</i> = 6.5 Hz, 1H), 1.85–1.77 (m, 2H), 1.75–1.66 (m, 2H), 1.60–1.50 (m, 2H), 1.40–1.32 (m, 2H).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-Methyl 2-((3-Bromobenzyl)amino)butanoate (<b>12d</b>)</h4><div class="NLM_p last"><b>12d</b> was synthesized in 92% yield (yellow oil, 1.37 g, 4.79 mmol) according to the same procedure as <b>12a</b>, from (<i>R</i>)-methyl 2-aminobutanoate <b>11a</b> (HCl salt, 800 mg, 5.21 mmol) and 3-bromobenzaldehyde (0.61 mL, 5.21 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 286.0431, [C<sub>12</sub>H<sub>17</sub>BrNO<sub>2</sub>]<sup>+</sup> requires 286.0437; [α]<sub class="stack">D</sub><sup class="stack">21.9</sup>: +22.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.52 (t, <i>J</i> = 1.6 Hz, 1H), 7.38 (dt, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.28–7.25 (m, 1H), 7.20–7.17 (m, 1H), 3.80 (d, <i>J</i> = 13.2 Hz, 1H), 3.74 (s, 3H), 3.60 (d, <i>J</i> = 13.2 Hz, 1H), 3.20 (t, <i>J</i> = 6.6 Hz, 1H), 1.76–1.62 (m, 2H), 0.96 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-Methyl 2-(((3-Methylthiophen-2-yl)methyl)amino)butanoate (<b>12e</b>)</h4><div class="NLM_p last"><b>12e</b> was synthesized in 74% yield (yellow oil, 720 mg, 3.17 mmol) according to the same procedure as <b>12d</b>, from (<i>R</i>)-methyl 2-aminobutanote <b>11a</b> (HCl salt, 500 mg, 4.27 mmol) and 3-methylthiophene-2-carbaldehyde (0.46 mL, 4.27 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 228.1061, [C<sub>11</sub>H<sub>18</sub>NO<sub>2</sub>S]<sup>+</sup> requires 228.1053; [α]<sub class="stack">D</sub><sup class="stack">22.6</sup>: +23.6 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.10 (d, <i>J</i> = 5.0 Hz, 1H), 6.78 (d, <i>J</i> = 5.4 Hz, 1H), 3.93 (d, <i>J</i> = 13.9 Hz, 1H), 3.76–3.73 (m, 4H), 3.27 (t, <i>J</i> = 6.6 Hz, 1H), 2.17 (s, 3H), 1.74–1.62 (m, 2H), 0.95 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-Methyl 2-(((4-Methylthiophen-2-yl)methyl)amino)butanoate (<b>12f</b>)</h4><div class="NLM_p last"><b>12f</b> was synthesized in 95% yield (yellow oil, 1.70 g, 7.48 mmol) according to the same procedure as <b>12d</b>, from (<i>R</i>)-methyl 2-aminobutanote <b>11a</b> (HCl salt, 1.20 mg, 7.81 mmol) and 4-methylthiophene-2-carbaldehyde (0.83 mL, 6.72 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 228.1062, [C<sub>11</sub>H<sub>18</sub>NO<sub>2</sub>S]<sup>+</sup> requires 228.1053; [α]<sub class="stack">D</sub><sup class="stack">22.5</sup>: +28.4 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 6.78 (t, <i>J</i> = 1.2 Hz, 1H), 6.73 (s, 1H), 3.98 (dd, <i>J</i> = 14.0, 0.8 Hz, 1H), 3.78 (dd, <i>J</i> = 14.0, 0.8 Hz, 1H), 3.74 (s, 3H), 3.29 (t, <i>J</i> = 6.5 Hz, 1H), 2.22 (d, <i>J</i> = 1.2 Hz, 3H), 1.74–1.62 (m, 2H), 0.95 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-Methyl 2-(((5-Methylthiophen-2-yl)methyl)amino)butanoate (<b>12g</b>)</h4><div class="NLM_p last"><b>12g</b> was synthesized in 77% yield (yellow oil, 892 mg, 3.92 mmol) according to the same procedure as <b>12d</b>, from (<i>R</i>)-methyl 2-aminobutanote <b>11a</b> (HCl salt, 600 mg, 5.12 mmol) and 5-methylthiophene-2-carbaldehyde (0.43 mL, 4.10 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 228.1049, [C<sub>11</sub>H<sub>18</sub>NO<sub>2</sub>S]<sup>+</sup> requires 228.1053; [α]<sub class="stack">D</sub><sup class="stack">22.2</sup>: +23.6 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 6.68 (d, <i>J</i> = 3.2 Hz, 1H), 6.58–6.55 (m, 1H), 3.95 (d, <i>J</i> = 13.9 Hz, 1H), 3.75 (d, <i>J</i> = 13.9 Hz, 1H), 3.73 (s, 3H), 3.28 (t, <i>J</i> = 6.6 Hz, 1H), 2.45 (s, 3H), 1.89 (s, 1H), 1.74–1.61 (m, 2H), 0.94 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)(cyclopentyl)amino)butanoate (<b>13a</b>)</h4><div class="NLM_p last"><b>12a</b> (700 mg, 3.78 mmol) and NaHCO<sub>3</sub> (635 mg, 7.6 mmol) were dissolved in cyclohexane (0.1 M) and stirred for 30 min. 2,4-Dichloro-5-nitropyrimidine (806 mg, 4.16 mmol) was added, and the reaction was stirred at 60 °C for 16 h. Upon completion, the reaction mixture was filtered, washed with CH<sub>2</sub>Cl<sub>2</sub>, and concentrated in vacuo. The residue was purified by Biotage column chromatography (cHex/EtOAc, 0–20%) to afford the title compound <b>13a</b> as a yellow solid (1.03 g, 2.99 mmol, 79%). HRMS (ESI +ve): found [M]<sup>+</sup> 343.1165, [C<sub>14</sub>H<sub>20</sub>ClN<sub>4</sub>O<sub>4</sub>]<sup>+</sup> requires 343.1173; [α]<sub class="stack">D</sub><sup class="stack">21.8</sup>: +228.5 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.67 (s, 1H), 3.78–3.72 (m, 1H), 3.76 (s, 3H), 3.60–3.52 (m, 1H), 2.47–2.36 (m, 1H), 2.26–2.17 (m, 1H), 2.09–1.98 (m, 1H), 1.98–1.91 (m, 1H), 1.84–1.56 (m, 6H), 1.05 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)(cyclopentyl)amino)butanoate (<b>13b</b>)</h4><div class="NLM_p last"><b>13b</b> was synthesized in 32% yield (yellow solid, 830 mg, 2.42 mmol) according to the same procedure as <b>13d</b>, from <b>12b</b> (1.40 g, 7.56 mmol) and 2,4-dichloro-5-nitropyrimidine (1.61 g, 8.31 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 343.1171, [C<sub>14</sub>H<sub>20</sub>ClN<sub>4</sub>O<sub>4</sub>]<sup>+</sup> requires 343.1173; [α]<sub class="stack">D</sub><sup class="stack">22.0</sup>: −229.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (CDCl<sub>3</sub>, 500 MHz): 8.67 (s, 1H), 3.78–3.72 (m, 1H), 3.76 (s, 3H), 3.60–3.51 (m, 1H), 2.46–2.36 (m, 1H), 2.25–2.17 (m, 1H), 2.09–2.01 (m, 1H), 1.99–1.90 (m, 1H), 1.84–1.47 (m, 6H), 1.05 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Methyl <i>N</i>-(2-Chloro-5-nitropyrimidin-4-yl)-<i>N</i>-cyclopentylglycinate (<b>13c</b>)</h4><div class="NLM_p last"><b>13c</b> was synthesized in 78% yield (yellow solid, 416 mg, 1.32 mmol) according to the same procedure as <b>13d</b>, from <b>12c</b> (265 mg, 1.69 mmol) and 2,4-dichloro-5-nitropyrimidine (360 mg, 1.85 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 315.0843, [C<sub>12</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>4</sub>]<sup>+</sup> requires 315.0860; δ<sub>H</sub> (CDCl<sub>3</sub>, 500 MHz): 8.65 (s, 1H), 4.17 (s, 2H), 3.98–3.88 (m, 1H), 3.79 (s, 3H), 2.16–2.07 (m, 2H), 1.78–1.70 (m, 2H), 1.64–1.53 (m, 4H).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-Methyl 2-((3-Bromobenzyl)(2-chloro-5-nitropyrimidin-4-yl)amino)butanoate (<b>13d</b>)</h4><div class="NLM_p last"><b>13d</b> was synthesized in 90% yield (yellow oil, 1.81 g, 4.08 mmol) according to the same procedure as <b>13a</b>, from <b>12d</b> (1.30 g, 4.54 mmol) and 2,4-dichloro-5-nitropyrimidine (970 mg, 5.00 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 443.0118, [C<sub>16</sub>H<sub>17</sub>BrClN<sub>4</sub>O<sub>4</sub>]<sup>+</sup> requires 443.0122; [α]<sub class="stack">D</sub><sup class="stack">22.0</sup>: +12.0 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.64 (s, 1H), 7.45 (s, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 1H), 7.23 (d, <i>J</i> = 7.8 Hz, 1H), 7.17–7.13 (m, 1H), 4.75 (d, <i>J</i> = 15.8 Hz, 1H), 4.73–4.68 (m, 1H), 4.59 (d, <i>J</i> = 15.8 Hz, 1H), 3.82 (s, 3H), 2.32–2.23 (m, 1H), 2.10–2.00 (m, 1H), 1.07 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((3-methylthiophen-2-yl)methyl)amino)butanoate (<b>13e</b>)</h4><div class="NLM_p last"><b>13e</b> was synthesized in 90% yield (yellow solid, 1.18 g, 3.07 mmol) according to the same procedure as <b>13d</b>, from <b>12e</b> (770 mg, 3.39 mmol) and 2,4-dichloro-5-nitropyrimidine (723 mg, 3.72 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 385.0732, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>4</sub>S]<sup>+</sup> requires 385.0732; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: +4.85 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.65 (s, 1H), 7.15 (d, <i>J</i> = 5.2 Hz, 1H), 6.70 (d, <i>J</i> = 5.2 Hz, H2), 4.92 (dd, <i>J</i> = 5.4, 4.1 Hz, 1H), 4.75 (s, 2H), 3.80 (s, 3H), 2.30–2.20 (m, 1H), 2.16 (s, 3H), 2.07–2.00 (m, 1H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>R</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((4-methylthiophen-2-yl)methyl)amino)butanoate (<b>13f</b>)</h4><div class="NLM_p last"><b>13f</b> was synthesized in 81% yield (yellow solid, 2.32 g, 6.03 mmol) according to the same procedure as <b>13d</b>, from <b>12f</b> (1.70 g, 7.48 mmol) and 2,4-dichloro-5-nitropyrimidine (1.60 g, 8.23 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 385.0738, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>4</sub>S]<sup>+</sup> requires 385.0732; [α]<sub class="stack">D</sub><sup class="stack">22.5</sup>: +5.54 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.70 (s, 1H), 6.82–6.81 (m, 1H), 6.71 (s, 1H), 4.95–4.80 (m, 3H), 3.82 (s, 3H), 2.32–2.22 (m, 1H), 2.18 (s, 3H), 2.09–2.00 (m, 1H), 1.07 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>R</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)((5-methylthiophen-2-yl)methyl)amino)butanoate (<b>13g</b>)</h4><div class="NLM_p last"><b>13g</b> was synthesized in 86% yield (yellow gum, 1.30 g, 3.38 mmol) according to the same procedure as <b>13d</b>, from <b>12g</b> (892 mg, 3.92 mmol) and 2,4-dichloro-5-nitropyrimidine (837 mg, 4.31 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 385.0732, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>4</sub>S]<sup>+</sup> requires 385.0732; [α]<sub class="stack">D</sub><sup class="stack">22.4</sup>: −2.78 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.68 (s, 1H), 6.67 (d, <i>J</i> = 2.5 Hz, 1H), 6.52 (d, <i>J</i> = 2.5 Hz, H2), 4.98–4.93 (m, 1H), 4.84 (d, <i>J</i> = 15.9 Hz, 1H), 4.81 (d, <i>J</i> = 15.9 Hz, 1H), 3.81 (s, 3H), 2.38 (s, 3H), 2.31–2.21 (m, 1H), 2.08–2.00 (m, 1H), 1.06 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-2-Chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14a</b>)</h4><div class="NLM_p last">A mixture of <b>13a</b> (1.00 g, 2.92 mmol) in AcOH (0.4 M) was heated to 100 °C. Iron powder (196 mg, 3.5 mmol) was added batchwise, and the reaction was stirred for 6 h. Upon completion, the mixture was filtered through celite, washed with MeOH, and concentrated in vacuo. The residue was purified by Biotage column chromatography (cHex/EtOAc, 0–40%) to afford the title compound <b>14a</b> as a yellow solid (345 mg, 1.23 mmol, 25%). HRMS (ESI +ve): found [M]<sup>+</sup> 281.1163, [C<sub>13</sub>H<sub>18</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 281.1169; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: −96.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 9.39 (s, 1H), 7.68 (s, 1H), 4.37–4.29 (m, 1H), 4.21 (dd, <i>J</i> = 7.4, 3.6 Hz, 1H), 2.11–2.05 (m, 1H), 2.00–1.74 (m, 7H), 1.70–1.61 (m, 2H), 0.96 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>S</i>)-2-Chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14b</b>)</h4><div class="NLM_p last"><b>14b</b> was synthesized in 28% yield (yellow solid, 186 mg, 0.66 mmol) according to the same procedure as <b>14d</b>, from <b>13b</b> (815 mg, 2.38 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 281.1163, [C<sub>13</sub>H<sub>18</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 281.1169; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: +95.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 9.67 (s, 1H), 7.70 (s, 1H), 4.32 (quin, <i>J</i> = 8.4 Hz, 1H), 4.21 (dd, <i>J</i> = 7.3, 3.5 Hz, 1H), 2.12–2.04 (m, 1H), 2.00–1.73 (m, 7H), 1.70–1.60 (m, 2H), 0.94 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Chloro-8-cyclopentyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14c</b>)</h4><div class="NLM_p last"><b>14c</b> was synthesized in 31% yield (orange solid, 101 mg, 0.40 mmol) according to the same procedure as <b>14d</b>, from <b>13c</b> (410 mg, 1.30 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 281.1163, [C<sub>13</sub>H<sub>18</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 281.1169; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: +95.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.98 (s, 1H), 7.60 (s, 1H), 6.15 (quin, <i>J</i> = 8.4 Hz, 1H), 4.11 (s, 2H), 1.98–1.89 (m, 2H), 1.80–1.57 (m, 6H).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-2-Chloro-8-(3-bromobenzyl)-7-ethyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14d</b>)</h4><div class="NLM_p last"><b>14d</b> was synthesized in 42% yield (orange solid, 387 mg, 1.01 mmol) according to the same procedure as <b>14a</b>, from <b>13d</b> (1.80 g, 4.06 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 383.0078, [C<sub>15</sub>H<sub>15</sub>BrClN<sub>4</sub>O]<sup>+</sup> requires 383.0091; [α]<sub class="stack">D</sub><sup class="stack">22.0</sup>: −18.0 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 9.33 (s, 1H), 7.71 (s, 1H), 7.48–7.45 (m, 1H), 7.45 (s, 1H), 7.26–7.23 (m, 2H), 5.62 (d, <i>J</i> = 15.1, 1H), 4.16–4.12 (m, 1H), 4.08 (d, <i>J</i> = 15.1, 1H), 2.05–1.97 (m, 1H), 1.96–1.86 (m, 1H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>R</i>)-2-Chloro-7-ethyl-8-((3-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14e</b>)</h4><div class="NLM_p last"><b>14e</b> was synthesized in 47% yield (orange solid, 380 mg, 1.17 mmol) according to the same procedure as <b>14d</b>, from <b>13e</b> (960 mg, 2.49 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 323.0724, [C<sub>14</sub>H<sub>15</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 323.0728; [α]<sub class="stack">D</sub><sup class="stack">22.2</sup>: −11.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.70 (s, 1H), 7.65 (s, 1H), 6.86 (d, <i>J</i> = 3.3 Hz, 1H), 6.63–6.61 (m, 1H), 5.55 (d, <i>J</i> = 15.5, 1H), 4.33–4.29 (m, 2H), 2.46 (s, 3H), 2.07–1.88 (m, 2H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>R</i>)-2-Chloro-7-ethyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14f</b>)</h4><div class="NLM_p last"><b>14f</b> was synthesized in 42% yield (orange solid, 300 mg, 0.93 mmol) according to the same procedure as <b>14d</b>, from <b>13f</b> (860 mg, 2.23 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 323.0728, [C<sub>14</sub>H<sub>15</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 323.0728; [α]<sub class="stack">D</sub><sup class="stack">22.8</sup>: −18.0 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.73 (s, 1H), 6.86 (s, 1H), 6.83 (d, <i>J</i> = 1.0 Hz, 1H), 5.58 (d, <i>J</i> = 15.5 Hz, 1H), 4.32–4.28 (m, 2H), 2.23 (s, 3H), 2.07–1.99 (m, 1H), 1.97–1.86 (m, 1H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-2-Chloro-7-ethyl-8-((5-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>14g</b>)</h4><div class="NLM_p last"><b>14g</b> was synthesized in 18% yield (orange solid, 200 mg, 0.62 mmol) according to the same procedure as <b>14d</b>, from <b>13g</b> (1.30 g, 3.38 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 323.0727, [C<sub>14</sub>H<sub>15</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 323.0728; [α]<sub class="stack">D</sub><sup class="stack">22.5</sup>: +18.7 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 9.20 (s, 1H), 7.69 (s, 1H), 7.18 (d, <i>J</i> = 5.2 Hz, 1H), 6.83 (d, <i>J</i> = 5.2 Hz, 1H), 5.64 (d, <i>J</i> = 15.5 Hz, 1H), 4.29 (d, <i>J</i> = 15.5 Hz, 1H), 4.24 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 2.26 (s, 3H), 2.05–1.99 (m, 1H), 1.98–1.87 (m, 1H), 0.92 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>R</i>)-2-Chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15a</b>)</h4><div class="NLM_p last"><b>14a</b> (200 mg, 0.72 mmol) was dissolved in DMF (0.1 M), methyl iodide (58 μL, 0.93 mmol) was added, and the mixture was cooled to −10 °C. NaH (22 mg, 0.93 mmol) was added, and the reaction was stirred for 16 h. Upon completion, ice was added and the aqueous phase was extracted with EtOAc (×3). The combined organic phases were washed with water, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (cHex/EtOAc, 0–20%) to afford the title compound <b>15a</b> as a white solid (200 mg, 0.68 mmol, 71%). HRMS (ESI +ve): found [M]<sup>+</sup> 295.1321, [C<sub>14</sub>H<sub>20</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 295.1326; [α]<sub class="stack">D</sub><sup class="stack">21.4</sup>: −88.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.62 (s, 1H), 4.41–4.29 (m, 1H), 4.25 (dd, <i>J</i> = 7.6, 3.5 Hz, 1H), 3.33 (s, 3H), 2.12–2.04 (m, 1H), 2.02–1.58 (m, 9H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>S</i>)-2-Chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15b</b>)</h4><div class="NLM_p last"><b>15b</b> was synthesized in 95% yield (white solid, 180 mg, 0.61 mmol) according to the same procedure as <b>15d</b>, from <b>14b</b> (180 mg, 0.64 mmol) and methyl iodide (52 μL, 0.83 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 295.1321, [C<sub>14</sub>H<sub>20</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 295.1326; [α]<sub class="stack">D</sub><sup class="stack">21.5</sup>: +93.5 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.65 (s, 1H), 4.37–4.28 (m, 1H), 4.23 (dd, <i>J</i> = 7.6, 3.8 Hz, 1H), 3.31 (s, 3H), 2.10–2.02 (m, 1H), 2.00–1.58 (m, 9H), 0.85 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-Chloro-8-cyclopentyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15c</b>)</h4><div class="NLM_p last"><b>15c</b> was synthesized in 59% yield (white solid, 53 mg, 0.20 mmol) according to the same procedure as <b>15d</b>, from <b>14c</b> (85 mg, 0.37 mmol) and methyl iodide (27 μL, 0.43 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 267.0995, [C<sub>12</sub>H<sub>15</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 267.1007; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.67 (s, 1H), 5.14 (quin, <i>J</i> = 8.4 Hz, 1H), 4.13 (s, 2H), 4.37–4.28 (m, 1H), 3.33 (s, 3H), 1.97–1.91 (m, 2H), 1.81–1.65 (m, 4H), 1.64–1.56 (m, 2H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>R</i>)-8-(3-Bromobenzyl)-2-chloro-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15d</b>)</h4><div class="NLM_p last"><b>15d</b> was synthesized in 71% yield (yellow solid, 200 mg, 0.51 mmol) according to the same procedure as <b>15a</b>, from <b>14d</b> (270 mg, 0.71 mmol) and methyl iodide (58 μL, 0.92 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 395.0269, [C<sub>16</sub>H<sub>17</sub>BrClN<sub>4</sub>O]<sup>+</sup> requires 395.0274; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: +15.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.73 (s, 1H), 7.48–7.44 (m, 2H), 7.25–7.22 (m, 2H), 5.62 (d, <i>J</i> = 15.1 Hz, 1H), 4.17 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 4.09 (d, <i>J</i> = 15.1 Hz, 1H), 3.35 (s, 3H), 2.02–1.93 (m, 1H), 1.90–1.80 (m, 1H), 0.84 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>R</i>)-2-Chloro-7-ethyl-5-methyl-8-(3-methylthiophen-2-yl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15e</b>)</h4><div class="NLM_p last"><b>15e</b> was synthesized in 48% yield (yellow solid, 186 mg, 0.55 mmol) according to the same procedure as <b>15d</b>, from <b>14e</b> (370 mg, 1.15 mmol) and methyl iodide (72 μL, 1.15 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 337.0901, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 337.0884; [α]<sub class="stack">D</sub><sup class="stack">23.3</sup>: +6.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.69 (s, 1H), 7.17 (d, <i>J</i> = 5.4 Hz, 1H), 6.83 (d, <i>J</i> = 5.4 Hz, 1H), 5.61 (d, <i>J</i> = 15.3 Hz, 1H), 4.29 (d, <i>J</i> = 15.3 Hz, 1H), 4.27 (dd, <i>J</i> = 6.6, 3.5 Hz, 1H), 3.32 (s, 3H), 2.25 (s, 3H), 2.03–1.93 (m, 1H), 1.91–1.81 (m, 1H), 0.84 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>R</i>)-2-Chloro-7-ethyl-5-methyl-8-(4-methylthiophen-2-yl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15f</b>)</h4><div class="NLM_p last"><b>15f</b> was synthesized in 53% yield (yellow oil, 260 mg, 0.77 mmol) according to the same procedure as <b>15d</b>, from <b>14f</b> (470 mg, 1.46 mmol) and methyl iodide (19 μL, 1.90 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 337.0881, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 337.0884; [α]<sub class="stack">D</sub><sup class="stack">23.3</sup>: +4.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.69 (s, 1H), 6.86 (s, 1H), 6.82 (s, 1H), 5.56 (d, <i>J</i> = 15.5 Hz, 1H), 4.33–4.29 (2H, m), 3.31 (s, 3H), 2.22 (s, 3H), 2.03–1.95 (m, 1H), 1.91–1.84 (m, 1H), 0.81 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>R</i>)-2-Chloro-7-ethyl-5-methyl-8-(5-methylthiophen-2-yl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>15g</b>)</h4><div class="NLM_p last"><b>15g</b> was synthesized in 53% yield (yellow solid, 110 mg, 0.33 mmol) according to the same procedure as <b>15d</b>, from <b>14g</b> (200 mg, 0.62 mmol) and methyl iodide (39 μL, 0.62 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 337.0866, [C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>OS]<sup>+</sup> requires 337.0884; [α]<sub class="stack">D</sub><sup class="stack">23.5</sup>: +1.7 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.69 (s, 1H), 6.85 (d, <i>J</i> = 3.5 Hz, 1H), 6.61–6.59 (m, 1H), 5.53 (d, <i>J</i> = 15.5 Hz, 1H), 4.33–4.29 (2H, m), 3.32 (s, 3H), 2.45 (s, 3H), 2.04–1.95 (m, 1H), 1.91–1.83 (m, 1H), 0.82 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-8-Cyclopentyl-7-ethyl-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16a</b>)</h4><div class="NLM_p last">To <b>15a</b> (25 mg, 80 μmol) and <b>10b</b> (18 mg, 80 μmol) in a solvent mixture of dioxane/EtOH/H<sub>2</sub>O (1:1:1, 0.1 M) was added conc. HCl (24 μL, 110 μmol). The reaction was stirred at 120 °C for 48 h. Upon completion, the reaction mixture was partitioned between EtOAc and NaOH (1 M) and the aqueous layer was further extracted with EtOAc (×2). The organic phase was combined, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by Biotage column chromatography (DCM/20% amm. MeOH, 0–40%) and reverse phase column chromatography (water/MeOH, 0–100%) to afford <b>16a</b> as a yellow solid (9.0 mg, 19 μmol, 22%). HRMS (ESI +ve): found [M]<sup>+</sup> 479.3101, [C<sub>27</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 479.3129; [α]<sub class="stack">D</sub><sup class="stack">21.8</sup>: −9.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.20 (d, <i>J</i> = 8.2 Hz, 1H), 7.88 (s, 1H), 7.61 (s, 1H), 6.80 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.75 (d, <i>J</i> = 1.9 Hz, 1H), 4.42 (quin, <i>J</i> = 8.0 Hz, 1H), 4.21 (dd, <i>J</i> = 7.7. 3.6 Hz, 1H), 3.90 (s, 3H), 3.59 (d, <i>J</i> = 10.7 Hz, 2H), 3.31 (s, 3H), 2.75 (s, 3H), 2.77–2.67 (m, 3H), 2.27 (q, <i>J</i> = 12.5 Hz, 2H), 2.14–1.92 (m, 4H), 1.92–1.60 (m, 8H), 0.87 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>R</i>)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-isobutoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16b</b>)</h4><div class="NLM_p last"><b>16b</b> was synthesized in 28% yield (white solid, 7.0 mg, 12 μmol) according to the same procedure as <b>16h</b>, from <b>15a</b> (13 mg, 44 μmol) and <b>5a</b> (14 mg, 44 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 564.3652, [C<sub>31</sub>H<sub>45</sub>N<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 564.3657; [α]<sub class="stack">D</sub><sup class="stack">20.8</sup>: −31.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.68 (s, 1H), 7.67 (s, 1H), 7.40 (d, <i>J</i> = 1.6 Hz, 1H), 7.22 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.50 (d, <i>J</i> = 6.9 Hz, 1H), 4.40–4.32 (m, 1H), 4.23 (dd, <i>J</i> = 7.4, 3.3 Hz, 1H), 4.22–4.17 (m, 1H), 3.90 (d, <i>J</i> = 6.3 Hz, 2H), 3.41 (d, <i>J</i> = 10.4 Hz, 2H), 3.33 (s, 3H), 2.68 (t, <i>J</i> = 8.0 Hz, 2H), 2.33 (s, 3H), 2.26–1.65 (m, 15H), 1.09 (d, <i>J</i> = 6.6 Hz, 6H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>R</i>)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16c</b>)</h4><div class="NLM_p last"><b>16c</b> was synthesized in 24% yield (white solid, 13 mg, 24 μmol) according to the same procedure as <b>16h</b>, from <b>15a</b> (30 mg, 102 μmol) and <b>5b</b> (28 mg, 102 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 536.3345, [C<sub>29</sub>H<sub>41</sub>N<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 536.3349; [α]<sub class="stack">D</sub><sup class="stack">21.8</sup>: −62.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.55 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (s, 1H), 7.68 (s, 1H), 7.41 (d, <i>J</i> = 1.9 Hz, 1H), 7.35 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.56 (s, 1H), 4.52–4.44 (m, 1H), 4.28–4.18 (m, 4H), 3.50 (d, <i>J</i> = 10.4 Hz, 2H), 3.34 (s, 3H), 2.72–2.64 (m, 2H), 2.74 (s, 3H), 2.20–1.97 (m, 6H), 1.93–1.68 (m, 8H), 1.51 (t, <i>J</i> = 6.9 Hz, 3H), 0.88 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>S</i>)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16d</b>)</h4><div class="NLM_p last"><b>16d</b> was synthesized in 42% yield (white solid, 23 mg, 43 μmol) according to the same procedure as <b>16h</b>, from <b>15b</b> (30 mg, 102 μmol) and <b>5b</b> (28 mg, 102 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 536.3329, [C<sub>29</sub>H<sub>41</sub>N<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 536.3349; [α]<sub class="stack">D</sub><sup class="stack">21.8</sup>: +51.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.55 (d, <i>J</i> = 8.2 Hz, 1H), 7.89 (s, 1H), 7.67 (s, 1H), 7.45 (d, <i>J</i> = 1.9 Hz, 1H), 7.35 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.56 (s, 1H), 4.52–4.44 (m, 1H), 4.33–4.23 (m, 2H), 4.20 (q, <i>J</i> = 6.9 Hz, 2H), 3.50 (d, <i>J</i> = 10.4 Hz, 2H), 3.33 (s, 3H), 2.72–2.64 (m, 2H), 2.78 (s, 3H), 2.20–1.97 (m, 6H), 1.93–1.68 (m, 8H), 1.50 (t, <i>J</i> = 6.9 Hz, 3H), 0.88 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-((8-Cyclopentyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16e</b>)</h4><div class="NLM_p last"><b>16e</b> was synthesized in 6.6% yield (white solid, 2.0 mg, 3.9 μmol) according to the same procedure as <b>16h</b>, from <b>15c</b> (16 mg, 60 μmol) and <b>5b</b> (16 mg, 57 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 508.3028, [C<sub>29</sub>H<sub>41</sub>N<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 508.3031; δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.41 (d, <i>J</i> = 1.8 Hz, 1H), 7.23 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 5.91 (s, 1H), 5.16 (quin, <i>J</i> = 8.1 Hz, H3), 4.22 (q, <i>J</i> = 7.6 Hz, 2H), 4.09 (s, 2H), 4.03–3.94 (m, 1H), 3.33 (s, 3H), 2.88–2.80 (m, 2H), 2.32 (s, 3H), 2.20–2.15 (m, 2H), 2.06 (m, 2H), 2.01–1.93 (m, 2H), 1.84–1.58 (m, 8H), 1.52 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>R</i>)-4-((8-(3-Bromobenzyl)-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16f</b>)</h4><div class="NLM_p last"><b>16f</b> was synthesized in 53% yield (white solid, 55 mg, 86 μmol) according to the same procedure as <b>16h</b>, from <b>15d</b> (65 mg, 164 μmol) and <b>5b</b> (46 mg, 164 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 622.2302, [C<sub>31</sub>H<sub>38</sub>BrN<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 636.2298; [α]<sub class="stack">D</sub><sup class="stack">22.1</sup>: +5.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.23 (d, <i>J</i> = 8.5 Hz, 1H), 7.74 (s, 1H), 7.63 (s, 1H), 7.50 (t, <i>J</i> = 1.6 Hz, 1H), 7.44 (dt, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.42 (d, <i>J</i> = 1.9 Hz, 1H), 7.28–7.20 (m, 2H), 7.14 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 5.96 (d, <i>J</i> = 7.9 Hz, 1H), 5.51 (d, <i>J</i> = 15.8 Hz, 1H), 4.23–4.16 (m, 4H), 4.04–3.94 (m, 1H), 3.38 (s, 3H), 2.76–2.67 (m, 2H), 2.31 (s, 3H), 2.17 (t, <i>J</i> = 10.9 Hz, 2H), 2.09–2.01 (m, 2H), 2.00–1.93 (m, 1H), 1.89–1.80 (m, 1H), 1.63–1.58 (m, 2H) 1.49 (t, <i>J</i> = 7.1 Hz, 3H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>R</i>)-4-((8-Benzyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-ethoxy-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>16g</b>)</h4><div class="NLM_p last"><b>16g</b> was synthesized in 46% yield (pale yellow solid, 4.0 mg, 7.2 μmol) according to the same procedure as <b>16i</b>, from <b>16f</b> (10 mg, 16 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 558.3161, [C<sub>31</sub>H<sub>39</sub>N<sub>7</sub>O<sub>3</sub>]<sup>+</sup> requires 558.3193; [α]<sub class="stack">D</sub><sup class="stack">21.9</sup>: −9.7 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.45 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (s, 1H), 7.73 (s, 1H), 7.42 (d, <i>J</i> = 1.6 Hz, 1H), 7.40–7.29 (m, 6H), 6.61 (d, <i>J</i> = 8.2 Hz, 1H), 5.66 (d, <i>J</i> = 15.1 Hz, 1H), 4.28–4.19 (m, 4H), 4.18 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 3.48 (d, <i>J</i> = 11.7 Hz, 2H), 3.37 (s, 3H), 2.80–2.72 (m, 2H), 2.73 (s, 3H), 2.20–2.12 (m, 4H), 2.01–1.92 (m, 1H), 1.91–1.82 (m, 1H), 1.51 (t, <i>J</i> = 6.9 Hz, 3H), 0.87 (t, <i>J</i> = 7.9 Hz, 3H).</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>R</i>)-8-(3-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16h</b>)</h4><div class="NLM_p last"><b>16h</b> was synthesized in 29% yield (white solid, 30 mg, 51 μmol) according to the same procedure as <b>16a</b>, from <b>15d</b> (69 mg, 174 μmol) and <b>10a</b> (39 mg, 166 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 593.2209, [C<sub>30</sub>H<sub>38</sub>BrN<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 593.2234; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: +1.7 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.13 (s, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.68 (s, 1H), 7.46–7.42 (m, 2H), 7.23–7.20 (m, 2H), 6.74–6.70 (m, 2H), 5.51 (d, <i>J</i> = 15.5 Hz, 1H), 4.19–4.13 (m, 2H), 4.11 (q, <i>J</i> = 6.9 Hz, 2H), 3.67–3.63 (m, 2H), 3.35 (s, 3H), 2.85–2.75 (m, 2H), 2.82 (s, 3H), 2.70–2.61 (m, 1H), 2.28 (q, <i>J</i> = 12.3 Hz, 2H), 2.05–1.94 (m, 3H), 1.90–1.80 (m, 1H), 1.47 (t, <i>J</i> = 6.9 Hz, 3H), 0.85 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>R</i>)-8-Benzyl-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16i</b>)</h4><div class="NLM_p last">A solution of <b>16h</b> (14 mg, 24 μmol) and 10% Pd·C (1.5 mg, 14 μmol) in MeOH (0.01 M) was stirred at rt under a hydrogen atmosphere (1 atm) for 1 h. The mixture was filtered through celite and washed with MeOH. The solvent was removed in vacuo, and the residue was purified by reverse phase column chromatography (water/MeOH, 0–100%) to give the title compound <b>16i</b> as a white solid (5.0 mg, 9.7 μmol, 41%). HRMS (ESI +ve): found [M]<sup>+</sup> 515.3114, [C<sub>30</sub>H<sub>40</sub>N<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 515.3129; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: +24.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.68 (s, 1H), 7.58 (s, 1H), 7.37–7.29 (m, 5H), 6.72 (d, <i>J</i> = 1.6 Hz, 1H), 6.70 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 5.62 (d, <i>J</i> = 15.1 Hz, 1H), 4.18–4.15 (m, 3H), 4.11 (q, <i>J</i> = 7.2 Hz, 2H), 3.64 (d, <i>J</i> = 10.4 Hz, 2H), 3.34 (s, 3H), 2.73 (s, 3H), 2.73–2.58 (m, 3H), 2.25–2.15 (m, 2H), 2.02–1.92 (m, 3H), 1.90–1.81 (m, 1H), 1.48 (t, <i>J</i> = 6.9 Hz, 3H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>R</i>)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((3-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16j</b>)</h4><div class="NLM_p last"><b>16j</b> was synthesized in 9.4% yield (yellow solid, 6.0 mg, 11 μmol) according to the same procedure as <b>16h</b>, from <b>15e</b> (40 mg, 120 μmol) and <b>10a</b> (26 mg, 110 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 535.2828, [C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>2</sub>S]<sup>+</sup> requires 535.2850; [α]<sub class="stack">D</sub><sup class="stack">23.5</sup>: +7.6 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.31 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (s, 1H), 7.64 (s, 1H), 7.15 (d, <i>J</i> = 5.0 Hz, 1H), 6.83 (d, <i>J</i> = 5.0 Hz, 1H), 6.78 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 6.73 (d, <i>J</i> = 1.6 Hz, 1H), 5.63 (d, <i>J</i> = 15.1 Hz, 1H), 4.33 (d, <i>J</i> = 15.1 Hz, 1H), 4.19 (dd, <i>J</i> = 6.5, 3.6 Hz, 1H), 4.13 (q, <i>J</i> = 6.9 Hz, 2H), 3.57 (d, <i>J</i> = 9.1 Hz, 2H), 3.32 (s, 3H), 2.76–2.60 (m, 6H), 2.25 (s, 3H), 2.24–2.15 (m, 2H), 2.02–1.91 (m, 3H), 1.88–1.79 (m, 1H), 1.49 (t, <i>J</i> = 6.9 Hz, 3H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>R</i>)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16k</b>)</h4><div class="NLM_p last"><b>16k</b> was synthesized in 23% yield (yellow solid, 20 mg, 37 μmol) according to the same procedure as <b>16h</b>, from <b>15f</b> (55 mg, 163 μmol) and <b>10a</b> (36 mg, 155 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 535.2835, [C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>2</sub>S]<sup>+</sup> requires 535.2850; [α]<sub class="stack">D</sub><sup class="stack">22.6</sup>: +7.6 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (s, 1H), 7.45 (s, 1H), 7.14 (d, <i>J</i> = 1.3 Hz, 1H), 6.85 (s, 1H), 6.82–6.76 (m, 3H), 5.61 (d, <i>J</i> = 15.5 Hz, 1H), 4.34 (d, <i>J</i> = 15.5 Hz, 1H), 4.25 (dd, <i>J</i> = 6.3, 3.5 Hz 1H), 4.11 (q, <i>J</i> = 6.9 Hz, 2H), 3.35–3.29 (m, 5H), 2.60 (s, 3H), 2.58–2.46 (m, 3H), 2.22 (s, 3H), 2.20–2.12 (m, 2H), 2.00–1.92 (m, 3H), 1.89–1.80 (m, 1H), 1.48 (t, <i>J</i> = 6.9 Hz, 3H), 0.85 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>R</i>)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((5-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>16l</b>)</h4><div class="NLM_p last"><b>16l</b> was synthesized in 25% yield (yellow oil, 18 mg, 34 μmol) according to the same procedure as <b>16h</b>, from <b>15g</b> (45 mg, 134 μmol) and <b>10a</b> (30 mg, 127 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 535.2833, [C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>2</sub>S]<sup>+</sup> requires 535.2850; [α]<sub class="stack">D</sub><sup class="stack">23.6</sup>: +11.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (s, 1H), 7.63 (s, 1H), 6.83 (d, <i>J</i> = 3.2 Hz, 1H), 6.79 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.75 (d, <i>J</i> = 1.8 Hz, 1H), 6.60 (d, <i>J</i> = 3.2 Hz, 1H), 5.57 (d, <i>J</i> = 15.5 Hz, 1H), 4.43 (d, <i>J</i> = 15.5 Hz, 1H), 4.26 (dd, <i>J</i> = 6.2, 3.6 Hz, 1H), 4.14 (q, <i>J</i> = 6.9 Hz, 2H), 3.57 (d, <i>J</i> = 10.1 Hz, 2H), 3.32 (s, 3H), 2.73 (s, 3H), 2.73–2.61 (m, 3H), 2.44 (s, 3H), 2.25–2.15 (m, 2H), 2.02–1.92 (m, 3H), 1.89–1.80 (m, 1H), 1.60 (t, <i>J</i> = 6.9 Hz, 3H), 0.84 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>R</i>)-Methyl 2-((2,4-Dimethoxybenzyl)amino)butanoate (<b>17</b>)</h4><div class="NLM_p last"><b>17</b> was synthesized in 97% yield (yellow oil, 27.0 g, 101 mmol) according to the same procedure as <b>12d</b>, from (<i>R</i>)-methyl 2-aminobutanoate <b>11a</b> (HCl salt, 16.0 g, 104 mmol) and 2,4-dimethoxybenzaldehye (17.3 g, 101 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 268.1541, [C<sub>14</sub>H<sub>21</sub>NO<sub>4</sub>]<sup>+</sup> requires 268.1543; [α]<sub class="stack">D</sub><sup class="stack">23.9</sup>: +11.8 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.13 (d, <i>J</i> = 7.9 Hz, 1H), 6.45–6.41 (m, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.71 (d, <i>J</i> = 13.2 Hz, 1H), 3.67–3.74 (m, 4H), 3.21 (t, <i>J</i> = 6.5 Hz, 1H), 1.73–1.63 (m, 2H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>R</i>)-Methyl 2-((2-Chloro-5-nitropyrimidin-4-yl)(2,4-dimethoxybenzyl)amino)butanoate (<b>18</b>)</h4><div class="NLM_p last"><b>18</b> was synthesized in 78% yield (yellow gum, 33.4 g, 78.6 mmol) according to the same procedure as <b>13d</b>, from <b>17</b> (27.0 g, 101 mmol) and 2,4-dichloro-5-nitropyrimidine <b>15</b> (21.6 g, 111 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 425.1211, [C<sub>18</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>6</sub>]<sup>+</sup> requires 425.1222; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: −6.9 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.65 (s, 1H), 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 6.40–6.37 (m, 2H), 4.47–4.43 (m, 2H), 4.40 (d, <i>J</i> = 16.1 Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H), 3.62 (s, 3H), 2.28–2.18 (m, 1H), 2.07–1.99 (m, 1H), 1.05 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>R</i>)-2-Chloro-8-(2,4-dimethoxybenzyl)-7-ethyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>19</b>)</h4><div class="NLM_p last">A solution of <b>18</b> (13.0 g, 30.6 mmol), 10% Pt·C (597 mg, 3.06 mmol), and VO(acac)<sub>2</sub> (650 mg, 2.45 mmol) in THF (0.3 M) was stirred at rt under a hydrogen atmosphere (1 atm) for 48 h. The mixture was filtered through celite, and the solvent was removed in vacuo to give <b>19</b> as a brown solid (11.0 g, 30.3 mmol, 98%). HRMS (ESI +ve): found [M]<sup>+</sup> 363.1198, [C<sub>17</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>3</sub>]<sup>+</sup> requires 363.1218; [α]<sub class="stack">D</sub><sup class="stack">23.4</sup>: +15.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 9.72 (1H), 7.65 (s, 1H), 7.30 (d, <i>J</i> = 9.1 Hz, 1H), 6.47–6.45 (m, 2H), 5.35 (d, <i>J</i> = 14.7 Hz, 2H), 4.28 (dd, <i>J</i> = 5.4, 4.4 Hz, 1H), 4.20 (d, <i>J</i> = 14.7 Hz, 1H), 3.80 (s, 6H), 2.03–1.94 (m, 2H), 0.94 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>R</i>)-2-Chloro-8-(2,4-dimethoxybenzyl)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>20</b>)</h4><div class="NLM_p last"><b>20</b> was synthesized in 86% yield (yellow oil, 9.66 g, 25.6 mmol) according to the same procedure as <b>15d</b>, from <b>19</b> (10.8 g, 29.8 mmol) and methyl iodide (2.42 mL, 38.7 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 377.1366, [C<sub>18</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>3</sub>]<sup>+</sup> requires 377.1375; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: +35.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.62 (s, 1H), 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 6.47–6.45 (m, 2H), 5.34 (d, <i>J</i> = 14.5 Hz, 1H), 4.34 (dd, <i>J</i> = 6.3, 3.8 Hz, 1H), 4.20 (d, <i>J</i> = 14.7 Hz, 1H), 3.81 (s, 6H), 3.30 (s, 3H), 1.99–1.85 (m, 2H), 0.85 (t, <i>J</i> = 7.9 Hz, 3H).</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>R</i>)-2-Chloro-7-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>21</b>)</h4><div class="NLM_p last">A solution of <b>20</b> (5.09 g, 13.5 mmol) in TFA (1.3 M) was stirred at 80 °C for 4 h. Upon completion, the reaction was concentrated in vacuo to remove the majority of the TFA. The remaining TFA was quenched with sat. NaHCO<sub>3</sub> until pH 7–8 was reached and extracted with DCM (×3). The organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (DCM/MeOH, 0–15%) to give <b>21</b> as a brown solid (2.02 g, 8.91 mmol, 66%). HRMS (ESI +ve): found [M]<sup>+</sup> 227.0695, [C<sub>9</sub>H<sub>11</sub>ClN<sub>4</sub>O]<sup>+</sup> requires 227.0694; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: +35.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.73 (s, 1H), 6.39 (s, 1H), 4.34 (dd, <i>J</i> = 6.3, 4.7 Hz, 1H), 3.34 (s, 3H), 2.03–1.87 (m, 2H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>R</i>)-2-Chloro-8-(3-chlorobenzyl)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>22a</b>)</h4><div class="NLM_p last">To a solution of <b>21</b> (50 mg, 0.22 mmol) in DMF (0.2 M) was added 1-(bromomethyl)-3-chlorobenzene (36 μL, 0.28 mmol). The mixture was cooled to −10 °C, NaH (12 mg, 0.50 mmol) was added, and then the mixture was stirred at rt for 18 h. Upon completion, ice was added and the reaction was partitioned between EtOAc and water. The aqueous layer was further extracted with EtOAc (×3). The combined organic phases were washed with water (×2), dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by Biotage column chromatography (cHex/EtOAc, 0–20%) to give <b>22a</b> as an orange solid (51 mg, 0.15 mmol, 66%). HRMS (ESI +ve): found [M]<sup>+</sup> 351.0775, [C<sub>16</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>4</sub>O]<sup>+</sup> requires 351.0774; [α]<sub class="stack">D</sub><sup class="stack">23.6</sup>: −1.4 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.73 (s, 1H), 7.32–7.28 (m, 3H), 7.20–7.18 (m, 1H), 5.62 (d, <i>J</i> = 15.1 Hz, 1H), 4.17 (dd, <i>J</i> = 6.2, 3.2 Hz, 1H), 4.08 (d, <i>J</i> = 15.1 Hz, 1H), 3.35 (s, 3H), 2.00–1.81 (m, 3H), 0.84 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>R</i>)-3-((2-Chloro-7-ethyl-5-methyl-6-oxo-6,7-dihydropteridin-8(5<i>H</i>)-yl)methyl)benzonitrile (<b>22b</b>)</h4><div class="NLM_p last"><b>22b</b> was synthesized in 37% yield (white solid, 28 mg, 0.08 mmol) according to the same procedure as <b>22a</b>, from <b>21</b> (50 mg, 0.22 mmol) and 3-(bromomethyl)benzonitrile (35 μL, 0.28 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 341.1112, [C<sub>17</sub>H<sub>16</sub>ClN<sub>5</sub>O]<sup>+</sup> requires 342.1116; [α]<sub class="stack">D</sub><sup class="stack">23.7</sup>: −1.4 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.74 (s, 1H), 7.63–7.56 (m, 2H), 7.56 (d, <i>J</i> = 7.7 Hz, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 1H), 5.58 (d, <i>J</i> = 15.5 Hz, 1H), 4.18 (d, <i>J</i> = 15.5 Hz, 1H), 4.15 (dd, <i>J</i> = 6.5, 3.6 Hz, 1H), 3.35 (s, 3H), 2.01–1.94 (m, 1H), 1.87–1.78 (m, 1H), 0.83 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (<i>R</i>)-2-Chloro-7-ethyl-8-(3-methoxybenzyl)-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>22c</b>)</h4><div class="NLM_p last"><b>22c</b> was synthesized in 65% yield (colorless oil, 50 mg, 0.14 mmol) according to the same procedure as <b>22a</b>, from <b>21</b> (50 mg, 0.22 mmol) and 3-methoxybenzyl bromide (39 μL, 0.28 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 347.1269, [C<sub>17</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub>]<sup>+</sup> requires 347.1269; [α]<sub class="stack">D</sub><sup class="stack">23.6</sup>: −9.7 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.69 (s, 1H), 7.28–7.24 (m, 1H), 6.87–6.84 (m, 3H), 5.63 (d, <i>J</i> = 15.1 Hz, 1H), 4.19 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 4.10 (d, <i>J</i> = 15.1 Hz, 1H), 3.79 (s, 3H), 3.35 (s, 3H), 2.00–1.93 (m, 1H), 1.93–1.81 (m, 1H), 0.82 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (<i>R</i>)-2-Chloro-8-(2-bromobenzyl)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>22d</b>)</h4><div class="NLM_p last"><b>22d</b> was synthesized in 62% yield (orange solid, 87 mg, 0.22 mmol) according to the same procedure as <b>22a</b>, from <b>21</b> (80 mg, 0.35 mmol) and 1-(bromomethyl)-2-chloro-benzene (111 mg, 0.45 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 397.0250, [C<sub>16</sub>H<sub>16</sub>BrClN<sub>4</sub>O]<sup>+</sup> requires 397.0274; [α]<sub class="stack">D</sub><sup class="stack">21.5</sup>: −20.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.72 (s, 1H), 7.58 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.36 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.30 (m, 1H), 7.19 (m, 1H), 5.63 (d, <i>J</i> = 15.1 Hz, 1H), 4.33 (d, <i>J</i> = 15.1 Hz, 1H), 4.19 (dd, <i>J</i> = 6.3, 3.8 Hz, 1H), 3.35 (s, 3H), 1.98–1.86 (m, 2H), 0.87 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>R</i>)-2-Chloro-8-(4-bromobenzyl)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>22e</b>)</h4><div class="NLM_p last"><b>22e</b> was synthesized in 21% yield (white solid, 35 mg, 0.09 mmol) according to the same procedure as <b>22a</b>, from <b>21</b> (95 mg, 0.42 mmol) and 1-(bromomethyl)-4-chloro-benzene (83 μL, 0.50 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 397.0249, [C<sub>16</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>4</sub>O]<sup>+</sup> requires 397.0247; [α]<sub class="stack">D</sub><sup class="stack">22.3</sup>: −47.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 7.71 (s, 1H), 7.47 (d, <i>J</i> = 8.5 Hz, 2H), 7.18 (d, <i>J</i> = 8.5 Hz, 2H), 5.52 (d, <i>J</i> = 15.1 Hz, 1H), 4.14 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 4.10 (d, <i>J</i> = 15.1 Hz, 1H), 3.33 (s, 3H), 1.98–1.90 (m, 1H), 1.86–1.77 (m, 1H), 0.81 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>R</i>)-2-Chloro-7-ethyl-5-methyl-8-((4-methylthiazol-5-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>22f</b>)</h4><div class="NLM_p last"><b>22f</b> was synthesized in 39% yield (white solid, 41 mg, 0.12 mmol) according to the same procedure as <b>22a</b>, from <b>21</b> (70 mg, 0.31 mmol) and 5-(chloromethyl)-4-methyl-1,3-thiazole (HCl salt, 68 mg, 0.37 mmol). HRMS (ESI +ve): found [M]<sup>+</sup> 338.0838, [C<sub>14</sub>H<sub>16</sub>ClN<sub>5</sub>OS]<sup>+</sup> requires 338.0837; [α]<sub class="stack">D</sub><sup class="stack">22.7</sup>: −14.5 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.68 (s, 1H), 7.71 (s, 1H), 5.46 (d, <i>J</i> = 15.5 Hz, 1H), 4.46 (d, <i>J</i> = 15.5 Hz, 1H), 4.27 (dd, <i>J</i> = 6.3, 3.5 Hz, 1H), 3.33 (s, 3H), 2.53 (s, 3H), 2.04–1.98 (m, 1H), 1.88–1.70 (m, 1H), 0.83 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>R</i>)-8-(3-Chlorobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>23a</b>)</h4><div class="NLM_p last"><b>23a</b> was synthesized in 13% yield (white solid, 8.0 mg, 15 μmol) according to the same procedure as <b>16h</b>, from <b>22a</b> (40 mg, 110 μmol) and <b>10a</b> (25 mg, 110 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 549.2727, [C<sub>30</sub>H<sub>37</sub>ClN<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 549.2739; [α]<sub class="stack">D</sub><sup class="stack">23.1</sup>: +15.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.71 (s, 1H), 7.46 (s, 1H), 7.30–7.27 (m, 2H), 7.23–7.20 (m, 1H), 6.76–6.70 (m, 2H), 5.58 (d, <i>J</i> = 15.5 Hz, 1H), 4.18–4.09 (m, 4H), 3.50 (d, <i>J</i> = 11.0 Hz, 2H), 3.36 (s, 3H), 2.69 (s, 3H), 2.69–2.59 (m, 3H), 2.17 (q, <i>J</i> = 12.3 Hz, 2H), 2.00–1.91 (m, 3H), 1.88–1.80 (m, 1H), 1.47 (t, <i>J</i> = 7.6 Hz, 3H), 0.87 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (<i>R</i>)-3-((2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-6-oxo-6,7-dihydropteridin-8(5<i>H</i>)-yl)methyl)benzonitrile (<b>23b</b>)</h4><div class="NLM_p last"><b>23b</b> was synthesized in 10% yield (white solid, 6.6 mg, 12 μmol) according to the same procedure as <b>16h</b>, from <b>22b</b> (40 mg, 120 μmol) and <b>10a</b> (26 mg, 110 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 540.3071, [C<sub>31</sub>H<sub>37</sub>N<sub>7</sub>O<sub>2</sub>]<sup>+</sup> requires 540.3081; [α]<sub class="stack">D</sub><sup class="stack">24.0</sup>: −2.1 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.08 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (s, 1H), 7.62–7.55 (m, 3H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.41 (s, 1H), 6.73–6.69 (m, 2H), 5.55 (d, <i>J</i> = 15.5 Hz, 1H), 4.23 (d, <i>J</i> = 15.5 Hz, 1H), 4.14–4.07 (m, 3H), 3.44 (d, <i>J</i> = 11.7 Hz, 2H), 3.37 (s, 3H), 2.64 (s, 3H), 2.63–2.52 (m, 3H), 2.12 (q, <i>J</i> = 13.2 Hz, 2H), 2.00–1.91 (m, 3H), 1.86–1.77 (m, 1H), 1.46 (t, <i>J</i> = 6.9 Hz, 3H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>R</i>)-8-(3-Methoxybenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>23c</b>)</h4><div class="NLM_p last"><b>23c</b> was synthesized in 32% yield (yellow solid, 20 mg, 37 μmol) according to the same procedure as <b>16h</b>, from <b>22c</b> (40 mg, 120 μmol) and <b>10a</b> (26 mg, 110 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 545.3221, [C<sub>31</sub>H<sub>40</sub>N<sub>6</sub>O<sub>3</sub>]<sup>+</sup> requires 545.3235; [α]<sub class="stack">D</sub><sup class="stack">24.0</sup>: +13.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.71 (s, 1H), 7.67 (1H), 7.29–7.26 (m, 1H), 6.91 (d, <i>J</i> = 7.6 Hz, 1H), 6.88–6.84 (m, 2H), 6.75–6.72 (m, 2H), 5.61 (d, <i>J</i> = 15.1 Hz, 1H), 4.18–4.09 (m, 4H), 3.77 (s, 3H), 3.61 (d, <i>J</i> = 8.8 Hz, 2H), 3.34 (s, 3H), 2.80–2.69 (m, 2H), 2.75 (s, 3H), 2.67–2.60 (m, 1H), 2.19 (q, <i>J</i> = 12.4 Hz, 2h), 2.02–1.90 (m, 3H), 1.89–1.80 (m, 1H), 1.48 (t, <i>J</i> = 6.9 Hz, 3H), 0.85 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>R</i>)-8-(2-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>23d</b>)</h4><div class="NLM_p last"><b>23d</b> was synthesized in 13% yield (yellow solid, 7.1 mg, 12 μmol) according to the same procedure as <b>16h</b>, from <b>22d</b> (36 mg, 91 μmol) and <b>10a</b> (20 mg, 86 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 593.2210, [C<sub>30</sub>H<sub>37</sub>BrN<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 593.2231; [α]<sub class="stack">D</sub><sup class="stack">22.0</sup>: −19.39 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.06 (d, <i>J</i> = 8.8 Hz, 1H), 7.70 (s, 1H), 7.57 (d, <i>J</i> = 7.6 Hz, 1H), 7.52 (s, 1H), 7.29–7.26 (m, 2H), 7.19–7.16 (m, 1H), 6.72–6.70 (m, 2H), 5.41 (d, <i>J</i> = 16.1 Hz, 1H), 4.30 (d, <i>J</i> = 16.1 Hz, 1H), 4.15 (dd, <i>J</i> = 6.6, 3.8 Hz, 1H), 4.10 (q, <i>J</i> = 6.9 Hz, 2H), 3.54 (d, <i>J</i> = 10.7 Hz, 2H), 3.37 (s, 3H), 2.74–2.60 (m, 6H), 2.17 (m, 2H), 2.02–1.86 (m, 4H), 1.47 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>R</i>)-8-(4-Bromobenzyl)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>23e</b>)</h4><div class="NLM_p last"><b>23e</b> was synthesized in 6% yield (yellow solid, 3.4 mg, 5.7 μmol) according to the same procedure as <b>16h</b>, from <b>22e</b> (35 mg, 89 μmol) and <b>10b</b> (20 mg, 84 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 593.2242, [C<sub>30</sub>H<sub>37</sub>BrN<sub>6</sub>O<sub>2</sub>]<sup>+</sup> requires 593.2234; [α]<sub class="stack">D</sub><sup class="stack">23.4</sup>: +6.2 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.16 (d, <i>J</i> = 7.9 Hz, 1H), 7.69 (s, 1H), 7.59 (s, 1H), 7.47 (d, <i>J</i> = 8.2 Hz, 2H), 7.20 (d, <i>J</i> = 8.2 Hz, 2H), 6.74–6.69 (m, 2H), 5.51 (d, <i>J</i> = 15.5 Hz, 1H), 4.19–4.09 (m, 4H), 3.58 (d, <i>J</i> = 9.1 Hz, 2H), 3.34 (s, 3H), 2.74 (s, 3H), 2.75–2.59 (m, 3H), 2.19 (m, 2H), 2.02–1.90 (m, 3H), 1.85–1.76 (m, 1H), 1.47 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>R</i>)-2-((2-Ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiazol-5-yl)methyl)-7,8-dihydropteridin-6(5<i>H</i>)-one (<b>23f</b>)</h4><div class="NLM_p last"><b>23f</b> was synthesized in 31% yield (yellow solid, 17 mg, 32 μmol) according to the same procedure as <b>16h</b>, from <b>22f</b> (35 mg, 100 μmol) and <b>10a</b> (23 mg, 100 μmol). HRMS (ESI +ve): found [M]<sup>+</sup> 536.2787, [C<sub>28</sub>H<sub>37</sub>N<sub>7</sub>O<sub>2</sub>S]<sup>+</sup> requires 536.2802; [α]<sub class="stack">D</sub><sup class="stack">22.8</sup>: −8.3 (<i>c</i> 1.0, MeOH); δ<sub>H</sub> (500 MHz, CDCl<sub>3</sub>): 8.65 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (s, 1H), 7.64 (s, 1H), 6.77 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 6.74 (d, <i>J</i> = 1.8 Hz, 1H), 5.47 (d, <i>J</i> = 15.8 Hz, 1H), 4.48 (d, <i>J</i> = 15.8 Hz, 1H), 4.17 (d, <i>J</i> = 6.5, 3.6 Hz, 1H), 4.13 (q, <i>J</i> = 7.0 Hz, 2H), 3.61 (d, <i>J</i> = 10.4 Hz, 2H), 3.32 (s, 3H), 2.75 (s, 3H), 2.75–2.70 (m, 2H), 2.66–2.63 (m, 1H), 2.52 (s, 3H), 2.26–2.15 (m, 2H), 2.03–1.94 (m, 3H), 1.86–1.76 (m, 1H), 1.49 (t, <i>J</i> = 7.0 Hz, 3H), 0.84 (t, <i>J</i> = 7.6 Hz, 3H).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> ALK<sup>F1174L</sup> Kinase Assay</h3><div class="NLM_p last">ALK<sup>F1174L</sup> activity was measured in a LanthaScreen Eu kinase binding assay. The assay was performed in 384-well plates containing ALK<sup>F1174L</sup> enzyme (5 nM, Carna Biosciences), Kinase Tracer 236 (30 nM, Thermo Fisher Scientific), LanthaScreen Eu-anti-GST antibody (2 nM, Thermo Fisher Scientific), either 1% (v/v) dimethyl sulfoxide (DMSO) or the test compound (in the range from 0.5 nM to 100 μM in 1% (v/v) DMSO), and assay buffer (50 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES) pH 7.5; 10 mM MgCl<sub>2</sub>; 1 mM ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid and 0.01% (w/v) Brij-35; 1 mM dithiothreitol). The reaction was incubated for 60 min at room temperature. The plate was read on an EnVision multilabel plate reader (PerkinElmer, U.K.) calculating an emission ratio between the acceptor/tracer emission (665 nM) and the antibody/donor emission (615 nM). IC<sub>50</sub> values were determined using a nonlinear regression fit of the log(inhibitor concentration) versus emission ratio with a variable slope equation.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Bromodomain Thermal Shift</h3><div class="NLM_p last">BRD4 thermal shift was measured in a differential scanning fluorimetry (DSF) assay. The assay was performed on a Stratagene Mx3005P system quantitative polymerase chain reaction (qPCR). The assay was performed in 96-well plates with 20 μL of protein at 2 μM in DSF-assay buffer (10 mM HEPES pH 7.5, 500 mM NaCl) to which 4 μL of Sypro orange dye and 0.4 μL of 10 μM compound in DMSO was added. The plate was sealed and centrifuged (1 min, 1000 rpm), and the qPCR machine was used to detect SYPRO fluorescence while increasing the temperature from 25 to 95 °C in 71 cycles. The sigmoidal part of the fluorescence signal was fitted using the Boltzmann equation, the points of change were defined, and the thermal shift was calculated by subtracting the protein/DMSO <i>T</i><sub>m</sub> shift from the protein/compound <i>T</i><sub>m</sub> shift.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> BRD4 Isothermal Calorimetry</h3><div class="NLM_p last">BRD4 activity was measured by isothermal calorimetry. The sample cell, sample syringe, and injection syringe were all equilibrated with gel filtration buffer (10 mM HEPES, 150 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 5% glycerol). The sample syringe was filled with compound solution (30–40 μM in gel filtration buffer), and the injection syringe was filled with protein solution (300 μM in gel filtration buffer). After equilibration of the machine, protein was injected over 21–30 injections, 8 μL each time. For the analysis of the data, the baseline and integration points were defined to determine binding heats. Data was fitted to the Boltzmann equation to determine thermodynamic parameters.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> PLK-1 Kinase Assay</h3><div class="NLM_p last">All PLK-1 IC<sub>50</sub>s and percentage inhibitions at 10 and 100 nM were tested by Thermo Fisher Scientific in a Ź-LYTE activity assay using their SelectScreen biochemical kinase profiling service.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Kinase Selectivity Profiling</h3><div class="NLM_p last">Compound X was assayed at 1 μM in the DiscoveRx KINOMEscan (<i>scan</i>EDGE) assay platform. The results for single-concentration binding interactions are reported as “%Ctrl” (DMSO = 100%Ctrl), where lower numbers indicate stronger hits.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Immunoassay and Immunoblotting</h3><div class="NLM_p last">The human neuroblastoma Kelly cell line was maintained in RPMI with 10% fetal calf serum. For dose–response experiments, cells were seeded into 10 cm dishes and, following attachment, treated with the indicated compound concentration in fresh media. After 3 h, the plates were transferred onto ice, the media were taken off, and the cells were washed once with ice-cold phosphate-buffered saline (PBS), before adding 5% CHAPS lysis buffer. After 20 min in lysis buffer, cells were scraped, transferred into Eppendorfs, and spun at 4 °C for 12 min at 12 000 rpm. The supernatant was transferred to a fresh tube, and the protein content was quantified using the Direct Detect system (Millipore). For ALK immunoassay analysis, 15 μg of protein per well was added in duplicate for each sample to measure either total or pY1586 ALK, and for immunoblotting, 5 μg of denatured lysates were loaded into 4–12% Bis/Tris gels, both according to previously published methods.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Crystallization, Data collection, and Processing</h3><div class="NLM_p">Purified protein in 25 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 5% glycerol was cocrystallized with compounds in 1:3 molar ratio at 293 K using sitting drop vapor diffusion. Reservoir solutions contained 25% poly(ethylene glycol)3350, 0.2 M ammonium sulfate, 0.1 M Bis–Tris pH 6.5 or 30% pentaerythritol ethoxylate 15/4, 0.05 ammonium sulfate, 0.1 M Bis–Tris pH 6.5 respectively.</div><div class="NLM_p last">Diffraction data were collected at the SLS X06S overlaid with X-ray A and BESSY II 14.2 and processed using either XDS (PMID 20124692) or iMOSFLM (PMID 28569763). The data was scaled using aimless from the CCP4 suite (PMID 29533233) and phased with PHASER (PMID 28573584) using PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OGI">4OGI</a> (PMID 24584101) as initial model. Manual model rebuilding alternated with structure refinement was performed in COOT (PMID 28291755) and REFMAC (PMID 15572771), respectively. Geometry of the final models was verified using MolProbity (PMID 29067766). Data collection and refinement statistics are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">Supp. Table 3</a>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> NanoBRET Target Engagement Assay</h3><div class="NLM_p last">The NanoBRET target engagement assay in principle was performed as described previously.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> The full-length ALK and BRDBD1 plasmid containing C-terminal placements of NanoLuc were obtained by the manufacturer (Promega). To lower intracellular expression levels of the reporter fusion, the NanoLuc/kinase fusion construct was diluted into carrier DNA (pGEM3ZF-, Promega) at a mass ratio of 1:10 (mass/mass), prior to forming FuGENE HD complexes according to the manufacturer’s instructions (Promega). DNA–FuGENE complexes were formed at a ratio of 1:3 (μg DNA/μL FuGENE). One part of the transfection complexes was then mixed with 20 parts (v/v) of HEK293T cells suspended at a density of 2 × 10<sup>5</sup>/mL in Dulbecco’s modified Eagle’s medium (Gibco) + 10% fetal bovine serum (GE Healthcare), seeded into T75 flasks, and allowed to express for 20 h. For target engagement, both serially diluted test compound and NanoBRET Kinase Tracer K5 (ALK) and BRD-Tracer (BRD4BD1) (Promega) at a final concentration of 2 and 0.5 μM, respectively, were pipetted into white 96-well plates (Corning 3600). The corresponding ALK or BRD4BD1-transfected cells were added and reseeded at a density of 2 × 10<sup>5</sup>/mL after trypsinization and resuspending in Opti-MEM without phenol red (Life Technologies). The system was allowed to equilibrate for 2 h at 37 °C/5% CO<sub>2</sub> prior to BRET measurements. To measure BRET, NanoBRET NanoGlo substrate + extracellular NanoLuc inhibitor (Promega) was added as per the manufacturer’s protocol, and filtered luminescence was measured on a CLARIOstar plate reader (BMG Labtech) equipped with a 450 nm band-pass filter (donor) and a 610 nm low-pass filter (acceptor). Competitive displacement data were then graphed using GraphPad Prism 7 software using a four-parameter curve fit with the following equation: <i>Y</i> = bottom + (top – bottom)/(1 + 10<sup>((Log IC<sub>50</sub> – <i>X</i>) × HillSlope)</sup>).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Western Blot Analysis</h3><div class="NLM_p last">Protein extracts of cells were prepared by lysis in radioimmunoprecipitation assay buffer (Sigma) supplemented with protease inhibitors (complete protease inhibitor cocktail, Roche). Protein extracts (25 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto poly(vinylidene difluoride) membranes using the Trans-Blot Turbo transfer system (BioRad). After blocking with 5% bovine serum albumin in PBS with 0.1% Tween-20 for 30 min, the membrane was incubated with primary antibodies for 1 h at room temperature. Horseradish peroxidase-linked secondary antibodies were incubated 30 min at room temperature followed by enhanced chemiluminescence (ECL) detection (ECL Western blot substrate, Pierce).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Antibodies</h3><div class="NLM_p last">Primary antibodies were obtained from the following sources: PLK-1 (05-844) and phosphohistone H3 (Ser10) (05806) from Millipore; pPlk1-T210 (5472) from Cell Signaling; pPlk1-S137 (21738) from Abcam; and cyclin B1 (GNS1) and β-actin (A2228) from Sigma-Aldrich served as loading control.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Docking</h3><div class="NLM_p last">Docking studies were performed using Glide, Schrödinger, LLC, New York, NY, 2018. Preparation of ALK using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a> was performed using Schrödinger Suite 2018-3 Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2018, and preparation of ligands was performed using LigPrep, Schrödinger, LLC, New York, NY, 2018.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01947" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01947" class="ext-link">10.1021/acs.jmedchem.8b01947</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Tables with standard deviations for all compounds; data collection and refinement statistics for BRD4–ligand complexes with <b>16i</b> and <b>16k</b>; kinase and bromodomain selectivity profiling of <b>16k</b>; chiral shift NMR and HPLC experiments; and cell cycle analysis of BI-2536 and <b>16k</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv">jm8b01947_si_001.csv (1.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_002.pdf">jm8b01947_si_002.pdf (765.12 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes for <b>16i</b> and <b>16k</b> bound to BRD4(1) are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y">6Q3Y</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z">6Q3Z</a>, respectively.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b01947" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin Bellenie</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#edaf8883878c808483c3af88818188838488ad848e9fc38c8ec39886"><span class="__cf_email__" data-cfemail="2b694e45414a46424505694e47474e45424e6b424859054a48055e40">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Swen Hoelder</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8636-1488" title="Orcid link">http://orcid.org/0000-0001-8636-1488</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5c0f2b3932721433393038392e1c353f2e723d3f722937"><span class="__cf_email__" data-cfemail="8bd8fceee5a5c3e4eee7efeef9cbe2e8f9a5eae8a5fee0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ellen Watts</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Heidenreich</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Chemistry, Johann Wolfgang
Goethe-University, Max-von-Laue-Strasse
9, D-60438 Frankfurt
am Main, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, BMLS, Goethe-University
Frankfurt, 60438 Frankfurt, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Tucker</span> - <span class="hlFld-Affiliation affiliation">Paediatric
and Solid Tumour Biology and Therapeutics Group, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika Raab</span> - <span class="hlFld-Affiliation affiliation">Department
of Gynecology and Obstetrics, Johann Wolfgang
Goethe-University, Theodor-Stern
Kai 7, 60590 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Klaus Strebhardt</span> - <span class="hlFld-Affiliation affiliation">Department
of Gynecology and Obstetrics, Johann Wolfgang
Goethe-University, Theodor-Stern
Kai 7, 60590 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Chesler</span> - <span class="hlFld-Affiliation affiliation">Paediatric
and Solid Tumour Biology and Therapeutics Group, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Knapp</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Chemistry, Johann Wolfgang
Goethe-University, Max-von-Laue-Strasse
9, D-60438 Frankfurt
am Main, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, BMLS, Goethe-University
Frankfurt, 60438 Frankfurt, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">German Cancer
Network (DKTK), Site
Frankfurt/Mainz, D-60438 Frankfurt am Main, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5995-6494" title="Orcid link">http://orcid.org/0000-0001-5995-6494</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6779-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">E.W. was funded by the Sir John Fisher Foundation. We also acknowledge funding from Cancer Research UK (Grant Number C309/A11566). E.T. and L.C. acknowledge funding from Cancer Research UK Programme Grant, C18339, and ICR HEFCE. S.K. and D.H. are grateful for support by the SGC, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD grant no. 115766), Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome (106169/ZZ14/Z), and the DFG-funded center of excellence (CEF) at Frankfurt University. S.K. is grateful for support by the German cancer network DKTK. We thank Dr. Amin Mirza, Dr. Maggie Liu, Meirion Richards, and Katia Grira for their help with LC, NMR, and mass spectrometry. We also thank Drs. Jack Cheung and Angela Hayes for collection of solubility and permeability data, respectively and to Yvette Newbatt for help with developing the kinase binding assay.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromo- and extra-terminal domain</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain 4</p></td></tr><tr><td class="NLM_term">DMB</td><td class="NLM_def"><p class="first last">dimethoxybenzyl</p></td></tr><tr><td class="NLM_term">INSR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">MSD</td><td class="NLM_def"><p class="first last">meso-scale discovery</p></td></tr><tr><td class="NLM_term">MYCN</td><td class="NLM_def"><p class="first last"><i>n</i>-myc proto-oncogene protein</p></td></tr><tr><td class="NLM_term">PLK</td><td class="NLM_def"><p class="first last">polo-like kinase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81820" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81820" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H.</span></span> <span> </span><span class="NLM_article-title">Neuroblastoma: Biology, Prognosis, and Treatment</span>. <i>Pediatr. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.pcl.2007.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.pcl.2007.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=18242317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Fos1Srtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=97-120&author=J.+R.+Parkauthor=A.+Eggertauthor=H.+Caron&title=Neuroblastoma%3A+Biology%2C+Prognosis%2C+and+Treatment&doi=10.1016%2Fj.pcl.2007.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroblastoma: biology, prognosis, and treatment</span></div><div class="casAuthors">Park Julie R; Eggert Angelika; Caron Huib</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric clinics of North America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-120, x</span>
        ISSN:<span class="NLM_cas:issn">0031-3955</span>.
    </div><div class="casAbstract">Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy.  Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise.  Neuroblastoma serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence.  This article summarizes our understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcRDeDkCpDYeb6AVA-44PTfW6udTcc2ebVNHu2AJSxYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Fos1Srtg%253D%253D&md5=984f729e5c97ba15df82c216e3173a1f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pcl.2007.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pcl.2007.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BR.%26aulast%3DEggert%26aufirst%3DA.%26aulast%3DCaron%26aufirst%3DH.%26atitle%3DNeuroblastoma%253A%2520Biology%252C%2520Prognosis%252C%2520and%2520Treatment%26jtitle%3DPediatr.%2520Clin.%2520North%2520Am.%26date%3D2008%26volume%3D55%26spage%3D97%26epage%3D120%26doi%3D10.1016%2Fj.pcl.2007.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetharoy, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.ccr.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22789543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=117-130&author=T.+Berryauthor=W.+Lutherauthor=N.+Bhatnagarauthor=Y.+Jaminauthor=E.+Poonauthor=T.+Sandaauthor=D.+Peiauthor=B.+Sharmaauthor=W.+R.+Vetharoyauthor=A.+Hallsworthauthor=Z.+Ahmadauthor=K.+Barkerauthor=L.+Moreauauthor=H.+Webberauthor=W.+Wangauthor=Q.+Liuauthor=A.+Perez-Ataydeauthor=S.+Rodigauthor=N.-K.+Cheungauthor=F.+Raynaudauthor=B.+Hallbergauthor=S.+P.+Robinsonauthor=N.+S.+Grayauthor=A.+D.+J.+Pearsonauthor=S.+A.+Ecclesauthor=L.+Cheslerauthor=R.+E.+George&title=The+ALKF1174L+Mutation+Potentiates+the+Oncogenic+Activity+of+MYCN+in+Neuroblastoma&doi=10.1016%2Fj.ccr.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span></div><div class="casAuthors">Berry, Teeara; Luther, William; Bhatnagar, Namrata; Jamin, Yann; Poon, Evon; Sanda, Takaomi; Pei, Desheng; Sharma, Bandana; Vetharoy, Winston R.; Hallsworth, Albert; Ahmad, Zai; Barker, Karen; Moreau, Lisa; Webber, Hannah; Wang, Wenchao; Liu, Qingsong; Perez-Atayde, Antonio; Rodig, Scott; Cheung, Nai-Kong; Raynaud, Florence; Hallberg, Bengt; Robinson, Simon P.; Gray, Nathanael S.; Pearson, Andrew D. J.; Eccles, Suzanne A.; Chesler, Louis; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The ALKF1174L mutation is assocd. with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma.  In this study, we generated a mouse model overexpressing ALKF1174L in the neural crest.  Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality.  ALKF1174L/MYCN tumors exhibited increased MYCN dosage due to ALKF1174L-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects.  Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALKF1174L/MYCN tumors to crizotinib.  Our findings demonstrate a pathogenic role for ALKF1174L in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-pos. neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQvwCqpbNJsbVg90H21EOLACvtfcHk0ljv2WSjowxIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ&md5=17eaed93b440461999c4f8f099f57723</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DBhatnagar%26aufirst%3DN.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DVetharoy%26aufirst%3DW.%2BR.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DBarker%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DL.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DN.-K.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DThe%2520ALKF1174L%2520Mutation%2520Potentiates%2520the%2520Oncogenic%2520Activity%2520of%2520MYCN%2520in%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D117%26epage%3D130%26doi%3D10.1016%2Fj.ccr.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haglund, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plegaria, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toporovskaya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span> <span> </span><span class="NLM_article-title">Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">108ra114</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3002950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1126%2Fscitranslmed.3002950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22072639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=S.+C.+Breslerauthor=A.+C.+Woodauthor=E.+A.+Haglundauthor=J.+Courtrightauthor=L.+T.+Belcastroauthor=J.+S.+Plegariaauthor=K.+Coleauthor=Y.+Toporovskayaauthor=H.+Zhaoauthor=E.+L.+Carpenterauthor=J.+G.+Christensenauthor=J.+M.+Marisauthor=M.+A.+Lemmonauthor=Y.+P.+Moss%C3%A9&title=Differential+Inhibitor+Sensitivity+of+Anaplastic+Lymphoma+Kinase+Variants+Found+in+Neuroblastoma&doi=10.1126%2Fscitranslmed.3002950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002950%26sid%3Dliteratum%253Aachs%26aulast%3DBresler%26aufirst%3DS.%2BC.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DHaglund%26aufirst%3DE.%2BA.%26aulast%3DCourtright%26aufirst%3DJ.%26aulast%3DBelcastro%26aufirst%3DL.%2BT.%26aulast%3DPlegaria%26aufirst%3DJ.%2BS.%26aulast%3DCole%26aufirst%3DK.%26aulast%3DToporovskaya%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarpenter%26aufirst%3DE.%2BL.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26atitle%3DDifferential%2520Inhibitor%2520Sensitivity%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520Variants%2520Found%2520in%2520Neuroblastoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3002950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span>Study Of Lorlatinib (PF-06463922)
- NCT03107988.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+Of+Lorlatinib+%28PF-06463922%29%0A-+NCT03107988."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthery, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekritz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F2159-8290.CD-12-0418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=308-323&author=A.+Puissantauthor=S.+M.+Frummauthor=G.+Alexeauthor=C.+F.+Bassilauthor=J.+Qiauthor=Y.+H.+Chantheryauthor=E.+A.+Nekritzauthor=R.+Zeidauthor=W.+C.+Gustafsonauthor=P.+Greningerauthor=M.+J.+Garnettauthor=U.+McDermottauthor=C.+H.+Benesauthor=A.+L.+Kungauthor=W.+A.+Weissauthor=J.+E.+Bradnerauthor=K.+Stegmaier&title=Targeting+MYCN+in+Neuroblastoma+by+BET+Bromodomain+Inhibition&doi=10.1158%2F2159-8290.CD-12-0418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0418%26sid%3Dliteratum%253Aachs%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DFrumm%26aufirst%3DS.%2BM.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DBassil%26aufirst%3DC.%2BF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChanthery%26aufirst%3DY.%2BH.%26aulast%3DNekritz%26aufirst%3DE.%2BA.%26aulast%3DZeid%26aufirst%3DR.%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DTargeting%2520MYCN%2520in%2520Neuroblastoma%2520by%2520BET%2520Bromodomain%2520Inhibition%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D308%26epage%3D323%26doi%3D10.1158%2F2159-8290.CD-12-0418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delmore, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastritis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpatrick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakoc, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span> <span> </span><span class="NLM_article-title">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.cell.2011.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21889194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=904-917&author=J.+E.+Delmoreauthor=G.+C.+Issaauthor=M.+E.+Lemieuxauthor=P.+B.+Rahlauthor=J.+Shiauthor=H.+M.+Jacobsauthor=E.+Kastritisauthor=T.+Gilpatrickauthor=R.+M.+Paranalauthor=J.+Qiauthor=M.+Chesiauthor=A.+C.+Schinzelauthor=M.+R.+McKeownauthor=T.+P.+Heffernanauthor=C.+R.+Vakocauthor=P.+L.+Bergsagelauthor=I.+M.+Ghobrialauthor=P.+G.+Richardsonauthor=R.+A.+Youngauthor=W.+C.+Hahnauthor=K.+C.+Andersonauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=C.+S.+Mitsiades&title=BET+Bromodomain+Inhibition+as+a+Therapeutic+Strategy+to+Target+c-Myc&doi=10.1016%2Fj.cell.2011.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span></div><div class="casAuthors">Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E.; Rahl, Peter B.; Shi, Jun-Wei; Jacobs, Hannah M.; Kastritis, Efstathios; Gilpatrick, Timothy; Paranal, Ronald M.; Qi, Jun; Chesi, Marta; Schinzel, Anna C.; McKeown, Michael R.; Heffernan, Timothy P.; Vakoc, Christopher R.; Bergsagel, P. Leif; Ghobrial, Irene M.; Richardson, Paul G.; Young, Richard A.; Hahn, William C.; Anderson, Kenneth C.; Kung, Andrew L.; Bradner, James E.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-917</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist.  Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation.  Using a selective small-mol. bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc.  BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes.  In exptl. models of multiple myeloma, a Myc-dependent hematol. malignancy, JQ1 produces a potent antiproliferative effect assocd. with cell-cycle arrest and cellular senescence.  Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathol. activation of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpevD1QHKmOhLVg90H21EOLACvtfcHk0lh9ImQijN5STg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF&md5=013674b8224214a9a1c8f0b75583a5a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DIssa%26aufirst%3DG.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DKastritis%26aufirst%3DE.%26aulast%3DGilpatrick%26aufirst%3DT.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DBET%2520Bromodomain%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520c-Myc%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D904%26epage%3D917%26doi%3D10.1016%2Fj.cell.2011.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">16669</span>– <span class="NLM_lpage">16674</span>, <span class="refDoi"> DOI: 10.1073/pnas.1108190108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.1108190108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21949397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16669-16674&author=J.+A.+Mertzauthor=A.+R.+Coneryauthor=B.+M.+Bryantauthor=P.+Sandyauthor=S.+Balasubramanianauthor=D.+A.+Meleauthor=L.+Bergeronauthor=R.+J.+Sims&title=Targeting+MYC+Dependence+in+Cancer+by+Inhibiting+BET+Bromodomains&doi=10.1073%2Fpnas.1108190108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependence in cancer by inhibiting BET bromodomains</span></div><div class="casAuthors">Mertz, Jennifer A.; Conery, Andrew R.; Bryant, Barbara M.; Sandy, Peter; Balasubramanian, Srividya; Mele, Deanna A.; Bergeron, Louise; Sims, Robert J., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16669-16674, S16669/1-S16669/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies.  However, pharmacol. inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions.  Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small mol. inhibitors of the BET family of chromatin adaptors.  MYC transcriptional suppression was obsd. in the context of the natural, chromosomally translocated, and amplified gene locus.  Inhibition of BET bromodomain-promoter interactions and subsequent redn. of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines.  Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors.  MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor.  Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia.  These findings demonstrate that pharmacol. inhibition of MYC is achievable through targeting BET bromodomains.  Such inhibitors may have clin. utility given the widespread pathogenetic role of MYC in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UHj1YB_ikrVg90H21EOLACvtfcHk0lh9ImQijN5STg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL&md5=b1f0fd41fa56bbfcbb1ad6c8d48f7f80</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108190108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108190108%26sid%3Dliteratum%253Aachs%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520MYC%2520Dependence%2520in%2520Cancer%2520by%2520Inhibiting%2520BET%2520Bromodomains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D108%26spage%3D16669%26epage%3D16674%26doi%3D10.1073%2Fpnas.1108190108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bromodomains: Epigenetic Readers of Lysine Acetylation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrd4286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnrd4286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=24751816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=337-356&author=P.+Filippakopoulosauthor=S.+Knapp&title=Targeting+Bromodomains%3A+Epigenetic+Readers+of+Lysine+Acetylation&doi=10.1038%2Fnrd4286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting bromodomains: epigenetic readers of lysine acetylation</span></div><div class="casAuthors">Filippakopoulos, Panagis; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-356</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases.  Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes.  These complexes can then initiate transcriptional programs that result in phenotypic changes.  The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncol., where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins.  In addn., targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection.  Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSIcwBJKj4LVg90H21EOLACvtfcHk0lh4J5GvqgD8qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D&md5=77049c82ce6a19b4685e3b7950399a07</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd4286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4286%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DTargeting%2520Bromodomains%253A%2520Epigenetic%2520Readers%2520of%2520Lysine%2520Acetylation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D337%26epage%3D356%26doi%3D10.1038%2Fnrd4286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span> <span> </span><span class="NLM_article-title">New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5814</span>– <span class="NLM_lpage">5821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F1078-0432.CCR-13-0680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=23965898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5814-5821&author=G.+Baroneauthor=J.+Andersonauthor=A.+D.+J.+Pearsonauthor=K.+Petrieauthor=L.+Chesler&title=New+Strategies+in+Neuroblastoma%3A+Therapeutic+Targeting+of+MYCN+and+ALK&doi=10.1158%2F1078-0432.CCR-13-0680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK</span></div><div class="casAuthors">Barone, Giuseppe; Anderson, John; Pearson, Andrew D. J.; Petrie, Kevin; Chesler, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5814-5821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Clin. outcome remains poor in patients with high-risk neuroblastoma, in which chemoresistant relapse is common following high-intensity conventional multimodal therapy.  Novel treatment approaches are required.  Although recent genomic profiling initiatives have not revealed a high frequency of mutations in any significant no. of therapeutically targeted genes, two exceptions, amplification of the MYCN oncogene and somatically acquired tyrosine kinase domain point mutations in anaplastic lymphoma kinase (ALK), present exciting possibilities for targeted therapy.  In contrast with the situation with ALK, in which a robust pipeline of pharmacol. agents is available from early clin. use in adult malignancy, therapeutic targeting of MYCN (and MYC oncoproteins in general) represents a significant medicinal chem. challenge that has remained unsolved for two decades.  We review the latest approaches envisioned for blockade of ALK activity in neuroblastoma, present a classification of potential approaches for therapeutic targeting of MYCN, and discuss how recent developments in targeting of MYC proteins seem to make therapeutic inhibition of MYCN a reality in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKH_mYvOHk7Vg90H21EOLACvtfcHk0lh4J5GvqgD8qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbjK&md5=abc7c5311a0c461cc0b419c985ccb171</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0680%26sid%3Dliteratum%253Aachs%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DPetrie%26aufirst%3DK.%26aulast%3DChesler%26aufirst%3DL.%26atitle%3DNew%2520Strategies%2520in%2520Neuroblastoma%253A%2520Therapeutic%2520Targeting%2520of%2520MYCN%2520and%2520ALK%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5814%26epage%3D5821%26doi%3D10.1158%2F1078-0432.CCR-13-0680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology – Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology+%E2%80%93+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lh4J5GvqgD8qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%2520%25E2%2580%2593%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amirouchene-Angelozzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Tumor Evolution as a Therapeutic Target</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F2159-8290.CD-17-0343" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=805-817&author=N.+Amirouchene-Angelozziauthor=C.+Swantonauthor=A.+Bardelli&title=Tumor+Evolution+as+a+Therapeutic+Target&doi=10.1158%2F2159-8290.CD-17-0343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0343%26sid%3Dliteratum%253Aachs%26aulast%3DAmirouchene-Angelozzi%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DTumor%2520Evolution%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D805%26epage%3D817%26doi%3D10.1158%2F2159-8290.CD-17-0343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhi, B.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition: a Novel Promising Pharmacological Approach for Different Disease Conditions</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.2010.01236.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1111%2Fj.2042-7158.2010.01236.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21401597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=459-471&author=S.+Patyarauthor=A.+Prakashauthor=B.+Medhi&title=Dual+Inhibition%3A+a+Novel+Promising+Pharmacological+Approach+for+Different+Disease+Conditions&doi=10.1111%2Fj.2042-7158.2010.01236.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span></div><div class="casAuthors">Patyar, Sazal; Prakash, Ajay; Medhi, Bikash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-471</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  To overcome the problems assocd. with polypharmacy, which include medication non compliance, adverse drug reactions, drug-drug interactions, and increased pill-burden, various strategies, such as sustained-release drugs and fixed-dose combination regimens (polypills), were developed.  Out of these, a novel and very much promising approach is the use of dual-action drugs.  Amongst the dual-action drugs, there is a class of compds. known as dual inhibitors, which possess the dual inhibitory activity.  The most common examples of dual inhibitors are rivastigmine, ladostigil, asenapine, phenserine, amitriptyline, clomipramine, doxepin, and desipramine.  This review article focuses on the conventional drugs used in different diseases which possess dual inhibition activity as well as those which are still in the preclin./clin. phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoimW_BGkApX7Vg90H21EOLACvtfcHk0lgNfi7HL7lfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D&md5=5cae05a18a9246b765e400230e8ef62f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2010.01236.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2010.01236.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatyar%26aufirst%3DS.%26aulast%3DPrakash%26aufirst%3DA.%26aulast%3DMedhi%26aufirst%3DB.%26atitle%3DDual%2520Inhibition%253A%2520a%2520Novel%2520Promising%2520Pharmacological%2520Approach%2520for%2520Different%2520Disease%2520Conditions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D63%26spage%3D459%26epage%3D471%26doi%3D10.1111%2Fj.2042-7158.2010.01236.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockway-Lunardi, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonk, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohoney, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meech, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer</span>. <i>JNCI, J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1093/jnci/djr246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1093%2Fjnci%2Fdjr246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21765011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVygtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2011&pages=1222-1226&author=R.+W.+Humphreyauthor=L.+M.+Brockway-Lunardiauthor=D.+T.+Bonkauthor=K.+M.+Dohoneyauthor=J.+H.+Doroshowauthor=S.+J.+Meechauthor=M.+J.+Ratainauthor=S.+L.+Topalianauthor=D.+M.+Pardoll&title=Opportunities+and+Challenges+in+the+Development+of+Experimental+Drug+Combinations+for+Cancer&doi=10.1093%2Fjnci%2Fdjr246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer</span></div><div class="casAuthors">Humphrey, Rachel W.; Brockway-Lunardi, Laura M.; Bonk, David T.; Dohoney, Kathleen M.; Doroshow, James H.; Meech, Sandra J.; Ratain, Mark J.; Topalian, Suzanne L.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1222-1226</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  It is becoming increasingly evident that cancers are dependent on a no. of altered mol. pathways and can develop diverse mechanisms of resistance to therapy with single agents.  Therefore, combination regimens may provide the best hope for effective therapies with durable effects.  Despite preclin. data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers.  A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolOCYp6_ctwbVg90H21EOLACvtfcHk0lgNfi7HL7lfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVygtrfF&md5=8b704a9777938e23cc73c2e8307ed374</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr246%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DR.%2BW.%26aulast%3DBrockway-Lunardi%26aufirst%3DL.%2BM.%26aulast%3DBonk%26aufirst%3DD.%2BT.%26aulast%3DDohoney%26aufirst%3DK.%2BM.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DMeech%26aufirst%3DS.%2BJ.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DOpportunities%2520and%2520Challenges%2520in%2520the%2520Development%2520of%2520Experimental%2520Drug%2520Combinations%2520for%2520Cancer%26jtitle%3DJNCI%252C%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D103%26spage%3D1222%26epage%3D1226%26doi%3D10.1093%2Fjnci%2Fdjr246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&author=P.+Ciceriauthor=S.+Mullerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+A.+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0lgNfi7HL7lfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1021/cb500072z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500072z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1160-1171&author=S.+W.+J.+Emberauthor=J.-Y.+Zhuauthor=S.+H.+Olesenauthor=M.+P.+Martinauthor=A.+Beckerauthor=N.+Berndtauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Acetyl-lysine+Binding+Site+of+Bromodomain-Containing+Protein+4+%28BRD4%29+Interacts+with+Diverse+Kinase+Inhibitors&doi=10.1021%2Fcb500072z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span></div><div class="casAuthors">Ember, Stuart W. J.; Zhu, Jin-Yi; Olesen, Sanne H.; Martin, Mathew P.; Becker, Andreas; Berndt, Norbert; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1171</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research.  In co-crystn. screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and characterized 14 kinase inhibitors (10 distinct chem. scaffolds) as ligands of the KAc binding site.  Among these, the PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 displayed strongest inhibitory potential against BRD4 (IC50 = 25 nM and 130 nM, resp.) and high selectivity for BET bromodomains.  Comparative structural anal. revealed markedly different binding modes of kinase hinge-binding scaffolds in the KAc binding site, suggesting that BET proteins are potential off-targets of diverse kinase inhibitors.  Combined, these findings provide a new structural framework for the rational design of next-generation BET-selective and dual-activity BET-kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0X1hjt7cBbVg90H21EOLACvtfcHk0lhysPRcSSJn0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D&md5=5ca37df00cdaa0ba81c0cb4a0f70ba5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fcb500072z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500072z%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.-Y.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DAcetyl-lysine%2520Binding%2520Site%2520of%2520Bromodomain-Containing%2520Protein%25204%2520%2528BRD4%2529%2520Interacts%2520with%2520Diverse%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1160%26epage%3D1171%26doi%3D10.1021%2Fcb500072z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dittmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fälth
Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1021/cb400789e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400789e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=495-502&author=A.+Dittmannauthor=T.+Wernerauthor=C.-W.+Chungauthor=M.+M.+Savitskiauthor=M.+F%C3%A4lth%0ASavitskiauthor=P.+Grandiauthor=C.+Hopfauthor=M.+Lindonauthor=G.+Neubauerauthor=R.+K.+Prinjhaauthor=M.+Bantscheffauthor=G.+Drewes&title=The+Commonly+Used+PI3-Kinase+Probe+LY294002+Is+an+Inhibitor+of+BET+Bromodomains&doi=10.1021%2Fcb400789e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span></div><div class="casAuthors">Dittmann, Antje; Werner, Thilo; Chung, Chun-Wa; Savitski, Mikhail M.; Faelth Savitski, Maria; Grandi, Paola; Hopf, Carsten; Lindon, Matthew; Neubauer, Gitte; Prinjha, Rabinder K.; Bantscheff, Marcus; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A commonly used small-mol. probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002.  Quant. chemoproteomic profiling shows that LY294002 and LY303511, a close analog devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.  Both compds. competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell exts.  X-ray crystallog. shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbIVXFQARTKLVg90H21EOLACvtfcHk0lhysPRcSSJn0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO&md5=13435c7d6a6747dc5699e3c3865c8243</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb400789e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400789e%26sid%3Dliteratum%253Aachs%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DF%25C3%25A4lth%2BSavitski%26aufirst%3DM.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThe%2520Commonly%2520Used%2520PI3-Kinase%2520Probe%2520LY294002%2520Is%2520an%2520Inhibitor%2520of%2520BET%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D495%26epage%3D502%26doi%3D10.1021%2Fcb400789e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span> <span> </span><span class="NLM_article-title">Dual-activity PI3K–BRD4 Inhibitor for the Orthogonal Inhibition of MYC to Block Tumor Growth and Metastasis</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E1072</span>– <span class="NLM_lpage">E1080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1613091114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.1613091114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28137841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E1072-E1080&author=F.+H.+Andrewsauthor=A.+R.+Singhauthor=S.+Joshiauthor=C.+A.+Smithauthor=G.+A.+Moralesauthor=J.+R.+Garlichauthor=D.+L.+Durdenauthor=T.+G.+Kutateladze&title=Dual-activity+PI3K%E2%80%93BRD4+Inhibitor+for+the+Orthogonal+Inhibition+of+MYC+to+Block+Tumor+Growth+and+Metastasis&doi=10.1073%2Fpnas.1613091114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis</span></div><div class="casAuthors">Andrews, Forest H.; Singh, Alok R.; Joshi, Shweta; Smith, Cassandra A.; Morales, Guillermo A.; Garlich, Joseph R.; Durden, Donald L.; Kutateladze, Tatiana G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E1072-E1080</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MYC is a major cancer driver but is documented to be a difficult therapeutic target itself.  Here, we report on the biol. activity, the structural basis, and therapeutic effects of the family of multitargeted compds. that simultaneously disrupt functions of two crit. MYC-mediating factors through inhibiting the acetyllysine binding of BRD4 and the kinase activity of PI3K.  We show that the dual-action inhibitor impairs PI3K/BRD4 signaling in vitro and in vivo and affords maximal MYC down-regulation.  The concomitant inhibition of PI3K and BRD4 blocks MYC expression and activation, promotes MYC degrdn., and markedly inhibits cancer cell growth and metastasis.  Collectively, our findings suggest that the dual-activity inhibitor represents a highly promising lead compd. for the development of novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHgfwKeBVd7Vg90H21EOLACvtfcHk0lhTYgNeLvycwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7Y%253D&md5=f890d20c18d443f5f36d1b13bad9b3b8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1613091114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1613091114%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DF.%2BH.%26aulast%3DSingh%26aufirst%3DA.%2BR.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BA.%26aulast%3DMorales%26aufirst%3DG.%2BA.%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26atitle%3DDual-activity%2520PI3K%25E2%2580%2593BRD4%2520Inhibitor%2520for%2520the%2520Orthogonal%2520Inhibition%2520of%2520MYC%2520to%2520Block%2520Tumor%2520Growth%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2017%26volume%3D114%26spage%3DE1072%26epage%3DE1080%26doi%3D10.1073%2Fpnas.1613091114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span> <span> </span><span class="NLM_article-title">BI-2536 and BI-6727, Dual Polo-like Kinase/Bromodomain Inhibitors, Effectively Reactivate Latent HIV-1</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">3521</span> <span class="refDoi"> DOI: 10.1038/s41598-018-21942-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fs41598-018-21942-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=29476067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A280%3ADC%252BC1MrkvVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=J.+Gohdaauthor=K.+Suzukiauthor=K.+Liuauthor=X.+Xieauthor=H.+Takeuchiauthor=J.-i.+Inoueauthor=Y.+Kawaguchiauthor=T.+Ishida&title=BI-2536+and+BI-6727%2C+Dual+Polo-like+Kinase%2FBromodomain+Inhibitors%2C+Effectively+Reactivate+Latent+HIV-1&doi=10.1038%2Fs41598-018-21942-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1</span></div><div class="casAuthors">Gohda Jin; Liu Kai; Xie Xialin; Ishida Takaomi; Gohda Jin; Inoue Jun-Ichiro; Kawaguchi Yasushi; Ishida Takaomi; Suzuki Kazuo; Takeuchi Hiroaki; Inoue Jun-Ichiro; Kawaguchi Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3521</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HIV-1 latent reservoirs harbouring silenced but replication-competent proviruses are a major obstacle against viral eradication in infected patients.  The "shock and kill" strategy aims to reactivate latent provirus with latency reversing agents (LRAs) in the presence of antiretroviral drugs, necessitating the development of effective and efficient LRAs.  We screened a chemical library for potential LRAs and identified two dual Polo-like kinase (PLK)/bromodomain inhibitors, BI-2536 and BI-6727 (volasertib), which are currently undergoing clinical trials against various cancers.  BI-2536 and BI-6727 significantly reactivated silenced HIV-1 provirus at both the mRNA and protein level in two latently infected model cell lines (ACH2 and U1).  BI-2536 dramatically reactivated transcription of latent HIV-1 provirus in peripheral blood mononuclear cells derived from infected patients.  Long terminal repeat activation by the inhibitors was associated with bromodomain rather than PLK inhibition.  We also found that BI-2536 synergistically activates the latent provirus in combination with SAHA, a histone deacetylase inhibitor, or the non-tumour-promoting phorbol ester prostratin.  Our findings strongly suggest that BI-2536 and BI-6727 are potent LRAs for the "shock and kill" HIV-1 eradication strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaGpIqcKv4gMSzjBFCN0BJfW6udTcc2eYOhwZrI62dj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrkvVOhtQ%253D%253D&md5=36ef1811f0a960882117863bff60dc85</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-21942-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-21942-5%26sid%3Dliteratum%253Aachs%26aulast%3DGohda%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DJ.-i.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DT.%26atitle%3DBI-2536%2520and%2520BI-6727%252C%2520Dual%2520Polo-like%2520Kinase%252FBromodomain%2520Inhibitors%252C%2520Effectively%2520Reactivate%2520Latent%2520HIV-1%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-21942-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranfill, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0568-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F1535-7163.MCT-16-0568-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28336808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1054-1067&author=S.+W.+Emberauthor=Q.+T.+Lambertauthor=N.+Berndtauthor=S.+Gunawanauthor=M.+Ayazauthor=M.+Tauroauthor=J.-Y.+Zhuauthor=P.+J.+Cranfillauthor=P.+Greningerauthor=C.+C.+Lynchauthor=C.+H.+Benesauthor=H.+R.+Lawrenceauthor=G.+W.+Reutherauthor=N.+J.+Lawrenceauthor=E.+Sch%C3%B6nbrunn&title=Potent+Dual+BET+Bromodomain-Kinase+Inhibitors+as+Value-Added+Multitargeted+Chemical+Probes+and+Cancer+Therapeutics&doi=10.1158%2F1535-7163.MCT-16-0568-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span></div><div class="casAuthors">Ember, Stuart W.; Lambert, Que T.; Berndt, Norbert; Gunawan, Steven; Ayaz, Muhammad; Tauro, Marilena; Zhu, Jin-Yi; Cranfill, Paula J.; Greninger, Patricia; Lynch, Conor C.; Benes, Cyril H.; Lawrence, Harshani R.; Reuther, Gary W.; Lawrence, Nicholas J.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1054-1067</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers.  Using the chem. scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1.  Lead compds. showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm.  Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1.  Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing.  Combined, our findings indicate promising potential of these agents as novel chem. probes and cancer therapeutics.  Mol Cancer Ther; 16(6); 1054-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFXcj0XbzGLVg90H21EOLACvtfcHk0lhTYgNeLvycwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D&md5=1c0a838978c931fd8ad148a6696bda26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0568-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0568-T%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DAyaz%26aufirst%3DM.%26aulast%3DTauro%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.-Y.%26aulast%3DCranfill%26aufirst%3DP.%2BJ.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DC.%2BC.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DPotent%2520Dual%2520BET%2520Bromodomain-Kinase%2520Inhibitors%2520as%2520Value-Added%2520Multitargeted%2520Chemical%2520Probes%2520and%2520Cancer%2520Therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1054%26epage%3D1067%26doi%3D10.1158%2F1535-7163.MCT-16-0568-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krššák, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürtler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Kr%C5%A1%C5%A1%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+In+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0ljJNqpf5C20rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKr%25C5%25A1%25C5%25A1%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennie, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Research Article: Selectivity-determining Residues in Plk1</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.-H.+Ding&title=Research+Article%3A+Selectivity-determining+Residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0ljJNqpf5C20rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.-H.%26atitle%3DResearch%2520Article%253A%2520Selectivity-determining%2520Residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0ljJNqpf5C20rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0ljiKQ__lVSYyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheenstra, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strovel, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=764-769&author=L.+Chenauthor=J.+L.+Yapauthor=M.+Yoshiokaauthor=M.+E.+Lanningauthor=R.+N.+Fountainauthor=M.+Rajeauthor=J.+A.+Scheenstraauthor=J.+W.+Strovelauthor=S.+Fletcher&title=BRD4+Structure%E2%80%93Activity+Relationships+of+Dual+PLK1+Kinase%2FBRD4+Bromodomain+Inhibitor+BI-2536&doi=10.1021%2Facsmedchemlett.5b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span></div><div class="casAuthors">Chen, Lijia; Yap, Jeremy L.; Yoshioka, Makoto; Lanning, Maryanna E.; Fountain, Rachel N.; Raje, Mithun; Scheenstra, Jacob A.; Strovel, Jeffrey W.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">764-769</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused library of analogs of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepd. and then analyzed for BRD4 and PLK1 inhibitory activities.  Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiety afforded the most potent BRD4 inhibitor of the series (39j) with a Ki = 8.7 nM, which was equipotent against PLK1.  The superior affinity of 39j over the parental compd. to BRD4 possibly derives from improved interactions with the WPF shelf.  Meanwhile, substitution of the pyrimidine NH with an oxygen atom reversed the PLK1/BRD4 selectivity to convert BI-2536 into a BRD4-selective inhibitor, likely owing to the loss of a crit. hydrogen bond in PLK1.  We believe further fine-tuning will furnish a BRD4 "magic bullet" or an even more potent PLK1/BRD4 dual inhibitor toward the expansion and improved efficacy of the chemotherapy arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5UnNSmf1L17Vg90H21EOLACvtfcHk0ljiKQ__lVSYyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D&md5=f39070e652bca20c03a3bc5fe070a7fc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DYoshioka%26aufirst%3DM.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DFountain%26aufirst%3DR.%2BN.%26aulast%3DRaje%26aufirst%3DM.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DStrovel%26aufirst%3DJ.%2BW.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DBRD4%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Dual%2520PLK1%2520Kinase%252FBRD4%2520Bromodomain%2520Inhibitor%2520BI-2536%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D764%26epage%3D769%26doi%3D10.1021%2Facsmedchemlett.5b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosief, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthengi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">7785</span>– <span class="NLM_lpage">7795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=7785-7795&author=S.+Liuauthor=H.+O.+Yosiefauthor=L.+Daiauthor=H.+Huangauthor=G.+Dhawanauthor=X.+Zhangauthor=A.+M.+Muthengiauthor=J.+Robertsauthor=D.+L.+Buckleyauthor=J.+A.+Perryauthor=L.+Wuauthor=J.+E.+Bradnerauthor=J.+Qiauthor=W.+Zhang&title=Structure-Guided+Design+and+Development+of+Potent+and+Selective+Dual+Bromodomain+4+%28BRD4%29%2FPolo-like+Kinase+1+%28PLK1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00765%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYosief%26aufirst%3DH.%2BO.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DDhawan%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMuthengi%26aufirst%3DA.%2BM.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DStructure-Guided%2520Design%2520and%2520Development%2520of%2520Potent%2520and%2520Selective%2520Dual%2520Bromodomain%25204%2520%2528BRD4%2529%252FPolo-like%2520Kinase%25201%2520%2528PLK1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26spage%3D7785%26epage%3D7795%26doi%3D10.1021%2Facs.jmedchem.8b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-Dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lg8vlXMDLMM6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-Dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0licwExCMxrQBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2,4-Diaminopyrimidines Bearing Fused Tricyclic Ring Moiety for Anaplastic Lymphoma Kinase (ALK) Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2191</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.bmcl.2017.03.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2185-2191&author=R.+Acharyauthor=G.+R.+Mathiauthor=D.+H.+Leeauthor=C.+S.+Yunauthor=C.+O.+Leeauthor=H.+R.+Kimauthor=C.+H.+Parkauthor=P.+Kimauthor=J.+Y.+Hwang&title=Novel+2%2C4-Diaminopyrimidines+Bearing+Fused+Tricyclic+Ring+Moiety+for+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor&doi=10.1016%2Fj.bmcl.2017.03.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.073%26sid%3Dliteratum%253Aachs%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DMathi%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DYun%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DNovel%25202%252C4-Diaminopyrimidines%2520Bearing%2520Fused%2520Tricyclic%2520Ring%2520Moiety%2520for%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2185%26epage%3D2191%26doi%3D10.1016%2Fj.bmcl.2017.03.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span> <span> </span><span class="NLM_article-title">Replacing the Terminal Piperidine in Ceritinib with Aliphatic Amines Confers Activities Against Crizotinib-resistant Mutants including G1202R</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.ejmech.2016.11.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=536-549&author=G.+R.+Mathiauthor=C.+H.+Kangauthor=H.+K.+Leeauthor=R.+Acharyauthor=H.-Y.+Leeauthor=J.-Y.+Leeauthor=J.+D.+Haauthor=S.+Ahnauthor=C.+H.+Parkauthor=C.+O.+Leeauthor=J.+Y.+Hwangauthor=C.-S.+Yunauthor=H.+J.+Jungauthor=S.+Y.+Choauthor=H.+R.+Kimauthor=P.+Kim&title=Replacing+the+Terminal+Piperidine+in+Ceritinib+with+Aliphatic+Amines+Confers+Activities+Against+Crizotinib-resistant+Mutants+including+G1202R&doi=10.1016%2Fj.ejmech.2016.11.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DMathi%26aufirst%3DG.%2BR.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.-S.%26aulast%3DJung%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DP.%26atitle%3DReplacing%2520the%2520Terminal%2520Piperidine%2520in%2520Ceritinib%2520with%2520Aliphatic%2520Amines%2520Confers%2520Activities%2520Against%2520Crizotinib-resistant%2520Mutants%2520including%2520G1202R%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D536%26epage%3D549%26doi%3D10.1016%2Fj.ejmech.2016.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">9378</span>– <span class="NLM_lpage">9381</span>, <span class="refDoi"> DOI: 10.1002/anie.201103273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1002%2Fanie.201103273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9378-9381&author=G.+Budinauthor=K.+S.+Yangauthor=T.+Reinerauthor=R.+Weissleder&title=Bioorthogonal+Probes+for+Polo-like+Kinase+1+Imaging+and+Quantification&doi=10.1002%2Fanie.201103273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201103273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201103273%26sid%3Dliteratum%253Aachs%26aulast%3DBudin%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DReiner%26aufirst%3DT.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DBioorthogonal%2520Probes%2520for%2520Polo-like%2520Kinase%25201%2520Imaging%2520and%2520Quantification%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D9378%26epage%3D9381%26doi%3D10.1002%2Fanie.201103273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, M.</span></span> <span> </span><span class="NLM_article-title">Strong Reduction of Hydroxylamine Accumulation in the Catalytic Hydrogenation of Nitroarenes by Vanadium Promoters</span>. <i>Catal. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1023/A:1019034128024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1023%2FA%3A1019034128024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlCnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1997&pages=219-222&author=P.+Baumeisterauthor=H.-U.+Blaserauthor=M.+Studer&title=Strong+Reduction+of+Hydroxylamine+Accumulation+in+the+Catalytic+Hydrogenation+of+Nitroarenes+by+Vanadium+Promoters&doi=10.1023%2FA%3A1019034128024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Strong reduction of hydroxylamine accumulation in the catalytic hydrogenation of nitroarenes by vanadium promoters</span></div><div class="casAuthors">Baumeister, Peter; Blaser, Hans-Ulrich; Studer, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Catalysis Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3,4</span>),
    <span class="NLM_cas:pages">219-222</span>CODEN:
                <span class="NLM_cas:coden">CALEER</span>;
        ISSN:<span class="NLM_cas:issn">1011-372X</span>.
    
            (<span class="NLM_cas:orgname">Baltzer Science Publishers</span>)
        </div><div class="casAbstract">The accumulation of hydroxylamine intermediate during the catalytic hydrogenation of N-cyclohexyl-N-methyl-2-nitrobenzenesulfonamide could be reduced from >40% to <1% by the addn. of catalytic amts. of vanadium promoters, resulting in a faster reaction and purer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZO85_xbipTLVg90H21EOLACvtfcHk0lgmEu8X9dP7bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlCnu7g%253D&md5=300b2412eab310a52d6d5d81ac16932f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019034128024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019034128024%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DP.%26aulast%3DBlaser%26aufirst%3DH.-U.%26aulast%3DStuder%26aufirst%3DM.%26atitle%3DStrong%2520Reduction%2520of%2520Hydroxylamine%2520Accumulation%2520in%2520the%2520Catalytic%2520Hydrogenation%2520of%2520Nitroarenes%2520by%2520Vanadium%2520Promoters%26jtitle%3DCatal.%2520Lett.%26date%3D1997%26volume%3D49%26spage%3D219%26epage%3D222%26doi%3D10.1023%2FA%3A1019034128024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0lgmEu8X9dP7bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirguet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosmini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusq, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordaunt, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uings, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodème, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7501</span>– <span class="NLM_lpage">7515</span>, <span class="refDoi"> DOI: 10.1021/jm401088k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401088k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7501-7515&author=O.+Mirguetauthor=R.+Gosminiauthor=J.+Toumauthor=C.+A.+Cl%C3%A9mentauthor=M.+Barnathanauthor=J.-M.+Brusqauthor=J.+E.+Mordauntauthor=R.+M.+Grimesauthor=M.+Croweauthor=O.+Pineauauthor=M.+Ajakaneauthor=A.+Dauganauthor=P.+Jeffreyauthor=L.+Cutlerauthor=A.+C.+Haynesauthor=N.+N.+Smithersauthor=C.-w.+Chungauthor=P.+Bamboroughauthor=I.+J.+Uingsauthor=A.+Lewisauthor=J.+Witheringtonauthor=N.+Parrauthor=R.+K.+Prinjhaauthor=E.+Nicod%C3%A8me&title=Discovery+of+Epigenetic+Regulator+I-BET762%3A+Lead+Optimization+to+Afford+a+Clinical+Candidate+Inhibitor+of+the+BET+Bromodomains&doi=10.1021%2Fjm401088k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains</span></div><div class="casAuthors">Mirguet, Olivier; Gosmini, Romain; Toum, Jerome; Clement, Catherine A.; Barnathan, Melanie; Brusq, Jean-Marie; Mordaunt, Jacqueline E.; Grimes, Richard M.; Crowe, Miriam; Pineau, Olivier; Ajakane, Myriam; Daugan, Alain; Jeffrey, Phillip; Cutler, Leanne; Haynes, Andrea C.; Smithers, Nicholas N.; Chung, Chun-wa; Bamborough, Paul; Uings, Iain J.; Lewis, Antonia; Witherington, Jason; Parr, Nigel; Prinjha, Rab K.; Nicodeme, Edwige</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7501-7515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues.  This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4).  This work has yielded a potent, selective compd. I-BET762 (I) that is now under evaluation in a phase I/II clin. trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDitaXJSnFE7Vg90H21EOLACvtfcHk0lgmEu8X9dP7bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7jJ&md5=5d059b0be08a74a5721b72a120f7e090</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm401088k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401088k%26sid%3Dliteratum%253Aachs%26aulast%3DMirguet%26aufirst%3DO.%26aulast%3DGosmini%26aufirst%3DR.%26aulast%3DToum%26aufirst%3DJ.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DC.%2BA.%26aulast%3DBarnathan%26aufirst%3DM.%26aulast%3DBrusq%26aufirst%3DJ.-M.%26aulast%3DMordaunt%26aufirst%3DJ.%2BE.%26aulast%3DGrimes%26aufirst%3DR.%2BM.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DPineau%26aufirst%3DO.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DHaynes%26aufirst%3DA.%2BC.%26aulast%3DSmithers%26aufirst%3DN.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DUings%26aufirst%3DI.%2BJ.%26aulast%3DLewis%26aufirst%3DA.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DNicod%25C3%25A8me%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520Epigenetic%2520Regulator%2520I-BET762%253A%2520Lead%2520Optimization%2520to%2520Afford%2520a%2520Clinical%2520Candidate%2520Inhibitor%2520of%2520the%2520BET%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7501%26epage%3D7515%26doi%3D10.1021%2Fjm401088k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule–Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule%E2%80%93Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liyvJi8eHE6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule%25E2%2580%2593Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehlgans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanhaji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurunci-Csacsko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dötsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bug, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Mitotic Arrest and Slippage Induced by Pharmacological Inhibition of Polo-like Kinase 1</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.molonc.2014.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=25169932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=140-154&author=M.+Raabauthor=A.+Kr%C3%A4merauthor=S.+Hehlgansauthor=M.+Sanhajiauthor=E.+Kurunci-Csacskoauthor=C.+D%C3%B6tschauthor=G.+Bugauthor=O.+Ottmannauthor=S.+Beckerauthor=F.+Pachlauthor=B.+Kusterauthor=K.+Strebhardt&title=Mitotic+Arrest+and+Slippage+Induced+by+Pharmacological+Inhibition+of+Polo-like+Kinase+1&doi=10.1016%2Fj.molonc.2014.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1</span></div><div class="casAuthors">Raab, Monika; Kraemer, Andrea; Hehlgans, Stephanie; Sanhaji, Mourad; Kurunci-Csacsko, Elisabeth; Doetsch, Christina; Bug, Gesine; Ottmann, Oliver; Becker, Sven; Pachl, Fiona; Kuster, Bernhard; Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exposure to drugs that interfere with microtubule dynamics block cell cycle progression at mitosis by prolonged activation of the spindle assembly checkpoint (SAC).  Cells can evade mitotic arrest and proceed to interphase without chromosome segregation by a process termed mitotic slippage that involves Cyclin B1 degrdn. without checkpoint inactivation.  Here, we explored the cellular response to small-mol. inhibitors of Polo-like kinase 1 (Plk1), an important regulator of cell division.  We found that the clin. Plk1 inhibitors BI 2536 and BI 6727, both unexpectedly, induced a dose-dependent cellular drug response: While mitotic arrest was induced in cancer cell lines and primary non-transformed cells across the entire range of concns. tested, only high concns. seemed to promote mitotic slippage.  Since this observation contrasts with the effects expected from studies reporting RNAi-mediated Plk1 depletion in cancer cells, we wondered whether both ATP-competitive inhibitors target unknown kinases that are involved in signaling from the spindle assembly checkpoint (SAC) and might contribute to the mitotic slippage.  A chem. proteomics approach used to profile the selectivity of both inhibitors revealed that SAC kinases are not targeted directly.  Still, the activities of Cdk1/Cyclin B1 and Aurora B, which plays important roles in the error correction of false microtubule-kinetochore attachments and in checkpoint signaling, were shown to be downregulated at high inhibitor concns.  Our data suggest that the inhibition of Plk1 activity below a certain threshold influences Aurora B activity via reduced phosphorylation of Fox M1 and Survivin leading to diminished levels of Aurora B protein and alteration of its subcellular localization.  Within the spectrum of SAC proteins that are degraded during mitotic slippage, the degrdn. of Cyclin B1 and the downregulation of Aurora B activity by Plk1 inhibition seem to be crit. promoters of mitotic slippage.  The results indicate that careful dose-finding studies in cancer trials are necessary to limit or even prevent mitotic slippage, which could be assocd. with improved cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrii34p2M0gM7Vg90H21EOLACvtfcHk0liyvJi8eHE6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrs7bK&md5=fec5b964cacf93600fd16ccd1ec78a48</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DRaab%26aufirst%3DM.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DHehlgans%26aufirst%3DS.%26aulast%3DSanhaji%26aufirst%3DM.%26aulast%3DKurunci-Csacsko%26aufirst%3DE.%26aulast%3DD%25C3%25B6tsch%26aufirst%3DC.%26aulast%3DBug%26aufirst%3DG.%26aulast%3DOttmann%26aufirst%3DO.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMitotic%2520Arrest%2520and%2520Slippage%2520Induced%2520by%2520Pharmacological%2520Inhibition%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D140%26epage%3D154%26doi%3D10.1016%2Fj.molonc.2014.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span> <span> </span><span class="NLM_article-title">Immunoassays for the Quantification of ALK and Phosphorylated ALK Support the Evaluation of On-target ALK Inhibitors in Neuroblastoma</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1002%2F1878-0261.12069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28432815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=996-1006&author=E.+R.+Tuckerauthor=J.+R.+Tallauthor=L.+S.+Danielsonauthor=S.+Gowanauthor=Y.+Jaminauthor=S.+P.+Robinsonauthor=U.+Banerjiauthor=L.+Chesler&title=Immunoassays+for+the+Quantification+of+ALK+and+Phosphorylated+ALK+Support+the+Evaluation+of+On-target+ALK+Inhibitors+in+Neuroblastoma&doi=10.1002%2F1878-0261.12069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma</span></div><div class="casAuthors">Tucker, Elizabeth R.; Tall, Jennifer R.; Danielson, Laura S.; Gowan, Sharon; Jamin, Yann; Robinson, Simon P.; Banerji, Udai; Chesler, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">996-1006</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more potent compds. and pharmacodynamic methods with which to det. their efficacy.  We describe immunoassays designed to quantitate phosphorylation of ALK, and their use in preclin. models of neuroblastoma, a pediatric malignancy in which gain-of-function ALK mutations predict a poor overall outcome to conventional treatment.  Validation of the immunoassays is presented using a panel of neuroblastoma cell lines and evidence of on-target ALK inhibition provided by treatment of a genetically engineered murine model of neuroblastoma with two clin. ALK inhibitors, crizotinib and ceritinib, highlighting the superior efficacy of ceritinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpnqWY711H7Vg90H21EOLACvtfcHk0lgwcbEWulyEgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqt7bP&md5=3052aa18ccb10bf6056f3757f5f36880</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12069%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DTall%26aufirst%3DJ.%2BR.%26aulast%3DDanielson%26aufirst%3DL.%2BS.%26aulast%3DGowan%26aufirst%3DS.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DChesler%26aufirst%3DL.%26atitle%3DImmunoassays%2520for%2520the%2520Quantification%2520of%2520ALK%2520and%2520Phosphorylated%2520ALK%2520Support%2520the%2520Evaluation%2520of%2520On-target%2520ALK%2520Inhibitors%2520in%2520Neuroblastoma%26jtitle%3DMol.%2520Oncol.%26date%3D2017%26volume%3D11%26spage%3D996%26epage%3D1006%26doi%3D10.1002%2F1878-0261.12069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span> <span> </span><span class="NLM_article-title">Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">206.e11</span>– <span class="NLM_lpage">214.e11</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.chembiol.2017.10.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=206.e11-214.e11&author=J.+D.+Vastaauthor=C.+R.+Coronaauthor=J.+Wilkinsonauthor=C.+A.+Zimprichauthor=J.+R.+Hartnettauthor=M.+R.+Ingoldauthor=K.+Zimmermanauthor=T.+Machleidtauthor=T.+A.+Kirklandauthor=K.+G.+Huwilerauthor=R.+F.+Ohanaauthor=M.+Slaterauthor=P.+Ottoauthor=M.+Congauthor=C.+I.+Wellsauthor=B.-T.+Bergerauthor=T.+Hankeauthor=C.+Glasauthor=K.+Dingauthor=D.+H.+Drewryauthor=K.+V.+M.+Huberauthor=T.+M.+Willsonauthor=S.+Knappauthor=S.+M%C3%BCllerauthor=P.+L.+Meisenheimerauthor=F.+Fanauthor=K.+V.+Woodauthor=M.+B.+Robers&title=Quantitative%2C+Wide-Spectrum+Kinase+Profiling+in+Live+Cells+for+Assessing+the+Effect+of+Cellular+ATP+on+Target+Engagement&doi=10.1016%2Fj.chembiol.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DIngold%26aufirst%3DM.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DHuwiler%26aufirst%3DK.%2BG.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DBerger%26aufirst%3DB.-T.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DGlas%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26atitle%3DQuantitative%252C%2520Wide-Spectrum%2520Kinase%2520Profiling%2520in%2520Live%2520Cells%2520for%2520Assessing%2520the%2520Effect%2520of%2520Cellular%2520ATP%2520on%2520Target%2520Engagement%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D206.e11%26epage%3D214.e11%26doi%3D10.1016%2Fj.chembiol.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinn, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méndez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1804</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovFKkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1797-1804&author=T.+Machleidtauthor=C.+C.+Woodroofeauthor=M.+K.+Schwinnauthor=J.+M%C3%A9ndezauthor=M.+B.+Robersauthor=K.+Zimmermanauthor=P.+Ottoauthor=D.+L.+Danielsauthor=T.+A.+Kirklandauthor=K.+V.+Wood&title=NanoBRET%E2%80%94A+Novel+BRET+Platform+for+the+Analysis+of+Protein%E2%80%93Protein+Interactions&doi=10.1021%2Facschembio.5b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">NanoBRET-A Novel BRET Platform for the Analysis of Protein-Protein Interactions</span></div><div class="casAuthors">Machleidt, Thomas; Woodroofe, Carolyn C.; Schwinn, Marie K.; Mendez, Jacqui; Robers, Matthew B.; Zimmerman, Kris; Otto, Paul; Daniels, Danette L.; Kirkland, Thomas A.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1797-1804</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dynamic interactions between proteins comprise a key mechanism for temporal control of cellular function and thus hold promise for development of novel drug therapies.  It remains tech. challenging, however, to quant. characterize these interactions within the biol. relevant context of living cells.  Although, bioluminescence resonance energy transfer (BRET) has often been used for this purpose, its general applicability has been hindered by limited sensitivity and dynamic range.  We have addressed this by combining an extremely bright luciferase (Nanoluc) with a means for tagging intracellular proteins with a long-wavelength fluorophore (HaloTag).  The small size (19 kDa), high emission intensity, and relatively narrow spectrum (460 nm peak intensity) make Nanoluc luciferase well suited as an energy donor.  By selecting an efficient red-emitting fluorophore (635 nm peak intensity) for attachment onto the HaloTag, an overall spectral sepn. exceeding 175 nm was achieved.  This combination of greater light intensity with improved spectral resoln. results in substantially increased detection sensitivity and dynamic range over current BRET technologies.  Enhanced performance is demonstrated using several established model systems, as well as the ability to image BRET in individual cells.  The capabilities are further exhibited in a novel assay developed for analyzing the interactions of bromodomain proteins with chromatin in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6-h9HlReNabVg90H21EOLACvtfcHk0lgwcbEWulyEgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovFKkt7c%253D&md5=9f5f773b6cd14c40074a2ffbd6472008</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00143%26sid%3Dliteratum%253Aachs%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DSchwinn%26aufirst%3DM.%2BK.%26aulast%3DM%25C3%25A9ndez%26aufirst%3DJ.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DNanoBRET%25E2%2580%2594A%2520Novel%2520BRET%2520Platform%2520for%2520the%2520Analysis%2520of%2520Protein%25E2%2580%2593Protein%2520Interactions%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1797%26epage%3D1804%26doi%3D10.1021%2Facschembio.5b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Pan Tang, Jifa Zhang, Jie Liu, Cheng-Ming Chiang, <span class="NLM_string-name hlFld-ContribAuthor">Liang Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2419-2435. <a href="https://doi.org/10.1021/acs.jmedchem.0c01487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BBromodomain%252Band%252BExtraterminal%252BProteins%252Bfor%252BDrug%252BDiscovery%25253A%252BFrom%252BCurrent%252BProgress%252Bto%252BTechnological%252BDevelopment%26aulast%3DTang%26aufirst%3DPan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26082020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2419%26epage%3D2435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Corentine M. C. Laurin, Joseph P. Bluck, Anthony K. N. Chan, Michelle Keller, Andrew Boczek, Amy R. Scorah, K. F. Larissa See, Laura E. Jennings, David S. Hewings, Fern Woodhouse, Jessica K. Reynolds, Matthias Schiedel, Philip G. Humphreys, Philip C. Biggin, <span class="NLM_string-name hlFld-ContribAuthor">Stuart J. Conway</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Identification of Ligands for Bromodomain-Containing Factor 3 of Trypanosoma cruzi. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00618%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DFragment-Based%252BIdentification%252Bof%252BLigands%252Bfor%252BBromodomain-Containing%252BFactor%252B3%252Bof%252BTrypanosoma%252Bcruzi%26aulast%3DLaurin%26aufirst%3DCorentine%2BM.%2BC.%26date%3D2020%26date%3D2020%26date%3D31082020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kaikai Lv, Weicong Chen, Danqi Chen, Jie Mou, Huijie Zhang, Tiantian Fan, Yanlian Li, Danyan Cao, Xin Wang, Lin Chen, Jingkang Shen, Dongsheng Pei, <span class="NLM_string-name hlFld-ContribAuthor">Bing Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9787-9802. <a href="https://doi.org/10.1021/acs.jmedchem.0c00962" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00962%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Band%252BEvaluation%252Bof%252B6-%252528Pyrimidin-2-ylamino%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-ones%252Bas%252BPolypharmacological%252BInhibitors%252Bof%252BBET%252Band%252BKinases%26aulast%3DLv%26aufirst%3DKaikai%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D26082020%26date%3D11082020%26volume%3D63%26issue%3D17%26spage%3D9787%26epage%3D9802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jianping Hu, Chang-Qing Tian, Mohammadali Soleimani Damaneh, Yanlian Li, Danyan Cao, Kaikai Lv, Ting Yu, Tao Meng, Danqi Chen, Xin Wang, Lin Chen, Jian Li, Shan-Shan Song, Xia-Juan Huan, Lihuai Qin, Jingkang Shen, Ying-Qing Wang, Ze-Hong Miao, <span class="NLM_string-name hlFld-ContribAuthor">Bing Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (18)
                                     , 8642-8663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01094" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01094%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDiscovery%252Band%252BDevelopment%252Bof%252Ba%252BSeries%252Bof%252BPotent%252Band%252BSelective%252BBromodomain%252Band%252BExtra-Terminal%252BProtein%252BInhibitors%26aulast%3DHu%26aufirst%3DJianping%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07072019%26date%3D16092019%26date%3D06092019%26volume%3D62%26issue%3D18%26spage%3D8642%26epage%3D8663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela
S. Carlson, Huarui Cui, Anand Divakaran, Jorden A. Johnson, Ryan M. Brunner, William C. K. Pomerantz, <span class="NLM_string-name hlFld-ContribAuthor">Joseph J. Topczewski</span>. </span><span class="cited-content_cbyCitation_article-title">Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (9)
                                     , 1296-1301. <a href="https://doi.org/10.1021/acsmedchemlett.9b00227" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00227%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSystematically%252BMitigating%252Bthe%252Bp38%2525CE%2525B1%252BActivity%252Bof%252BTriazole-based%252BBET%252BInhibitors%26aulast%3DCarlson%26aufirst%3DAngela%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20052019%26date%3D02082019%26date%3D07082019%26date%3D02082019%26volume%3D10%26issue%3D9%26spage%3D1296%26epage%3D1301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faraz  Shaikh</span>, <span class="hlFld-ContribAuthor ">Hio Kuan  Tai</span>, <span class="hlFld-ContribAuthor ">Nirali  Desai</span>, <span class="hlFld-ContribAuthor ">Shirley W. I.  Siu</span>. </span><span class="cited-content_cbyCitation_article-title">LigTMap: ligand and structure-based target identification and activity prediction for small molecular compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-021-00523-1" title="DOI URL">https://doi.org/10.1186/s13321-021-00523-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-021-00523-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-021-00523-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DLigTMap%25253A%252Bligand%252Band%252Bstructure-based%252Btarget%252Bidentification%252Band%252Bactivity%252Bprediction%252Bfor%252Bsmall%252Bmolecular%252Bcompounds%26aulast%3DShaikh%26aufirst%3DFaraz%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew J.  Bellantoni</span>, <span class="hlFld-ContribAuthor ">Lars M.  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 3531. <a href="https://doi.org/10.3390/cancers13143531" title="DOI URL">https://doi.org/10.3390/cancers13143531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13143531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13143531%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPursuing%252BPrecision%25253A%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252BTreatment%252Bof%252BPediatric%252BSolid%252BTumors%26aulast%3DBellantoni%26aufirst%3DAndrew%2BJ.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D3531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Xing</span>, <span class="hlFld-ContribAuthor ">Peng  Guan</span>, <span class="hlFld-ContribAuthor ">Shubin  Song</span>, <span class="hlFld-ContribAuthor ">Guirong  You</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Tingting  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113314. <a href="https://doi.org/10.1016/j.ejmech.2021.113314" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113314%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bagents%252Btargeting%252Bpolo-like%252Bkinases%25253A%252BPromising%252Btherapeutic%252Bstrategies%26aulast%3DZhang%26aufirst%3DZheng%26date%3D2021%26volume%3D217%26spage%3D113314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonardo L.G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-54. <a href="https://doi.org/10.1002/0471266949.bmc141.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc141.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc141.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc141.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%2525E2%252580%252590Based%252BDrug%252BDesign%26aulast%3DFerreira%26aufirst%3DLeonardo%2BL.G.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D54%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Zdrazil</span>, <span class="hlFld-ContribAuthor ">Gerhard F.  Ecker</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer Drug Resistance – Targets and Therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-27. <a href="https://doi.org/10.1002/0471266949.bmc215.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc215.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc215.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc215.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DCancer%252BDrug%252BResistance%252B%2525E2%252580%252593%252BTargets%252Band%252BTherapies%26aulast%3DZdrazil%26aufirst%3DBarbara%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D27%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Chasák</span>, <span class="hlFld-ContribAuthor ">Lucie  Brulíková</span>. </span><span class="cited-content_cbyCitation_article-title">Polymer-Supported Synthesis of Various Pteridinones and Pyrimidodiazepinones. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (6)
                                     , 1603. <a href="https://doi.org/10.3390/molecules26061603" title="DOI URL">https://doi.org/10.3390/molecules26061603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26061603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26061603%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPolymer-Supported%252BSynthesis%252Bof%252BVarious%252BPteridinones%252Band%252BPyrimidodiazepinones%26aulast%3DChas%25C3%25A1k%26aufirst%3DJan%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D6%26spage%3D1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharon  Rossiter</span>, <span class="hlFld-ContribAuthor ">Mehrnoosh  Ostovar</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Pteridines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00040-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00040-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00040-8%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BPteridines%26aulast%3DRossiter%26aufirst%3DSharon%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaosa  Chang</span>, <span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Danfeng  Shi</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Yanmei  Chen</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Huidan  Tan</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 156-180. <a href="https://doi.org/10.1016/j.apsb.2020.06.003" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bquinazolin-4%2525283H%252529-one%252Bderivatives%252Bco-targeting%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Band%252Bbromodomain%252Bcontaining%252Bprotein%252B4%252Bfor%252Bbreast%252Bcancer%252Btherapy%26aulast%3DChang%26aufirst%3DXiaosa%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D156%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher A.  Raab</span>, <span class="hlFld-ContribAuthor ">Monika  Raab</span>, <span class="hlFld-ContribAuthor ">Sven  Becker</span>, <span class="hlFld-ContribAuthor ">Klaus  Strebhardt</span>. </span><span class="cited-content_cbyCitation_article-title">Non-mitotic functions of polo-like kinases in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2021,</strong> <em>1875 </em>
                                    (1)
                                     , 188467. <a href="https://doi.org/10.1016/j.bbcan.2020.188467" title="DOI URL">https://doi.org/10.1016/j.bbcan.2020.188467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2020.188467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2020.188467%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DNon-mitotic%252Bfunctions%252Bof%252Bpolo-like%252Bkinases%252Bin%252Bcancer%252Bcells%26aulast%3DRaab%26aufirst%3DChristopher%2BA.%26date%3D2021%26volume%3D1875%26issue%3D1%26spage%3D188467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiu  Li</span>, <span class="hlFld-ContribAuthor ">Xie-Er  Jian</span>, <span class="hlFld-ContribAuthor ">Yu-Feng  Ma</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Xian-Sen  Huo</span>, <span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Ren-Xin  He</span>, <span class="hlFld-ContribAuthor ">Wen-Wei  You</span>, <span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiproliferative evaluation of novel 8-cyclopentyl-7,8-dihydropteridin-6(5H)-one derivatives as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127684. <a href="https://doi.org/10.1016/j.bmcl.2020.127684" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127684%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bantiproliferative%252Bevaluation%252Bof%252Bnovel%252B8-cyclopentyl-7%25252C8-dihydropteridin-6%2525285H%252529-one%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DLi%26aufirst%3DQiu%26date%3D2021%26volume%3D31%26spage%3D127684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen E.  Guest</span>, <span class="hlFld-ContribAuthor ">Stephen D.  Pickett</span>, <span class="hlFld-ContribAuthor ">Jonathan D.  Hirst</span>. </span><span class="cited-content_cbyCitation_article-title">Structural variation of protein–ligand complexes of the first bromodomain of BRD4. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>1 </em><a href="https://doi.org/10.1039/D1OB00658D" title="DOI URL">https://doi.org/10.1039/D1OB00658D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00658D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00658D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DStructural%252Bvariation%252Bof%252Bprotein%2525E2%252580%252593ligand%252Bcomplexes%252Bof%252Bthe%252Bfirst%252Bbromodomain%252Bof%252BBRD4%26aulast%3DGuest%26aufirst%3DEllen%2BE.%26date%3D2021%26date%3D2021%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kendra R.  Vann</span>, <span class="hlFld-ContribAuthor ">Dhananjaya  Pal</span>, <span class="hlFld-ContribAuthor ">Guillermo A.  Morales</span>, <span class="hlFld-ContribAuthor ">Adam M.  Burgoyne</span>, <span class="hlFld-ContribAuthor ">Donald L.  Durden</span>, <span class="hlFld-ContribAuthor ">Tatiana G.  Kutateladze</span>. </span><span class="cited-content_cbyCitation_article-title">Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-68964-6" title="DOI URL">https://doi.org/10.1038/s41598-020-68964-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-68964-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-68964-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDesign%252Bof%252Bthienopyranone-based%252BBET%252Binhibitors%252Bthat%252Bbind%252Bmultiple%252Bsynthetic%252Blethality%252Btargets%26aulast%3DVann%26aufirst%3DKendra%2BR.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Tim  Zegar</span>, <span class="hlFld-ContribAuthor ">Tim  Weiser</span>, <span class="hlFld-ContribAuthor ">Feda H.  Hamdan</span>, <span class="hlFld-ContribAuthor ">Benedict‐Tilman  Berger</span>, <span class="hlFld-ContribAuthor ">Romain  Lucas</span>, <span class="hlFld-ContribAuthor ">Dimitrios‐IIias  Balourdas</span>, <span class="hlFld-ContribAuthor ">Swetlana  Ladigan</span>, <span class="hlFld-ContribAuthor ">Phyllis F.  Cheung</span>, <span class="hlFld-ContribAuthor ">Sven‐Thorsten  Liffers</span>, <span class="hlFld-ContribAuthor ">Marija  Trajkovic‐Arsic</span>, <span class="hlFld-ContribAuthor ">Bjoern  Scheffler</span>, <span class="hlFld-ContribAuthor ">Andreas C.  Joerger</span>, <span class="hlFld-ContribAuthor ">Stephan A.  Hahn</span>, <span class="hlFld-ContribAuthor ">Steven A.  Johnsen</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Jens T.  Siveke</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of a dual
              BET
              /
              HDAC
              inhibitor for treatment of pancreatic ductal adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2020,</strong> <em>147 </em>
                                    (10)
                                     , 2847-2861. <a href="https://doi.org/10.1002/ijc.33137" title="DOI URL">https://doi.org/10.1002/ijc.33137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.33137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.33137%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DCharacterization%252Bof%252Ba%252Bdual%252BBET%252B%25252F%252BHDAC%252Binhibitor%252Bfor%252Btreatment%252Bof%252Bpancreatic%252Bductal%252Badenocarcinoma%26aulast%3DZhang%26aufirst%3DXin%26date%3D2020%26date%3D2020%26volume%3D147%26issue%3D10%26spage%3D2847%26epage%3D2861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning-Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Xu</span>, <span class="hlFld-ContribAuthor ">Kun-Jie  Xiao</span>, <span class="hlFld-ContribAuthor ">Wei-Qiong  Zuo</span>, <span class="hlFld-ContribAuthor ">Yong-Xia  Zhu</span>, <span class="hlFld-ContribAuthor ">Rong  Hu</span>, <span class="hlFld-ContribAuthor ">Wan-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yao-Jie  Shi</span>, <span class="hlFld-ContribAuthor ">Luo-Ting  Yu</span>, <span class="hlFld-ContribAuthor ">Zhi-Hao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>191 </em>, 112152. <a href="https://doi.org/10.1016/j.ejmech.2020.112152" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112152%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B4%25252C5-dihydro-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-f%25255Dpteridine%252Bderivatives%252Bas%252Bnovel%252Bdual-PLK1%25252FBRD4%252Binhibitors%26aulast%3DWang%26aufirst%3DNing-Yu%26date%3D2020%26volume%3D191%26spage%3D112152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalie  Timme</span>, <span class="hlFld-ContribAuthor ">Youjia  Han</span>, <span class="hlFld-ContribAuthor ">Shuai  Liu</span>, <span class="hlFld-ContribAuthor ">Hailemichael O.  Yosief</span>, <span class="hlFld-ContribAuthor ">Heathcliff Dorado  García</span>, <span class="hlFld-ContribAuthor ">Yi  Bei</span>, <span class="hlFld-ContribAuthor ">Filippos  Klironomos</span>, <span class="hlFld-ContribAuthor ">Ian C.  MacArthur</span>, <span class="hlFld-ContribAuthor ">Annabell  Szymansky</span>, <span class="hlFld-ContribAuthor ">Jennifer  von Stebut</span>, <span class="hlFld-ContribAuthor ">Victor  Bardinet</span>, <span class="hlFld-ContribAuthor ">Constantin  Dohna</span>, <span class="hlFld-ContribAuthor ">Annette  Künkele</span>, <span class="hlFld-ContribAuthor ">Jana  Rolff</span>, <span class="hlFld-ContribAuthor ">Patrick  Hundsdörfer</span>, <span class="hlFld-ContribAuthor ">Andrej  Lissat</span>, <span class="hlFld-ContribAuthor ">Georg  Seifert</span>, <span class="hlFld-ContribAuthor ">Angelika  Eggert</span>, <span class="hlFld-ContribAuthor ">Johannes H.  Schulte</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Anton G.  Henssen</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (2)
                                     , 221-232. <a href="https://doi.org/10.1016/j.tranon.2019.09.013" title="DOI URL">https://doi.org/10.1016/j.tranon.2019.09.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2019.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2019.09.013%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DSmall-Molecule%252BDual%252BPLK1%252Band%252BBRD4%252BInhibitors%252Bare%252BActive%252BAgainst%252BPreclinical%252BModels%252Bof%252BPediatric%252BSolid%252BTumors%26aulast%3DTimme%26aufirst%3DNatalie%26date%3D2020%26volume%3D13%26issue%3D2%26spage%3D221%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Rong</span>, <span class="hlFld-ContribAuthor ">Zhan-Zhan  Feng</span>, <span class="hlFld-ContribAuthor ">Yao-Jie  Shi</span>, <span class="hlFld-ContribAuthor ">Jing  Ren</span>, <span class="hlFld-ContribAuthor ">Ying  Xu</span>, <span class="hlFld-ContribAuthor ">Ning-Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Xue</span>, <span class="hlFld-ContribAuthor ">Kun-Lin  Liu</span>, <span class="hlFld-ContribAuthor ">Shu-Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Luo-Ting  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (19)
                                     , 126577. <a href="https://doi.org/10.1016/j.bmcl.2019.07.036" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C5-dimethylisoxazole%252Band%252Bpyridone%252Bderivatives%252Bas%252BBRD4%252Binhibitors%26aulast%3DRong%26aufirst%3DJuan%26date%3D2019%26volume%3D29%26issue%3D19%26spage%3D126577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biochemical potencies of the dual PLK-1–BRD4 inhibitor BI-2536 and moieties of the molecule that form key interactions with BRD4 (orange) and the PLK-1 hinge region (violet).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structures of BI-2536 in complex with (a) BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OGI">4OGI</a>) and (b) PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>) highlighting key interactions. (c) Docking pose generated using Glide showing BI-2536 in complex with ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>), highlighting key interactions. (d) Four chosen areas for modification on BI-2536.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, 70 °C, 90%; (b) 1-iodo-2-methylpropane, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 50 °C, 88%; (c) LiOH, H<sub>2</sub>O, room temperature (rt), 71%; (d) 4-amino-1-methylpiperidine, HBTU, Et<sub>3</sub>N, DMF, rt, 77–86%; (e) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOAc/EtOH, 10:3, 50 °C, 53–55%; (f) 4-pyridylboronic acid, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/water 6:1, 110 °C, 54–65%; (g) MeI, MeCN, 50 °C, 91–99%; (h) NaBH<sub>4</sub>, MeOH, rt, 56–95%; (i) H<sub>2</sub>, PtO<sub>2</sub>, AcOH, 50 psi, 75–85%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, NaOAc, 1,2-dichloroethane (DCE), rt, 16 h, 39–94%; (b) 2,4-dichloronitropyrimidine, NaHCO<sub>3</sub>, cHex, 16 h, 50 °C, 34–90%; (c) Fe, AcOH, 3–4 h, 70 °C, 25–42%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 59–75%; (e) conc. HCl, EtOH/dioxane/H<sub>2</sub>O, 1:1:1, 120 °C, 24–48 h, 7–53%; (f) H<sub>2</sub>, 10% Pd·C, MeOH, rt, 1 h, 41–46%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, NaOAc, DCE, rt, 16 h, 97%; (b) 2,4-dichloronitropyrimidine, NaHCO<sub>3</sub>, cHex, 16 h, 50 °C, 78%; (c) H<sub>2</sub>, PtO<sub>2</sub>, VO(acac)<sub>2</sub>, tetrahydrofuran (THF), 98%; (d) MeI, NaH, DMF, 0 °C to rt, 16 h, 86%; (e) TFA, 80 °C, 4 h, 66%; (f) R<sup>2</sup>–X, NaH, DMF, rt, 16 h, 37–68%; (g) conc. HCl, EtOH/dioxane/H<sub>2</sub>O, 1:1:1, 120 °C, 24–48 h, 9–32%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Surfaces of (a) ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>) and (b) PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>) highlighting residues Leu1256 and Phe183. (c) Docking pose generated using Glide showing <b>16h</b> (orange) in complex with PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>), overlaid with X-ray structure of BI-2536 (yellow) in PLK-1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU">2RKU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Cocrystal structure of <b>16i</b> with BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y">6Q3Y</a>) and associated |2<i>F</i><sub>O</sub>| – |<i>F</i><sub>C</sub>| refined electron density map contoured at 1σ. (b) Cocrystal structure of <b>16k</b> with BRD4 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z">6Q3Z</a>) and associated |2<i>F</i><sub>O</sub>| – |<i>F</i><sub>C</sub>| refined electron density map contoured at 1σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Screening of <b>16k</b> against a panel of 25 bromodomains, showing Δ<i>T</i><sub>m</sub> as circles. Larger circles indicate greater Δ<i>T</i><sub>m</sub>. (b) Screening of <b>16k</b> against the DiscoverX <i>scan</i>EDGE panel of 97 kinases at a single point concentration of 1 μM. Larger circles indicate a stronger hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ALK MSD immunoassay measuring ALK phosphorylation in the Kelly cell line. The plot shows the ratio of phosphorylated ALK to total ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. NanoBRET data for lead compounds <b>16i</b>–<b>k</b> against ALK and BRD4 in HEK293T cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/medium/jm-2018-01947q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Induction of mitotic arrest by BI-2536 and <b>16k</b> in HeLa cells. Changes in the fraction of cells arrested in mitosis were analyzed by Western blots against phosphorylation sites pT210 and pS137 and mitotic markers PLK-1, cyclin B1, and phosphohistone H3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01947&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H.</span></span> <span> </span><span class="NLM_article-title">Neuroblastoma: Biology, Prognosis, and Treatment</span>. <i>Pediatr. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.pcl.2007.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.pcl.2007.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=18242317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Fos1Srtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=97-120&author=J.+R.+Parkauthor=A.+Eggertauthor=H.+Caron&title=Neuroblastoma%3A+Biology%2C+Prognosis%2C+and+Treatment&doi=10.1016%2Fj.pcl.2007.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroblastoma: biology, prognosis, and treatment</span></div><div class="casAuthors">Park Julie R; Eggert Angelika; Caron Huib</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric clinics of North America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-120, x</span>
        ISSN:<span class="NLM_cas:issn">0031-3955</span>.
    </div><div class="casAbstract">Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy.  Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise.  Neuroblastoma serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence.  This article summarizes our understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcRDeDkCpDYeb6AVA-44PTfW6udTcc2eZHp1i_4Ttbd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Fos1Srtg%253D%253D&md5=984f729e5c97ba15df82c216e3173a1f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pcl.2007.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pcl.2007.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BR.%26aulast%3DEggert%26aufirst%3DA.%26aulast%3DCaron%26aufirst%3DH.%26atitle%3DNeuroblastoma%253A%2520Biology%252C%2520Prognosis%252C%2520and%2520Treatment%26jtitle%3DPediatr.%2520Clin.%2520North%2520Am.%26date%3D2008%26volume%3D55%26spage%3D97%26epage%3D120%26doi%3D10.1016%2Fj.pcl.2007.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetharoy, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.ccr.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22789543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=117-130&author=T.+Berryauthor=W.+Lutherauthor=N.+Bhatnagarauthor=Y.+Jaminauthor=E.+Poonauthor=T.+Sandaauthor=D.+Peiauthor=B.+Sharmaauthor=W.+R.+Vetharoyauthor=A.+Hallsworthauthor=Z.+Ahmadauthor=K.+Barkerauthor=L.+Moreauauthor=H.+Webberauthor=W.+Wangauthor=Q.+Liuauthor=A.+Perez-Ataydeauthor=S.+Rodigauthor=N.-K.+Cheungauthor=F.+Raynaudauthor=B.+Hallbergauthor=S.+P.+Robinsonauthor=N.+S.+Grayauthor=A.+D.+J.+Pearsonauthor=S.+A.+Ecclesauthor=L.+Cheslerauthor=R.+E.+George&title=The+ALKF1174L+Mutation+Potentiates+the+Oncogenic+Activity+of+MYCN+in+Neuroblastoma&doi=10.1016%2Fj.ccr.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span></div><div class="casAuthors">Berry, Teeara; Luther, William; Bhatnagar, Namrata; Jamin, Yann; Poon, Evon; Sanda, Takaomi; Pei, Desheng; Sharma, Bandana; Vetharoy, Winston R.; Hallsworth, Albert; Ahmad, Zai; Barker, Karen; Moreau, Lisa; Webber, Hannah; Wang, Wenchao; Liu, Qingsong; Perez-Atayde, Antonio; Rodig, Scott; Cheung, Nai-Kong; Raynaud, Florence; Hallberg, Bengt; Robinson, Simon P.; Gray, Nathanael S.; Pearson, Andrew D. J.; Eccles, Suzanne A.; Chesler, Louis; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The ALKF1174L mutation is assocd. with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma.  In this study, we generated a mouse model overexpressing ALKF1174L in the neural crest.  Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality.  ALKF1174L/MYCN tumors exhibited increased MYCN dosage due to ALKF1174L-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects.  Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALKF1174L/MYCN tumors to crizotinib.  Our findings demonstrate a pathogenic role for ALKF1174L in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-pos. neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQvwCqpbNJsbVg90H21EOLACvtfcHk0lgm3GJpH9rFpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ&md5=17eaed93b440461999c4f8f099f57723</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DBhatnagar%26aufirst%3DN.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DVetharoy%26aufirst%3DW.%2BR.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DBarker%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DL.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DN.-K.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DThe%2520ALKF1174L%2520Mutation%2520Potentiates%2520the%2520Oncogenic%2520Activity%2520of%2520MYCN%2520in%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D117%26epage%3D130%26doi%3D10.1016%2Fj.ccr.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haglund, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plegaria, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toporovskaya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span> <span> </span><span class="NLM_article-title">Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">108ra114</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3002950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1126%2Fscitranslmed.3002950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22072639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=S.+C.+Breslerauthor=A.+C.+Woodauthor=E.+A.+Haglundauthor=J.+Courtrightauthor=L.+T.+Belcastroauthor=J.+S.+Plegariaauthor=K.+Coleauthor=Y.+Toporovskayaauthor=H.+Zhaoauthor=E.+L.+Carpenterauthor=J.+G.+Christensenauthor=J.+M.+Marisauthor=M.+A.+Lemmonauthor=Y.+P.+Moss%C3%A9&title=Differential+Inhibitor+Sensitivity+of+Anaplastic+Lymphoma+Kinase+Variants+Found+in+Neuroblastoma&doi=10.1126%2Fscitranslmed.3002950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002950%26sid%3Dliteratum%253Aachs%26aulast%3DBresler%26aufirst%3DS.%2BC.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DHaglund%26aufirst%3DE.%2BA.%26aulast%3DCourtright%26aufirst%3DJ.%26aulast%3DBelcastro%26aufirst%3DL.%2BT.%26aulast%3DPlegaria%26aufirst%3DJ.%2BS.%26aulast%3DCole%26aufirst%3DK.%26aulast%3DToporovskaya%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarpenter%26aufirst%3DE.%2BL.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26atitle%3DDifferential%2520Inhibitor%2520Sensitivity%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520Variants%2520Found%2520in%2520Neuroblastoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3002950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span>Study Of Lorlatinib (PF-06463922)
- NCT03107988.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+Of+Lorlatinib+%28PF-06463922%29%0A-+NCT03107988."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthery, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekritz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F2159-8290.CD-12-0418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=308-323&author=A.+Puissantauthor=S.+M.+Frummauthor=G.+Alexeauthor=C.+F.+Bassilauthor=J.+Qiauthor=Y.+H.+Chantheryauthor=E.+A.+Nekritzauthor=R.+Zeidauthor=W.+C.+Gustafsonauthor=P.+Greningerauthor=M.+J.+Garnettauthor=U.+McDermottauthor=C.+H.+Benesauthor=A.+L.+Kungauthor=W.+A.+Weissauthor=J.+E.+Bradnerauthor=K.+Stegmaier&title=Targeting+MYCN+in+Neuroblastoma+by+BET+Bromodomain+Inhibition&doi=10.1158%2F2159-8290.CD-12-0418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0418%26sid%3Dliteratum%253Aachs%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DFrumm%26aufirst%3DS.%2BM.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DBassil%26aufirst%3DC.%2BF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChanthery%26aufirst%3DY.%2BH.%26aulast%3DNekritz%26aufirst%3DE.%2BA.%26aulast%3DZeid%26aufirst%3DR.%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DTargeting%2520MYCN%2520in%2520Neuroblastoma%2520by%2520BET%2520Bromodomain%2520Inhibition%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D308%26epage%3D323%26doi%3D10.1158%2F2159-8290.CD-12-0418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delmore, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastritis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpatrick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakoc, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span> <span> </span><span class="NLM_article-title">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.cell.2011.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21889194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=904-917&author=J.+E.+Delmoreauthor=G.+C.+Issaauthor=M.+E.+Lemieuxauthor=P.+B.+Rahlauthor=J.+Shiauthor=H.+M.+Jacobsauthor=E.+Kastritisauthor=T.+Gilpatrickauthor=R.+M.+Paranalauthor=J.+Qiauthor=M.+Chesiauthor=A.+C.+Schinzelauthor=M.+R.+McKeownauthor=T.+P.+Heffernanauthor=C.+R.+Vakocauthor=P.+L.+Bergsagelauthor=I.+M.+Ghobrialauthor=P.+G.+Richardsonauthor=R.+A.+Youngauthor=W.+C.+Hahnauthor=K.+C.+Andersonauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=C.+S.+Mitsiades&title=BET+Bromodomain+Inhibition+as+a+Therapeutic+Strategy+to+Target+c-Myc&doi=10.1016%2Fj.cell.2011.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc</span></div><div class="casAuthors">Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E.; Rahl, Peter B.; Shi, Jun-Wei; Jacobs, Hannah M.; Kastritis, Efstathios; Gilpatrick, Timothy; Paranal, Ronald M.; Qi, Jun; Chesi, Marta; Schinzel, Anna C.; McKeown, Michael R.; Heffernan, Timothy P.; Vakoc, Christopher R.; Bergsagel, P. Leif; Ghobrial, Irene M.; Richardson, Paul G.; Young, Richard A.; Hahn, William C.; Anderson, Kenneth C.; Kung, Andrew L.; Bradner, James E.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-917</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist.  Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation.  Using a selective small-mol. bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc.  BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes.  In exptl. models of multiple myeloma, a Myc-dependent hematol. malignancy, JQ1 produces a potent antiproliferative effect assocd. with cell-cycle arrest and cellular senescence.  Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathol. activation of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpevD1QHKmOhLVg90H21EOLACvtfcHk0ljWDcneTgYonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fF&md5=013674b8224214a9a1c8f0b75583a5a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DIssa%26aufirst%3DG.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BE.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DKastritis%26aufirst%3DE.%26aulast%3DGilpatrick%26aufirst%3DT.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DVakoc%26aufirst%3DC.%2BR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DBET%2520Bromodomain%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520c-Myc%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D904%26epage%3D917%26doi%3D10.1016%2Fj.cell.2011.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">16669</span>– <span class="NLM_lpage">16674</span>, <span class="refDoi"> DOI: 10.1073/pnas.1108190108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.1108190108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21949397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16669-16674&author=J.+A.+Mertzauthor=A.+R.+Coneryauthor=B.+M.+Bryantauthor=P.+Sandyauthor=S.+Balasubramanianauthor=D.+A.+Meleauthor=L.+Bergeronauthor=R.+J.+Sims&title=Targeting+MYC+Dependence+in+Cancer+by+Inhibiting+BET+Bromodomains&doi=10.1073%2Fpnas.1108190108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependence in cancer by inhibiting BET bromodomains</span></div><div class="casAuthors">Mertz, Jennifer A.; Conery, Andrew R.; Bryant, Barbara M.; Sandy, Peter; Balasubramanian, Srividya; Mele, Deanna A.; Bergeron, Louise; Sims, Robert J., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16669-16674, S16669/1-S16669/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies.  However, pharmacol. inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions.  Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small mol. inhibitors of the BET family of chromatin adaptors.  MYC transcriptional suppression was obsd. in the context of the natural, chromosomally translocated, and amplified gene locus.  Inhibition of BET bromodomain-promoter interactions and subsequent redn. of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines.  Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors.  MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor.  Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia.  These findings demonstrate that pharmacol. inhibition of MYC is achievable through targeting BET bromodomains.  Such inhibitors may have clin. utility given the widespread pathogenetic role of MYC in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UHj1YB_ikrVg90H21EOLACvtfcHk0ljWDcneTgYonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWksrnL&md5=b1f0fd41fa56bbfcbb1ad6c8d48f7f80</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108190108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108190108%26sid%3Dliteratum%253Aachs%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520MYC%2520Dependence%2520in%2520Cancer%2520by%2520Inhibiting%2520BET%2520Bromodomains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D108%26spage%3D16669%26epage%3D16674%26doi%3D10.1073%2Fpnas.1108190108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bromodomains: Epigenetic Readers of Lysine Acetylation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrd4286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnrd4286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=24751816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=337-356&author=P.+Filippakopoulosauthor=S.+Knapp&title=Targeting+Bromodomains%3A+Epigenetic+Readers+of+Lysine+Acetylation&doi=10.1038%2Fnrd4286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting bromodomains: epigenetic readers of lysine acetylation</span></div><div class="casAuthors">Filippakopoulos, Panagis; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-356</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases.  Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes.  These complexes can then initiate transcriptional programs that result in phenotypic changes.  The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncol., where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins.  In addn., targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection.  Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSIcwBJKj4LVg90H21EOLACvtfcHk0lgk19EKxN4roQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D&md5=77049c82ce6a19b4685e3b7950399a07</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd4286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4286%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DTargeting%2520Bromodomains%253A%2520Epigenetic%2520Readers%2520of%2520Lysine%2520Acetylation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D337%26epage%3D356%26doi%3D10.1038%2Fnrd4286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span> <span> </span><span class="NLM_article-title">New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5814</span>– <span class="NLM_lpage">5821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F1078-0432.CCR-13-0680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=23965898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5814-5821&author=G.+Baroneauthor=J.+Andersonauthor=A.+D.+J.+Pearsonauthor=K.+Petrieauthor=L.+Chesler&title=New+Strategies+in+Neuroblastoma%3A+Therapeutic+Targeting+of+MYCN+and+ALK&doi=10.1158%2F1078-0432.CCR-13-0680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK</span></div><div class="casAuthors">Barone, Giuseppe; Anderson, John; Pearson, Andrew D. J.; Petrie, Kevin; Chesler, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5814-5821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Clin. outcome remains poor in patients with high-risk neuroblastoma, in which chemoresistant relapse is common following high-intensity conventional multimodal therapy.  Novel treatment approaches are required.  Although recent genomic profiling initiatives have not revealed a high frequency of mutations in any significant no. of therapeutically targeted genes, two exceptions, amplification of the MYCN oncogene and somatically acquired tyrosine kinase domain point mutations in anaplastic lymphoma kinase (ALK), present exciting possibilities for targeted therapy.  In contrast with the situation with ALK, in which a robust pipeline of pharmacol. agents is available from early clin. use in adult malignancy, therapeutic targeting of MYCN (and MYC oncoproteins in general) represents a significant medicinal chem. challenge that has remained unsolved for two decades.  We review the latest approaches envisioned for blockade of ALK activity in neuroblastoma, present a classification of potential approaches for therapeutic targeting of MYCN, and discuss how recent developments in targeting of MYC proteins seem to make therapeutic inhibition of MYCN a reality in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKH_mYvOHk7Vg90H21EOLACvtfcHk0lgk19EKxN4roQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbjK&md5=abc7c5311a0c461cc0b419c985ccb171</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0680%26sid%3Dliteratum%253Aachs%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DPetrie%26aufirst%3DK.%26aulast%3DChesler%26aufirst%3DL.%26atitle%3DNew%2520Strategies%2520in%2520Neuroblastoma%253A%2520Therapeutic%2520Targeting%2520of%2520MYCN%2520and%2520ALK%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5814%26epage%3D5821%26doi%3D10.1158%2F1078-0432.CCR-13-0680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology – Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology+%E2%80%93+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lgk19EKxN4roQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%2520%25E2%2580%2593%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amirouchene-Angelozzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Tumor Evolution as a Therapeutic Target</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F2159-8290.CD-17-0343" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=805-817&author=N.+Amirouchene-Angelozziauthor=C.+Swantonauthor=A.+Bardelli&title=Tumor+Evolution+as+a+Therapeutic+Target&doi=10.1158%2F2159-8290.CD-17-0343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0343%26sid%3Dliteratum%253Aachs%26aulast%3DAmirouchene-Angelozzi%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DTumor%2520Evolution%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D805%26epage%3D817%26doi%3D10.1158%2F2159-8290.CD-17-0343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhi, B.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition: a Novel Promising Pharmacological Approach for Different Disease Conditions</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.2010.01236.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1111%2Fj.2042-7158.2010.01236.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21401597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=459-471&author=S.+Patyarauthor=A.+Prakashauthor=B.+Medhi&title=Dual+Inhibition%3A+a+Novel+Promising+Pharmacological+Approach+for+Different+Disease+Conditions&doi=10.1111%2Fj.2042-7158.2010.01236.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span></div><div class="casAuthors">Patyar, Sazal; Prakash, Ajay; Medhi, Bikash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-471</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  To overcome the problems assocd. with polypharmacy, which include medication non compliance, adverse drug reactions, drug-drug interactions, and increased pill-burden, various strategies, such as sustained-release drugs and fixed-dose combination regimens (polypills), were developed.  Out of these, a novel and very much promising approach is the use of dual-action drugs.  Amongst the dual-action drugs, there is a class of compds. known as dual inhibitors, which possess the dual inhibitory activity.  The most common examples of dual inhibitors are rivastigmine, ladostigil, asenapine, phenserine, amitriptyline, clomipramine, doxepin, and desipramine.  This review article focuses on the conventional drugs used in different diseases which possess dual inhibition activity as well as those which are still in the preclin./clin. phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoimW_BGkApX7Vg90H21EOLACvtfcHk0liQ1w47VDsk_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D&md5=5cae05a18a9246b765e400230e8ef62f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2010.01236.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2010.01236.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatyar%26aufirst%3DS.%26aulast%3DPrakash%26aufirst%3DA.%26aulast%3DMedhi%26aufirst%3DB.%26atitle%3DDual%2520Inhibition%253A%2520a%2520Novel%2520Promising%2520Pharmacological%2520Approach%2520for%2520Different%2520Disease%2520Conditions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D63%26spage%3D459%26epage%3D471%26doi%3D10.1111%2Fj.2042-7158.2010.01236.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockway-Lunardi, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonk, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohoney, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meech, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer</span>. <i>JNCI, J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1093/jnci/djr246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1093%2Fjnci%2Fdjr246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=21765011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVygtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2011&pages=1222-1226&author=R.+W.+Humphreyauthor=L.+M.+Brockway-Lunardiauthor=D.+T.+Bonkauthor=K.+M.+Dohoneyauthor=J.+H.+Doroshowauthor=S.+J.+Meechauthor=M.+J.+Ratainauthor=S.+L.+Topalianauthor=D.+M.+Pardoll&title=Opportunities+and+Challenges+in+the+Development+of+Experimental+Drug+Combinations+for+Cancer&doi=10.1093%2Fjnci%2Fdjr246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer</span></div><div class="casAuthors">Humphrey, Rachel W.; Brockway-Lunardi, Laura M.; Bonk, David T.; Dohoney, Kathleen M.; Doroshow, James H.; Meech, Sandra J.; Ratain, Mark J.; Topalian, Suzanne L.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1222-1226</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  It is becoming increasingly evident that cancers are dependent on a no. of altered mol. pathways and can develop diverse mechanisms of resistance to therapy with single agents.  Therefore, combination regimens may provide the best hope for effective therapies with durable effects.  Despite preclin. data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers.  A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolOCYp6_ctwbVg90H21EOLACvtfcHk0liQ1w47VDsk_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVygtrfF&md5=8b704a9777938e23cc73c2e8307ed374</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr246%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DR.%2BW.%26aulast%3DBrockway-Lunardi%26aufirst%3DL.%2BM.%26aulast%3DBonk%26aufirst%3DD.%2BT.%26aulast%3DDohoney%26aufirst%3DK.%2BM.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DMeech%26aufirst%3DS.%2BJ.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DOpportunities%2520and%2520Challenges%2520in%2520the%2520Development%2520of%2520Experimental%2520Drug%2520Combinations%2520for%2520Cancer%26jtitle%3DJNCI%252C%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D103%26spage%3D1222%26epage%3D1226%26doi%3D10.1093%2Fjnci%2Fdjr246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&author=P.+Ciceriauthor=S.+Mullerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+A.+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0liQ1w47VDsk_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1021/cb500072z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500072z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1160-1171&author=S.+W.+J.+Emberauthor=J.-Y.+Zhuauthor=S.+H.+Olesenauthor=M.+P.+Martinauthor=A.+Beckerauthor=N.+Berndtauthor=G.+I.+Georgauthor=E.+Sch%C3%B6nbrunn&title=Acetyl-lysine+Binding+Site+of+Bromodomain-Containing+Protein+4+%28BRD4%29+Interacts+with+Diverse+Kinase+Inhibitors&doi=10.1021%2Fcb500072z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors</span></div><div class="casAuthors">Ember, Stuart W. J.; Zhu, Jin-Yi; Olesen, Sanne H.; Martin, Mathew P.; Becker, Andreas; Berndt, Norbert; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1171</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research.  In co-crystn. screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and characterized 14 kinase inhibitors (10 distinct chem. scaffolds) as ligands of the KAc binding site.  Among these, the PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 displayed strongest inhibitory potential against BRD4 (IC50 = 25 nM and 130 nM, resp.) and high selectivity for BET bromodomains.  Comparative structural anal. revealed markedly different binding modes of kinase hinge-binding scaffolds in the KAc binding site, suggesting that BET proteins are potential off-targets of diverse kinase inhibitors.  Combined, these findings provide a new structural framework for the rational design of next-generation BET-selective and dual-activity BET-kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0X1hjt7cBbVg90H21EOLACvtfcHk0lhiZolame1oyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymt7g%253D&md5=5ca37df00cdaa0ba81c0cb4a0f70ba5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fcb500072z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500072z%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.-Y.%26aulast%3DOlesen%26aufirst%3DS.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DAcetyl-lysine%2520Binding%2520Site%2520of%2520Bromodomain-Containing%2520Protein%25204%2520%2528BRD4%2529%2520Interacts%2520with%2520Diverse%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1160%26epage%3D1171%26doi%3D10.1021%2Fcb500072z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dittmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fälth
Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1021/cb400789e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400789e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=495-502&author=A.+Dittmannauthor=T.+Wernerauthor=C.-W.+Chungauthor=M.+M.+Savitskiauthor=M.+F%C3%A4lth%0ASavitskiauthor=P.+Grandiauthor=C.+Hopfauthor=M.+Lindonauthor=G.+Neubauerauthor=R.+K.+Prinjhaauthor=M.+Bantscheffauthor=G.+Drewes&title=The+Commonly+Used+PI3-Kinase+Probe+LY294002+Is+an+Inhibitor+of+BET+Bromodomains&doi=10.1021%2Fcb400789e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains</span></div><div class="casAuthors">Dittmann, Antje; Werner, Thilo; Chung, Chun-Wa; Savitski, Mikhail M.; Faelth Savitski, Maria; Grandi, Paola; Hopf, Carsten; Lindon, Matthew; Neubauer, Gitte; Prinjha, Rabinder K.; Bantscheff, Marcus; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A commonly used small-mol. probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002.  Quant. chemoproteomic profiling shows that LY294002 and LY303511, a close analog devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K.  Both compds. competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell exts.  X-ray crystallog. shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbIVXFQARTKLVg90H21EOLACvtfcHk0liTpI4MHHqNyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGnt7nO&md5=13435c7d6a6747dc5699e3c3865c8243</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb400789e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400789e%26sid%3Dliteratum%253Aachs%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DF%25C3%25A4lth%2BSavitski%26aufirst%3DM.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThe%2520Commonly%2520Used%2520PI3-Kinase%2520Probe%2520LY294002%2520Is%2520an%2520Inhibitor%2520of%2520BET%2520Bromodomains%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D495%26epage%3D502%26doi%3D10.1021%2Fcb400789e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span> <span> </span><span class="NLM_article-title">Dual-activity PI3K–BRD4 Inhibitor for the Orthogonal Inhibition of MYC to Block Tumor Growth and Metastasis</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E1072</span>– <span class="NLM_lpage">E1080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1613091114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.1613091114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28137841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E1072-E1080&author=F.+H.+Andrewsauthor=A.+R.+Singhauthor=S.+Joshiauthor=C.+A.+Smithauthor=G.+A.+Moralesauthor=J.+R.+Garlichauthor=D.+L.+Durdenauthor=T.+G.+Kutateladze&title=Dual-activity+PI3K%E2%80%93BRD4+Inhibitor+for+the+Orthogonal+Inhibition+of+MYC+to+Block+Tumor+Growth+and+Metastasis&doi=10.1073%2Fpnas.1613091114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis</span></div><div class="casAuthors">Andrews, Forest H.; Singh, Alok R.; Joshi, Shweta; Smith, Cassandra A.; Morales, Guillermo A.; Garlich, Joseph R.; Durden, Donald L.; Kutateladze, Tatiana G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E1072-E1080</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MYC is a major cancer driver but is documented to be a difficult therapeutic target itself.  Here, we report on the biol. activity, the structural basis, and therapeutic effects of the family of multitargeted compds. that simultaneously disrupt functions of two crit. MYC-mediating factors through inhibiting the acetyllysine binding of BRD4 and the kinase activity of PI3K.  We show that the dual-action inhibitor impairs PI3K/BRD4 signaling in vitro and in vivo and affords maximal MYC down-regulation.  The concomitant inhibition of PI3K and BRD4 blocks MYC expression and activation, promotes MYC degrdn., and markedly inhibits cancer cell growth and metastasis.  Collectively, our findings suggest that the dual-activity inhibitor represents a highly promising lead compd. for the development of novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHgfwKeBVd7Vg90H21EOLACvtfcHk0liTpI4MHHqNyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7Y%253D&md5=f890d20c18d443f5f36d1b13bad9b3b8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1613091114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1613091114%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DF.%2BH.%26aulast%3DSingh%26aufirst%3DA.%2BR.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BA.%26aulast%3DMorales%26aufirst%3DG.%2BA.%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26atitle%3DDual-activity%2520PI3K%25E2%2580%2593BRD4%2520Inhibitor%2520for%2520the%2520Orthogonal%2520Inhibition%2520of%2520MYC%2520to%2520Block%2520Tumor%2520Growth%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2017%26volume%3D114%26spage%3DE1072%26epage%3DE1080%26doi%3D10.1073%2Fpnas.1613091114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span> <span> </span><span class="NLM_article-title">BI-2536 and BI-6727, Dual Polo-like Kinase/Bromodomain Inhibitors, Effectively Reactivate Latent HIV-1</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">3521</span> <span class="refDoi"> DOI: 10.1038/s41598-018-21942-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fs41598-018-21942-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=29476067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A280%3ADC%252BC1MrkvVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=J.+Gohdaauthor=K.+Suzukiauthor=K.+Liuauthor=X.+Xieauthor=H.+Takeuchiauthor=J.-i.+Inoueauthor=Y.+Kawaguchiauthor=T.+Ishida&title=BI-2536+and+BI-6727%2C+Dual+Polo-like+Kinase%2FBromodomain+Inhibitors%2C+Effectively+Reactivate+Latent+HIV-1&doi=10.1038%2Fs41598-018-21942-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1</span></div><div class="casAuthors">Gohda Jin; Liu Kai; Xie Xialin; Ishida Takaomi; Gohda Jin; Inoue Jun-Ichiro; Kawaguchi Yasushi; Ishida Takaomi; Suzuki Kazuo; Takeuchi Hiroaki; Inoue Jun-Ichiro; Kawaguchi Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3521</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HIV-1 latent reservoirs harbouring silenced but replication-competent proviruses are a major obstacle against viral eradication in infected patients.  The "shock and kill" strategy aims to reactivate latent provirus with latency reversing agents (LRAs) in the presence of antiretroviral drugs, necessitating the development of effective and efficient LRAs.  We screened a chemical library for potential LRAs and identified two dual Polo-like kinase (PLK)/bromodomain inhibitors, BI-2536 and BI-6727 (volasertib), which are currently undergoing clinical trials against various cancers.  BI-2536 and BI-6727 significantly reactivated silenced HIV-1 provirus at both the mRNA and protein level in two latently infected model cell lines (ACH2 and U1).  BI-2536 dramatically reactivated transcription of latent HIV-1 provirus in peripheral blood mononuclear cells derived from infected patients.  Long terminal repeat activation by the inhibitors was associated with bromodomain rather than PLK inhibition.  We also found that BI-2536 synergistically activates the latent provirus in combination with SAHA, a histone deacetylase inhibitor, or the non-tumour-promoting phorbol ester prostratin.  Our findings strongly suggest that BI-2536 and BI-6727 are potent LRAs for the "shock and kill" HIV-1 eradication strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaGpIqcKv4gMSzjBFCN0BJfW6udTcc2ebuk57Gre2OErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrkvVOhtQ%253D%253D&md5=36ef1811f0a960882117863bff60dc85</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-21942-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-21942-5%26sid%3Dliteratum%253Aachs%26aulast%3DGohda%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DJ.-i.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DT.%26atitle%3DBI-2536%2520and%2520BI-6727%252C%2520Dual%2520Polo-like%2520Kinase%252FBromodomain%2520Inhibitors%252C%2520Effectively%2520Reactivate%2520Latent%2520HIV-1%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-21942-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranfill, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0568-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1158%2F1535-7163.MCT-16-0568-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28336808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1054-1067&author=S.+W.+Emberauthor=Q.+T.+Lambertauthor=N.+Berndtauthor=S.+Gunawanauthor=M.+Ayazauthor=M.+Tauroauthor=J.-Y.+Zhuauthor=P.+J.+Cranfillauthor=P.+Greningerauthor=C.+C.+Lynchauthor=C.+H.+Benesauthor=H.+R.+Lawrenceauthor=G.+W.+Reutherauthor=N.+J.+Lawrenceauthor=E.+Sch%C3%B6nbrunn&title=Potent+Dual+BET+Bromodomain-Kinase+Inhibitors+as+Value-Added+Multitargeted+Chemical+Probes+and+Cancer+Therapeutics&doi=10.1158%2F1535-7163.MCT-16-0568-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span></div><div class="casAuthors">Ember, Stuart W.; Lambert, Que T.; Berndt, Norbert; Gunawan, Steven; Ayaz, Muhammad; Tauro, Marilena; Zhu, Jin-Yi; Cranfill, Paula J.; Greninger, Patricia; Lynch, Conor C.; Benes, Cyril H.; Lawrence, Harshani R.; Reuther, Gary W.; Lawrence, Nicholas J.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1054-1067</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers.  Using the chem. scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1.  Lead compds. showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm.  Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1.  Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing.  Combined, our findings indicate promising potential of these agents as novel chem. probes and cancer therapeutics.  Mol Cancer Ther; 16(6); 1054-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFXcj0XbzGLVg90H21EOLACvtfcHk0lgXwN9_RnFUvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D&md5=1c0a838978c931fd8ad148a6696bda26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0568-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0568-T%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DAyaz%26aufirst%3DM.%26aulast%3DTauro%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.-Y.%26aulast%3DCranfill%26aufirst%3DP.%2BJ.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DC.%2BC.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSch%25C3%25B6nbrunn%26aufirst%3DE.%26atitle%3DPotent%2520Dual%2520BET%2520Bromodomain-Kinase%2520Inhibitors%2520as%2520Value-Added%2520Multitargeted%2520Chemical%2520Probes%2520and%2520Cancer%2520Therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1054%26epage%3D1067%26doi%3D10.1158%2F1535-7163.MCT-16-0568-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krššák, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürtler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Kr%C5%A1%C5%A1%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+In+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0lgXwN9_RnFUvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKr%25C5%25A1%25C5%25A1%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennie, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Research Article: Selectivity-determining Residues in Plk1</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.-H.+Ding&title=Research+Article%3A+Selectivity-determining+Residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0lgXwN9_RnFUvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.-H.%26atitle%3DResearch%2520Article%253A%2520Selectivity-determining%2520Residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lhsTcZWd7VgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhsTcZWd7VgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheenstra, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strovel, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=764-769&author=L.+Chenauthor=J.+L.+Yapauthor=M.+Yoshiokaauthor=M.+E.+Lanningauthor=R.+N.+Fountainauthor=M.+Rajeauthor=J.+A.+Scheenstraauthor=J.+W.+Strovelauthor=S.+Fletcher&title=BRD4+Structure%E2%80%93Activity+Relationships+of+Dual+PLK1+Kinase%2FBRD4+Bromodomain+Inhibitor+BI-2536&doi=10.1021%2Facsmedchemlett.5b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536</span></div><div class="casAuthors">Chen, Lijia; Yap, Jeremy L.; Yoshioka, Makoto; Lanning, Maryanna E.; Fountain, Rachel N.; Raje, Mithun; Scheenstra, Jacob A.; Strovel, Jeffrey W.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">764-769</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused library of analogs of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepd. and then analyzed for BRD4 and PLK1 inhibitory activities.  Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiety afforded the most potent BRD4 inhibitor of the series (39j) with a Ki = 8.7 nM, which was equipotent against PLK1.  The superior affinity of 39j over the parental compd. to BRD4 possibly derives from improved interactions with the WPF shelf.  Meanwhile, substitution of the pyrimidine NH with an oxygen atom reversed the PLK1/BRD4 selectivity to convert BI-2536 into a BRD4-selective inhibitor, likely owing to the loss of a crit. hydrogen bond in PLK1.  We believe further fine-tuning will furnish a BRD4 "magic bullet" or an even more potent PLK1/BRD4 dual inhibitor toward the expansion and improved efficacy of the chemotherapy arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5UnNSmf1L17Vg90H21EOLACvtfcHk0lhsTcZWd7VgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChtb0%253D&md5=f39070e652bca20c03a3bc5fe070a7fc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DYoshioka%26aufirst%3DM.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DFountain%26aufirst%3DR.%2BN.%26aulast%3DRaje%26aufirst%3DM.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DStrovel%26aufirst%3DJ.%2BW.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DBRD4%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Dual%2520PLK1%2520Kinase%252FBRD4%2520Bromodomain%2520Inhibitor%2520BI-2536%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D764%26epage%3D769%26doi%3D10.1021%2Facsmedchemlett.5b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosief, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthengi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">7785</span>– <span class="NLM_lpage">7795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=7785-7795&author=S.+Liuauthor=H.+O.+Yosiefauthor=L.+Daiauthor=H.+Huangauthor=G.+Dhawanauthor=X.+Zhangauthor=A.+M.+Muthengiauthor=J.+Robertsauthor=D.+L.+Buckleyauthor=J.+A.+Perryauthor=L.+Wuauthor=J.+E.+Bradnerauthor=J.+Qiauthor=W.+Zhang&title=Structure-Guided+Design+and+Development+of+Potent+and+Selective+Dual+Bromodomain+4+%28BRD4%29%2FPolo-like+Kinase+1+%28PLK1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00765%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYosief%26aufirst%3DH.%2BO.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DDhawan%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMuthengi%26aufirst%3DA.%2BM.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DStructure-Guided%2520Design%2520and%2520Development%2520of%2520Potent%2520and%2520Selective%2520Dual%2520Bromodomain%25204%2520%2528BRD4%2529%252FPolo-like%2520Kinase%25201%2520%2528PLK1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26spage%3D7785%26epage%3D7795%26doi%3D10.1021%2Facs.jmedchem.8b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-Dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lgbsFNGNEm7yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-Dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lgj71BHpJ-j0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2,4-Diaminopyrimidines Bearing Fused Tricyclic Ring Moiety for Anaplastic Lymphoma Kinase (ALK) Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2191</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.bmcl.2017.03.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2185-2191&author=R.+Acharyauthor=G.+R.+Mathiauthor=D.+H.+Leeauthor=C.+S.+Yunauthor=C.+O.+Leeauthor=H.+R.+Kimauthor=C.+H.+Parkauthor=P.+Kimauthor=J.+Y.+Hwang&title=Novel+2%2C4-Diaminopyrimidines+Bearing+Fused+Tricyclic+Ring+Moiety+for+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor&doi=10.1016%2Fj.bmcl.2017.03.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.073%26sid%3Dliteratum%253Aachs%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DMathi%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DYun%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DNovel%25202%252C4-Diaminopyrimidines%2520Bearing%2520Fused%2520Tricyclic%2520Ring%2520Moiety%2520for%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2185%26epage%3D2191%26doi%3D10.1016%2Fj.bmcl.2017.03.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span> <span> </span><span class="NLM_article-title">Replacing the Terminal Piperidine in Ceritinib with Aliphatic Amines Confers Activities Against Crizotinib-resistant Mutants including G1202R</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.ejmech.2016.11.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=536-549&author=G.+R.+Mathiauthor=C.+H.+Kangauthor=H.+K.+Leeauthor=R.+Acharyauthor=H.-Y.+Leeauthor=J.-Y.+Leeauthor=J.+D.+Haauthor=S.+Ahnauthor=C.+H.+Parkauthor=C.+O.+Leeauthor=J.+Y.+Hwangauthor=C.-S.+Yunauthor=H.+J.+Jungauthor=S.+Y.+Choauthor=H.+R.+Kimauthor=P.+Kim&title=Replacing+the+Terminal+Piperidine+in+Ceritinib+with+Aliphatic+Amines+Confers+Activities+Against+Crizotinib-resistant+Mutants+including+G1202R&doi=10.1016%2Fj.ejmech.2016.11.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DMathi%26aufirst%3DG.%2BR.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.-S.%26aulast%3DJung%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DP.%26atitle%3DReplacing%2520the%2520Terminal%2520Piperidine%2520in%2520Ceritinib%2520with%2520Aliphatic%2520Amines%2520Confers%2520Activities%2520Against%2520Crizotinib-resistant%2520Mutants%2520including%2520G1202R%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D536%26epage%3D549%26doi%3D10.1016%2Fj.ejmech.2016.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">9378</span>– <span class="NLM_lpage">9381</span>, <span class="refDoi"> DOI: 10.1002/anie.201103273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1002%2Fanie.201103273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9378-9381&author=G.+Budinauthor=K.+S.+Yangauthor=T.+Reinerauthor=R.+Weissleder&title=Bioorthogonal+Probes+for+Polo-like+Kinase+1+Imaging+and+Quantification&doi=10.1002%2Fanie.201103273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201103273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201103273%26sid%3Dliteratum%253Aachs%26aulast%3DBudin%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DReiner%26aufirst%3DT.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DBioorthogonal%2520Probes%2520for%2520Polo-like%2520Kinase%25201%2520Imaging%2520and%2520Quantification%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D9378%26epage%3D9381%26doi%3D10.1002%2Fanie.201103273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, M.</span></span> <span> </span><span class="NLM_article-title">Strong Reduction of Hydroxylamine Accumulation in the Catalytic Hydrogenation of Nitroarenes by Vanadium Promoters</span>. <i>Catal. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1023/A:1019034128024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1023%2FA%3A1019034128024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlCnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1997&pages=219-222&author=P.+Baumeisterauthor=H.-U.+Blaserauthor=M.+Studer&title=Strong+Reduction+of+Hydroxylamine+Accumulation+in+the+Catalytic+Hydrogenation+of+Nitroarenes+by+Vanadium+Promoters&doi=10.1023%2FA%3A1019034128024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Strong reduction of hydroxylamine accumulation in the catalytic hydrogenation of nitroarenes by vanadium promoters</span></div><div class="casAuthors">Baumeister, Peter; Blaser, Hans-Ulrich; Studer, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Catalysis Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3,4</span>),
    <span class="NLM_cas:pages">219-222</span>CODEN:
                <span class="NLM_cas:coden">CALEER</span>;
        ISSN:<span class="NLM_cas:issn">1011-372X</span>.
    
            (<span class="NLM_cas:orgname">Baltzer Science Publishers</span>)
        </div><div class="casAbstract">The accumulation of hydroxylamine intermediate during the catalytic hydrogenation of N-cyclohexyl-N-methyl-2-nitrobenzenesulfonamide could be reduced from >40% to <1% by the addn. of catalytic amts. of vanadium promoters, resulting in a faster reaction and purer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZO85_xbipTLVg90H21EOLACvtfcHk0lgGNVsZLqvYYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlCnu7g%253D&md5=300b2412eab310a52d6d5d81ac16932f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019034128024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019034128024%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DP.%26aulast%3DBlaser%26aufirst%3DH.-U.%26aulast%3DStuder%26aufirst%3DM.%26atitle%3DStrong%2520Reduction%2520of%2520Hydroxylamine%2520Accumulation%2520in%2520the%2520Catalytic%2520Hydrogenation%2520of%2520Nitroarenes%2520by%2520Vanadium%2520Promoters%26jtitle%3DCatal.%2520Lett.%26date%3D1997%26volume%3D49%26spage%3D219%26epage%3D222%26doi%3D10.1023%2FA%3A1019034128024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0lgGNVsZLqvYYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirguet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosmini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusq, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordaunt, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uings, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodème, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7501</span>– <span class="NLM_lpage">7515</span>, <span class="refDoi"> DOI: 10.1021/jm401088k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401088k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7501-7515&author=O.+Mirguetauthor=R.+Gosminiauthor=J.+Toumauthor=C.+A.+Cl%C3%A9mentauthor=M.+Barnathanauthor=J.-M.+Brusqauthor=J.+E.+Mordauntauthor=R.+M.+Grimesauthor=M.+Croweauthor=O.+Pineauauthor=M.+Ajakaneauthor=A.+Dauganauthor=P.+Jeffreyauthor=L.+Cutlerauthor=A.+C.+Haynesauthor=N.+N.+Smithersauthor=C.-w.+Chungauthor=P.+Bamboroughauthor=I.+J.+Uingsauthor=A.+Lewisauthor=J.+Witheringtonauthor=N.+Parrauthor=R.+K.+Prinjhaauthor=E.+Nicod%C3%A8me&title=Discovery+of+Epigenetic+Regulator+I-BET762%3A+Lead+Optimization+to+Afford+a+Clinical+Candidate+Inhibitor+of+the+BET+Bromodomains&doi=10.1021%2Fjm401088k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains</span></div><div class="casAuthors">Mirguet, Olivier; Gosmini, Romain; Toum, Jerome; Clement, Catherine A.; Barnathan, Melanie; Brusq, Jean-Marie; Mordaunt, Jacqueline E.; Grimes, Richard M.; Crowe, Miriam; Pineau, Olivier; Ajakane, Myriam; Daugan, Alain; Jeffrey, Phillip; Cutler, Leanne; Haynes, Andrea C.; Smithers, Nicholas N.; Chung, Chun-wa; Bamborough, Paul; Uings, Iain J.; Lewis, Antonia; Witherington, Jason; Parr, Nigel; Prinjha, Rab K.; Nicodeme, Edwige</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7501-7515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues.  This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4).  This work has yielded a potent, selective compd. I-BET762 (I) that is now under evaluation in a phase I/II clin. trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDitaXJSnFE7Vg90H21EOLACvtfcHk0lh9tFWrqh0QGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7jJ&md5=5d059b0be08a74a5721b72a120f7e090</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm401088k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401088k%26sid%3Dliteratum%253Aachs%26aulast%3DMirguet%26aufirst%3DO.%26aulast%3DGosmini%26aufirst%3DR.%26aulast%3DToum%26aufirst%3DJ.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DC.%2BA.%26aulast%3DBarnathan%26aufirst%3DM.%26aulast%3DBrusq%26aufirst%3DJ.-M.%26aulast%3DMordaunt%26aufirst%3DJ.%2BE.%26aulast%3DGrimes%26aufirst%3DR.%2BM.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DPineau%26aufirst%3DO.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DHaynes%26aufirst%3DA.%2BC.%26aulast%3DSmithers%26aufirst%3DN.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DUings%26aufirst%3DI.%2BJ.%26aulast%3DLewis%26aufirst%3DA.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DNicod%25C3%25A8me%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520Epigenetic%2520Regulator%2520I-BET762%253A%2520Lead%2520Optimization%2520to%2520Afford%2520a%2520Clinical%2520Candidate%2520Inhibitor%2520of%2520the%2520BET%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7501%26epage%3D7515%26doi%3D10.1021%2Fjm401088k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule–Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule%E2%80%93Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lh9tFWrqh0QGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule%25E2%2580%2593Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehlgans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanhaji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurunci-Csacsko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dötsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bug, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Mitotic Arrest and Slippage Induced by Pharmacological Inhibition of Polo-like Kinase 1</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.molonc.2014.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=25169932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=140-154&author=M.+Raabauthor=A.+Kr%C3%A4merauthor=S.+Hehlgansauthor=M.+Sanhajiauthor=E.+Kurunci-Csacskoauthor=C.+D%C3%B6tschauthor=G.+Bugauthor=O.+Ottmannauthor=S.+Beckerauthor=F.+Pachlauthor=B.+Kusterauthor=K.+Strebhardt&title=Mitotic+Arrest+and+Slippage+Induced+by+Pharmacological+Inhibition+of+Polo-like+Kinase+1&doi=10.1016%2Fj.molonc.2014.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1</span></div><div class="casAuthors">Raab, Monika; Kraemer, Andrea; Hehlgans, Stephanie; Sanhaji, Mourad; Kurunci-Csacsko, Elisabeth; Doetsch, Christina; Bug, Gesine; Ottmann, Oliver; Becker, Sven; Pachl, Fiona; Kuster, Bernhard; Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exposure to drugs that interfere with microtubule dynamics block cell cycle progression at mitosis by prolonged activation of the spindle assembly checkpoint (SAC).  Cells can evade mitotic arrest and proceed to interphase without chromosome segregation by a process termed mitotic slippage that involves Cyclin B1 degrdn. without checkpoint inactivation.  Here, we explored the cellular response to small-mol. inhibitors of Polo-like kinase 1 (Plk1), an important regulator of cell division.  We found that the clin. Plk1 inhibitors BI 2536 and BI 6727, both unexpectedly, induced a dose-dependent cellular drug response: While mitotic arrest was induced in cancer cell lines and primary non-transformed cells across the entire range of concns. tested, only high concns. seemed to promote mitotic slippage.  Since this observation contrasts with the effects expected from studies reporting RNAi-mediated Plk1 depletion in cancer cells, we wondered whether both ATP-competitive inhibitors target unknown kinases that are involved in signaling from the spindle assembly checkpoint (SAC) and might contribute to the mitotic slippage.  A chem. proteomics approach used to profile the selectivity of both inhibitors revealed that SAC kinases are not targeted directly.  Still, the activities of Cdk1/Cyclin B1 and Aurora B, which plays important roles in the error correction of false microtubule-kinetochore attachments and in checkpoint signaling, were shown to be downregulated at high inhibitor concns.  Our data suggest that the inhibition of Plk1 activity below a certain threshold influences Aurora B activity via reduced phosphorylation of Fox M1 and Survivin leading to diminished levels of Aurora B protein and alteration of its subcellular localization.  Within the spectrum of SAC proteins that are degraded during mitotic slippage, the degrdn. of Cyclin B1 and the downregulation of Aurora B activity by Plk1 inhibition seem to be crit. promoters of mitotic slippage.  The results indicate that careful dose-finding studies in cancer trials are necessary to limit or even prevent mitotic slippage, which could be assocd. with improved cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrii34p2M0gM7Vg90H21EOLACvtfcHk0lh9tFWrqh0QGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrs7bK&md5=fec5b964cacf93600fd16ccd1ec78a48</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DRaab%26aufirst%3DM.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DHehlgans%26aufirst%3DS.%26aulast%3DSanhaji%26aufirst%3DM.%26aulast%3DKurunci-Csacsko%26aufirst%3DE.%26aulast%3DD%25C3%25B6tsch%26aufirst%3DC.%26aulast%3DBug%26aufirst%3DG.%26aulast%3DOttmann%26aufirst%3DO.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMitotic%2520Arrest%2520and%2520Slippage%2520Induced%2520by%2520Pharmacological%2520Inhibition%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D140%26epage%3D154%26doi%3D10.1016%2Fj.molonc.2014.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span> <span> </span><span class="NLM_article-title">Immunoassays for the Quantification of ALK and Phosphorylated ALK Support the Evaluation of On-target ALK Inhibitors in Neuroblastoma</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1002%2F1878-0261.12069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=28432815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=996-1006&author=E.+R.+Tuckerauthor=J.+R.+Tallauthor=L.+S.+Danielsonauthor=S.+Gowanauthor=Y.+Jaminauthor=S.+P.+Robinsonauthor=U.+Banerjiauthor=L.+Chesler&title=Immunoassays+for+the+Quantification+of+ALK+and+Phosphorylated+ALK+Support+the+Evaluation+of+On-target+ALK+Inhibitors+in+Neuroblastoma&doi=10.1002%2F1878-0261.12069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma</span></div><div class="casAuthors">Tucker, Elizabeth R.; Tall, Jennifer R.; Danielson, Laura S.; Gowan, Sharon; Jamin, Yann; Robinson, Simon P.; Banerji, Udai; Chesler, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">996-1006</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more potent compds. and pharmacodynamic methods with which to det. their efficacy.  We describe immunoassays designed to quantitate phosphorylation of ALK, and their use in preclin. models of neuroblastoma, a pediatric malignancy in which gain-of-function ALK mutations predict a poor overall outcome to conventional treatment.  Validation of the immunoassays is presented using a panel of neuroblastoma cell lines and evidence of on-target ALK inhibition provided by treatment of a genetically engineered murine model of neuroblastoma with two clin. ALK inhibitors, crizotinib and ceritinib, highlighting the superior efficacy of ceritinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpnqWY711H7Vg90H21EOLACvtfcHk0lhKAt3l_X3j8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqt7bP&md5=3052aa18ccb10bf6056f3757f5f36880</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12069%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DTall%26aufirst%3DJ.%2BR.%26aulast%3DDanielson%26aufirst%3DL.%2BS.%26aulast%3DGowan%26aufirst%3DS.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DChesler%26aufirst%3DL.%26atitle%3DImmunoassays%2520for%2520the%2520Quantification%2520of%2520ALK%2520and%2520Phosphorylated%2520ALK%2520Support%2520the%2520Evaluation%2520of%2520On-target%2520ALK%2520Inhibitors%2520in%2520Neuroblastoma%26jtitle%3DMol.%2520Oncol.%26date%3D2017%26volume%3D11%26spage%3D996%26epage%3D1006%26doi%3D10.1002%2F1878-0261.12069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span> <span> </span><span class="NLM_article-title">Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">206.e11</span>– <span class="NLM_lpage">214.e11</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=10.1016%2Fj.chembiol.2017.10.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=206.e11-214.e11&author=J.+D.+Vastaauthor=C.+R.+Coronaauthor=J.+Wilkinsonauthor=C.+A.+Zimprichauthor=J.+R.+Hartnettauthor=M.+R.+Ingoldauthor=K.+Zimmermanauthor=T.+Machleidtauthor=T.+A.+Kirklandauthor=K.+G.+Huwilerauthor=R.+F.+Ohanaauthor=M.+Slaterauthor=P.+Ottoauthor=M.+Congauthor=C.+I.+Wellsauthor=B.-T.+Bergerauthor=T.+Hankeauthor=C.+Glasauthor=K.+Dingauthor=D.+H.+Drewryauthor=K.+V.+M.+Huberauthor=T.+M.+Willsonauthor=S.+Knappauthor=S.+M%C3%BCllerauthor=P.+L.+Meisenheimerauthor=F.+Fanauthor=K.+V.+Woodauthor=M.+B.+Robers&title=Quantitative%2C+Wide-Spectrum+Kinase+Profiling+in+Live+Cells+for+Assessing+the+Effect+of+Cellular+ATP+on+Target+Engagement&doi=10.1016%2Fj.chembiol.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DIngold%26aufirst%3DM.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DHuwiler%26aufirst%3DK.%2BG.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DBerger%26aufirst%3DB.-T.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DGlas%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26atitle%3DQuantitative%252C%2520Wide-Spectrum%2520Kinase%2520Profiling%2520in%2520Live%2520Cells%2520for%2520Assessing%2520the%2520Effect%2520of%2520Cellular%2520ATP%2520on%2520Target%2520Engagement%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D206.e11%26epage%3D214.e11%26doi%3D10.1016%2Fj.chembiol.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinn, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méndez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1804</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovFKkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1797-1804&author=T.+Machleidtauthor=C.+C.+Woodroofeauthor=M.+K.+Schwinnauthor=J.+M%C3%A9ndezauthor=M.+B.+Robersauthor=K.+Zimmermanauthor=P.+Ottoauthor=D.+L.+Danielsauthor=T.+A.+Kirklandauthor=K.+V.+Wood&title=NanoBRET%E2%80%94A+Novel+BRET+Platform+for+the+Analysis+of+Protein%E2%80%93Protein+Interactions&doi=10.1021%2Facschembio.5b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">NanoBRET-A Novel BRET Platform for the Analysis of Protein-Protein Interactions</span></div><div class="casAuthors">Machleidt, Thomas; Woodroofe, Carolyn C.; Schwinn, Marie K.; Mendez, Jacqui; Robers, Matthew B.; Zimmerman, Kris; Otto, Paul; Daniels, Danette L.; Kirkland, Thomas A.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1797-1804</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dynamic interactions between proteins comprise a key mechanism for temporal control of cellular function and thus hold promise for development of novel drug therapies.  It remains tech. challenging, however, to quant. characterize these interactions within the biol. relevant context of living cells.  Although, bioluminescence resonance energy transfer (BRET) has often been used for this purpose, its general applicability has been hindered by limited sensitivity and dynamic range.  We have addressed this by combining an extremely bright luciferase (Nanoluc) with a means for tagging intracellular proteins with a long-wavelength fluorophore (HaloTag).  The small size (19 kDa), high emission intensity, and relatively narrow spectrum (460 nm peak intensity) make Nanoluc luciferase well suited as an energy donor.  By selecting an efficient red-emitting fluorophore (635 nm peak intensity) for attachment onto the HaloTag, an overall spectral sepn. exceeding 175 nm was achieved.  This combination of greater light intensity with improved spectral resoln. results in substantially increased detection sensitivity and dynamic range over current BRET technologies.  Enhanced performance is demonstrated using several established model systems, as well as the ability to image BRET in individual cells.  The capabilities are further exhibited in a novel assay developed for analyzing the interactions of bromodomain proteins with chromatin in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6-h9HlReNabVg90H21EOLACvtfcHk0lhdxqYF9rRipA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovFKkt7c%253D&md5=9f5f773b6cd14c40074a2ffbd6472008</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00143%26sid%3Dliteratum%253Aachs%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DSchwinn%26aufirst%3DM.%2BK.%26aulast%3DM%25C3%25A9ndez%26aufirst%3DJ.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DNanoBRET%25E2%2580%2594A%2520Novel%2520BRET%2520Platform%2520for%2520the%2520Analysis%2520of%2520Protein%25E2%2580%2593Protein%2520Interactions%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1797%26epage%3D1804%26doi%3D10.1021%2Facschembio.5b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7','PDB','2XB7'); return false;">PDB: 2XB7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OGI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OGI','PDB','4OGI'); return false;">PDB: 4OGI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RKU','PDB','2RKU'); return false;">PDB: 2RKU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y','PDB','6Q3Y'); return false;">PDB: 6Q3Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z','PDB','6Q3Z'); return false;">PDB: 6Q3Z</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i98"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01947">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83452"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01947">10.1021/acs.jmedchem.8b01947</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv">CSV</a>)</p></li><li><p class="inline">Tables with standard deviations for all compounds; data collection and refinement statistics for BRD4–ligand complexes with <b>16i</b> and <b>16k</b>; kinase and bromodomain selectivity profiling of <b>16k</b>; chiral shift NMR and HPLC experiments; and cell cycle analysis of BI-2536 and <b>16k</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_001.csv">jm8b01947_si_001.csv (1.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01947/suppl_file/jm8b01947_si_002.pdf">jm8b01947_si_002.pdf (765.12 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes for <b>16i</b> and <b>16k</b> bound to BRD4(1) are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Y">6Q3Y</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q3Z">6Q3Z</a>, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01947&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01947%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-5%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01947" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f3727daad1c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
